courseId,chapterId,lessonId,taskId,courseName,coursedescription,chapterName,lessonName,taskTitle,scenario,pdfUrls,tallyUrls,answerKeyUrl,instructions,xp
course_1,ch_1_01,les_1_01_01,task_1_01_01_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Entering the Battlefield – QMS Basics & SOP Gap Review,L1: QMS Compliance Check,"Welcome to your first mission as a Junior Quality Control Analyst at Zenith Pharma Labs!
Your supervisor, Ms. Rhea Patel, Quality Assurance Supervisor, needs you to ensure the lab’s Quality Management System (QMS) is on point. You’ve been tasked with checking if the lab’s batch record-keeping follows the QMS rules outlined in the SOP. Your job is to review the SOP, compare it to a lab observation, and fill out a Compliance Verification Form to confirm if the process is compliant or flag any issues. This keeps the lab’s operations safe and reliable, like a well-coordinated army following its playbook.

CheckList:
1. Review the SOP for batch record-keeping.
2. Compare it to a lab observation to check compliance.
3. Complete the Compliance Verification Form (100–150 words) to report your findings.

Why This Matters:
 Checking QMS compliance ensures every pill is safe and meets standards, protecting patients and avoiding costly mistakes.",https://drive.google.com/file/d/1K0SDr6xPtfcQr_pH3YUCjAMVTI1it8zd/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1mFO3hiotOq3pHMEYGQtq--sIUvUq-OjA/view?usp=sharing,"Open SOP: Click “Reference Documents” → read Batch Record-Keeping Procedure (requires date, batch number, operator’s initials).
Review Observation: From Reference Documents → note issue: Some batch records missing operator’s initials.
Check Compliance: Compare SOP vs. observation → ask: Is the lab following the rule? What’s the gap?
Open Form: Click “Fillable Document” → Compliance Verification Form.
Complete Form:
Compliance Status: State if compliant or non-compliant.
Observation: Briefly describe the issue.
Recommendation: Suggest one practical fix (100–150 words).
Verify: Ensure findings are clear and solution is realistic.
Check Answer: Click “Answer Portal” → review correct Compliance Verification Form.",10
course_1,ch_1_01,les_1_01_02,task_1_01_02_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Control the Arsenal – Document Versioning & Register Mastery,L2: SOP Gap Review and DCR Submission.,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Mr. Vikram Desai, Quality Assurance Lead.
During a routine document audit, you notice that the SOP for sample storage (SOP-QC-002, v1.0) requires samples to be stored at 2–8°C, but the lab’s refrigerator log shows temperatures occasionally reaching 10°C due to a missing maintenance check step. Mr. Desai asks you to propose an update to the SOP using a Document Change Request (DCR) Form to add a daily maintenance check.


Deliverables

Completed Document Change Request (DCR) Form (100–150 words) identifying the SOP gap and proposing the addition of a daily refrigerator maintenance check.",https://drive.google.com/file/d/1y6RVPyWpTB_SD0sskQDxt5S8GbQxM4U4/view?usp=sharing,https://tally.so/r/wbJPeo,https://drive.google.com/file/d/1kt87iFAUiZUiOGBjjk6pkzhtk98MHi2k/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-002 and the refrigerator log.
Compare SOP (requires 2–8°C storage, no maintenance step) to the log (shows temperature deviations).
Open “Fillable Document” (DCR Form).
Fill the form: Identify SOP, describe gap (missing maintenance check), propose change (add daily check step), and justify (prevents temperature deviations).
Submit via “Answer Portal.”",10
course_1,ch_1_01,les_1_01_03,task_1_01_03_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Spot the Breach – Deviation Detection & Rapid Reporting,L3: Detecting and Classifying a Deviation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Ms. Priya Sharma, Quality Assurance Supervisor. During a routine in-process check (IPC) of a tablet batch (Batch No. TAB-2025-047), you notice that the tablet weight recorded by the automated weighing machine is 495 mg, below the SOP-QC-003 requirement of 500 ± 5 mg. After checking, you find the weighing machine was not calibrated before the shift, causing the deviation. Ms. Sharma instructs you to document this using the Deviation and Incident Report Form and propose immediate containment actions.


Deliverables

Completed Deviation and Incident Report Form (100–150 words total across fields) documenting the weight deviation, its cause, and containment actions.",https://drive.google.com/file/d/11Pqhs4bKzotVdEmLs_kL3RpEshaiO4HP/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1E7UVvyWtPSCLChXVtLDwIOFv95C4h3cj/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-003 and IPC Log.
Compare SOP (tablet weight 500 ± 5 mg) to IPC Log (weight 495 mg).
Open “Fillable Document” (Deviation and Incident Report Form).
Fill the form: Describe the deviation (low weight), identify cause (uncalibrated machine), classify severity (Major), and propose containment (quarantine batch, recalibrate machine).
Submit via “Answer Portal.”",10
course_1,ch_1_01,les_1_01_04,task_1_01_04_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Strike Back – Root Cause Analysis & CAPA Drafting,L4: The Mystery of the Failing Cold Room,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Mr. Anil Gupta, Quality Assurance Manager. During a routine dissolution test for tablet batch TAB-2025-049, 3 out of 20 tablets failed to meet the SOP-QC-004 dissolution specification (≥80% dissolution in 30 minutes). Initial investigation points to inconsistent granulation time. Mr. Gupta instructs you to perform a root cause analysis (RCA) using the 5 Whys method and document corrective and preventive actions using the CAPA Command Template.


Deliverables

Completed CAPA Command Template (100–150 words total across descriptive fields) documenting the root cause of the dissolution failure and proposing corrective and preventive actions.",https://drive.google.com/file/d/1lS8dLuDj7nq_pBJ-gJuvkEM6uKwkAt10/view?usp=sharing,https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1XuYqWUXV9iFj_VOmxN5zzPxP-k-wiEBb/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-004 and Dissolution Test Log.
Use the 5 Whys method to identify the root cause (start with: tablets failed dissolution test).
Open “Fillable Document” (CAPA Command Template).
Fill the form: Describe the issue, document RCA findings, propose corrective actions (e.g., retrain operators), and preventive actions (e.g., update equipment settings), assign responsibilities, and set deadlines.
Submit via “Answer Portal.”",10
course_1,ch_1_01,les_1_01_05,task_1_01_05_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,First Combat Drill – Internal Audit & Document Inspection Simulation,L5: Internal Audit & Document Inspection at Sunrise Hospital Lab,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, assigned as an internal auditor under Ms. Rhea Patel, QA Manager. During a mock process audit of the sample testing process, you review the Sample Testing Log (LOG-2025-016) against SOP-QC-005 (Sample Testing Procedure, v1.0). You notice that 4 out of 10 test records lack analyst signatures, violating SOP-QC-005’s requirement for signed documentation. Ms. Patel instructs you to document your findings and recommend corrective actions using the Audit & Inspection Form.


Deliverables

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting audit findings and recommending actions.",https://drive.google.com/file/d/1-oJxjHqSgFMuadS30z0e4X7S2Niym0Pd/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1KxGNxSxQjpedN8HdvsWo6Yr308ugNea8/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-005 and Sample Testing Log.
Compare SOP-QC-005 (requires analyst signatures on all test records) to LOG-2025-016 (4/10 records missing signatures).
Open “Fillable Document” (Audit & Inspection Form).
Fill the form: Check relevant criteria (e.g., Documentation complete and accurate: NO), provide REMARKS (e.g., missing signatures), and recommend actions in Others/Additional Observations (e.g., retrain staff, add checklist).
Submit via “Answer Portal.”",10
course_1,ch_1_01,les_1_01_06,task_1_01_06_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Defend the Lab – OOS/OOT Identification & First-line Investigation,L6: OOS Identification and First-line Investigation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Ms. Priya Sharma, Quality Assurance Supervisor. During a routine purity test for raw material batch RM-2025-105, the HPLC test result shows a purity of 98.5%, below the SOP-QC-006 specification of ≥99.5%. Initial checks suggest a possible lab error in sample preparation. Ms. Sharma instructs you to document the OOS result and perform a first-line investigation using the Deviation and Incident Report Form, noting immediate actions and initial findings.


Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the OOS result, immediate actions, and initial investigation findings.",https://drive.google.com/file/d/1wTls81wwbIgvuyF200uR2wvTn1RrQ3BB/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/11FmFmPckN-p-Fi83L-9PlpaknjLjnwqC/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-006 and HPLC Test Log.
Compare SOP-QC-006 (purity ≥99.5%) to HPLC Test Log (98.5% purity).
Open “Fillable Document” (Deviation and Incident Report Form).
Fill the form: Describe the OOS result, note immediate actions (e.g., quarantine batch, recheck data), provide initial RCA (e.g., possible sample preparation error), propose corrective/preventive actions, and assign responsibilities.
Submit via “Answer Portal.”",10
course_1,ch_1_01,les_1_01_07,task_1_01_07_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Guard the Data – ALCOA+ & Data Integrity Auditing,L7: ALCOA+ & Data Integrity Auditing,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, assigned as a data integrity auditor under Mr. Vikram Desai, QA Lead. During a mock audit of batch record data for tablet batch TAB-2025-053, you review the Batch Record Log (LOG-2025-020) against SOP-QA-007 (Batch Record Documentation). You notice that 5 out of 10 records have timestamps entered hours after the test, violating SOP-QA-007’s requirement for contemporaneous data entry (ALCOA+ principle). Mr. Desai instructs you to document your findings and recommend improvements using the Compliance Verification Form.

Deliverables

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the data integrity audit findings and proposed improvements.",https://drive.google.com/file/d/1P739y6U2m9-qzwXOWqGx5nlzXmIM3_Mf/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1JQytxpbHV5Nvr3OFjZ1YMdUu-8Tpm8Ow/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-007 and Batch Record Log.
Compare SOP-QA-007 (requires contemporaneous timestamps) to LOG-2025-020 (delayed timestamps).
Open “Fillable Document” (Compliance Verification Form).
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., delayed timestamps), detail deviation, and suggest improvements (e.g., retrain staff, use electronic logging).
Submit via “Answer Portal.”",10
course_1,ch_1_01,les_1_01_08,task_1_01_08_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,Full-Scale Operation – Deviation to CAPA Lifecycle Simulation,L8: Deviation to CAPA Lifecycle Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Ms. Rhea Patel, QA Manager. During a routine hardness test for tablet batch TAB-2025-055, the result is 3.5 kg, below the SOP-QC-008 specification of 4–6 kg (deviation detected). 

Initial assessment shows major impact on product quality, and RCA reveals a machine malfunction due to overdue maintenance. 
Ms. Patel instructs you to simulate the full Deviation to CAPA lifecycle using two forms: 

1. Deviation and Incident Report Form for detection, logging, assessment, containment, and RCA.
2. CAPA Command Template for drafting corrective/preventive actions, implementation, verification, and closure. 

This builds a complete, traceable cycle.


Deliverables

Two completed forms—Deviation and Incident Report Form (for initial stages) and CAPA Command Template (for CAPA stages)—documenting the full lifecycle from deviation detection to CAPA closure (100–150 words total across descriptive fields per form).",https://drive.google.com/file/d/1jj9qqQzB_q5WOEidKglhzecpc4aIbnmj/view?usp=sharing,https://tally.so/r/3jVqb9 | https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1RmlneEj-uWatsNRfzHI8muWo5itx4aCQ/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-008 and Hardness Test Log.
Simulate the initial stages: Log the deviation (hardness 3.5 kg), assess impact (major), contain (quarantine), and perform RCA (5 Whys to root cause).
Open “Fillable Document” (Deviation and Incident Report Form).
Fill the Deviation Form: Describe incident, note immediate actions, provide RCA, propose preliminary CAPA ideas, and set to Open. Submit via “Answer Portal” (this ""closes"" the deviation phase).
Transition to CAPA: Use the Deviation Form's RCA/output as input for detailed CAPA drafting.
Open “Fillable Document” (CAPA Command Template).
Fill the CAPA Template: Reference the deviation ID (DEV-2025-055), draft corrective/preventive actions, assign responsibilities, plan verification, and note closure date. Submit via “Answer Portal”.
Tip: This two-form workflow mimics real QA—deviation for quick response, CAPA for long-term fix. Keep descriptions concise and evidence-based.",10
course_1,ch_1_01,les_1_01_09,task_1_01_09_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Foundations of Quality Warfare,The War Game – Integrated QA/QC Crisis Assignment,L9: Integrated QA/QC Crisis Assignment,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Mr. Anil Gupta, QA Manager. A crisis erupts: an assay test for Batch TAB-2025-057 shows an OOS result (API content 97.8% vs. ≥99.0% per SOP-QC-009). Simultaneously, an audit uncovers missing training records for two analysts (AK003, VS004) on SOP-QC-009, and an FDA inspection is scheduled tomorrow. Mr. Gupta tasks you with managing the crisis using three forms: Crisis Tracker Dashboard to triage and prioritize issues, Deviation and Incident Report Form to detail the OOS with RCA, and CAPA Command Template to resolve the OOS with corrective/preventive actions.


Deliverables

Crisis Tracker Dashboard (triage/prioritize OOS and training issues, 100–150 words across descriptives).
Deviation and Incident Report Form (OOS detail/RCA, 100–150 words).
CAPA Command Template (OOS resolution, 100–150 words).",https://drive.google.com/file/d/1ruYNX4Z-tMs1C36Mp414nh5n_vO_QYzP/view?usp=sharing, https://tally.so/r/mYABqv | https://tally.so/r/3jVqb9 | https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1DVPWaaU2u6JKrJ_7dacXXee33wwWLgVo/view?usp=sharing,"Click “Reference Documents” to review SOP-QC-009, Assay Test Log, and Training Record Log.
Triage the crisis: List issues (OOS, missing records), assess risk, prioritize (OOS first).
Open “Fillable Document” (Crisis Tracker Dashboard).
Fill Dashboard: Describe issues, assign risk/priority (OOS: Major/High), note status, link to Deviation IDs. Submit via “Answer Portal” (sets crisis overview).
Focus on OOS (highest priority): Detail deviation and perform RCA.
Open “Fillable Document” (Deviation and Incident Report Form).
Fill Deviation Form: Describe OOS, note containment, RCA (5 Whys), preliminary CAPA. Submit via “Answer Portal”.
Resolve OOS: Use Deviation RCA for CAPA drafting.
Open “Fillable Document” (CAPA Command Template).
Fill CAPA Template: Reference Deviation ID, draft corrective/preventive actions, plan verification/closure. Submit via “Answer Portal”.
Tip: Dashboard is your crisis command center—link IDs across forms for traceability. Prioritize patient safety (OOS) for audit readiness.",10
,,,,,,,,,,,,,,
course_1,ch_1_02,les_1_02_01,task_1_02_01_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Entering the Ward Zone – Hospital QMS Framework & Accreditation Codes,Ward QMS Compliance Audit,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Meera Nair, Quality Assurance Lead. During a routine ward audit in Ward 3 (General Medicine), you review the Hand Hygiene Compliance Log (LOG-2025-027) against SOP-QA-010 (Hand Hygiene Protocol). 
You find that 6 out of 10 shift logs lack hand hygiene verification entries, violating SOP-QA-010 and NABH Standard AAC.5 (Access to Care and Continuity). Dr. Nair instructs you to document the non-compliance and recommend improvements using the Compliance Verification Form to prepare for an upcoming NABH audit.


Deliverables

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the ward audit findings and proposed improvements for NABH compliance.",https://drive.google.com/file/d/1Sz3g4chibpJOI18mRlH78C-gfuc26qsb/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1KYlll5nEFnTyrXlT_vJUpeQWJdS7ZdoW/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-010 and Hand Hygiene Compliance Log.
Compare SOP-QA-010 (requires hand hygiene verification entries per shift) to LOG-2025-027 (missing entries).
Open “Fillable Document” (Compliance Verification Form).
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing entries), detail deviation, and suggest improvements (e.g., retrain staff, add digital logging).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_02,task_1_02_02_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Code Control – SOP Command Chains & Access Authority,SOP Compliance and Access Authority Audit,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Vikram Desai, QA Lead. During a routine ward audit in Ward 4 (Surgical Unit), you review the SOP Register (REG-2025-002) against SOP-QA-011 (Surgical Instrument Sterilization Protocol). You find that 3 out of 5 SOP copies in use are version 1.0 (expired 01/06/2025), while the current version is 2.0, violating NABH Standard MOM.2 (Management of Medication). Dr. Desai instructs you to document the non-compliance and recommend improvements using the Compliance Verification Form to prepare for an upcoming NABH audit.

Deliverables
 
Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the SOP compliance audit findings and proposed improvements for NABH adherence.",https://drive.google.com/file/d/1RcJ_GoLC__evWJNRrXejtBKxIo_Si5MJ/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1yAlj2pOBvxfmbH5COv1L3ZCHi_pJ1-Jd/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-011 and SOP Register.
Compare SOP-QA-011 (version 2.0, effective 01/07/2025) to REG-2025-002 (outdated version 1.0 in use).
Open “Fillable Document” (Compliance Verification Form).
Fill the form: Check criteria (e.g., SOP followed as per latest revision: B - FAIL), provide REMARKS (e.g., outdated SOPs), detail deviation, and suggest improvements (e.g., recall old versions, implement digital SOP library).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_03,task_1_02_03_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Vitals Check – Patient Safety Indicators & Risk Flagging,Patient Safety Indicators and Risk Flagging Audit,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Priya Sharma, QA Supervisor. During a routine audit in Ward 5 (ICU), you review the Catheter Care Log (LOG-2025-029) against SOP-QA-012 (Catheter Care Protocol) to check PSI compliance for Catheter-Associated Urinary Tract Infections (CAUTIs). You find that 4 out of 10 catheter care logs lack nurse verification entries, increasing CAUTI risk and violating NABH Standard IPC.3 (Infection Prevention and Control). Dr. Sharma instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming NABH audit.

 Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the PSI audit findings and proposed improvements for NABH compliance.",https://drive.google.com/file/d/1wzsz668svfia0Iy3-AtfvrEprls__1SG/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/14fB10TY9f1zMSKUnt1uL8M4SSeks3yfs/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-012 and Catheter Care Log.
Compare SOP-QA-012 (requires nurse verification entries per shift) to LOG-2025-029 (missing entries).
Open “Fillable Document” (Audit & Inspection Form).
Fill the form: Check criteria (e.g., Documentation complete and accurate: NO), provide REMARKS (e.g., missing verification entries), and recommend improvements in Others/Additional Observations (e.g., retrain nurses, add digital alerts).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_04,task_1_02_04_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Contain the Breach – Incident Reporting & Escalation Pathways,Incident Reporting and Escalation Simulation,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Anil Gupta, QA Manager. During a night shift in Ward 6 (Emergency Department), a nurse reports a medication error: patient PT-2025-112 received 10 mg of a drug instead of 5 mg due to a misread prescription label, classified as a clinical incident. 
Dr. Gupta instructs you to document the incident, classify its severity, and outline initial actions using the Deviation and Incident Report Form, following SOP-QA-013 (Medication Administration Protocol) to ensure NABH Standard MOM.3 (Management of Medication) compliance.

 Deliverables 
 
Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the medication error, severity, immediate actions, and preliminary CAPA.",https://drive.google.com/file/d/1qmhtt20J2VQ5syh3h0LmTCn0zivMcras/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1KeyXyLmb4_quburfCQu9ZaF6NYC9VMqF/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-013 and Medication Administration Log.
Compare SOP-QA-013 (requires clear prescription labeling) to LOG-2025-030 (misread label caused error).
Open “Fillable Document” (Deviation and Incident Report Form).
Fill the form: Describe the incident (medication error), classify severity (moderate), note immediate actions (e.g., monitor patient, notify doctor), provide preliminary RCA (e.g., unclear label design), and propose CAPA (e.g., retrain staff, redesign labels).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_05,task_1_02_05_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Biohazard Defense – Infection Control Protocols & Isolation Measures,Infection Control and Isolation Audit,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Meera Nair, QA Lead. During a routine audit in Ward 7 (Infectious Diseases Unit), you review the Isolation Room Compliance Log (LOG-2025-031) against SOP-QA-014 (Infection Control and Isolation Protocol). You find that 3 out of 5 isolation rooms lack proper signage for contact precautions, violating NABH Standard IPC.3 (Infection Prevention and Control) and increasing HAI risk. Dr. Nair instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming NABH audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the IPC audit findings and proposed improvements for NABH compliance.",https://drive.google.com/file/d/1NCZgT_8h_5YojzRF-zeVX4-4s1Iq1qul/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1U2IrYIN_stpUAjGa6ouLT_pKcEQjS70M/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-014 and Isolation Room Compliance Log.
Compare SOP-QA-014 (requires contact precaution signage) to LOG-2025-031 (missing signage).
Open “Fillable Document” (Audit & Inspection Form).
Fill the form: Check criteria (e.g., Safety protocols followed: NO), provide REMARKS (e.g., missing signage), and recommend improvements in Others/Additional Observations (e.g., install signage, retrain staff).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_06,task_1_02_06_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Guard the Records – EMR/EHR Data Integrity & Access Logs,EMR/EHR Data Integrity and Access Log Audit,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Priya Sharma, QA Supervisor. During a routine EMR audit in Ward 8 (Cardiology Unit), you review the EMR Access Log (LOG-2025-032) against SOP-QA-015 (EMR Data Management Protocol). 
You find that 4 out of 10 patient record entries have delayed timestamps (entered 2–3 hours after patient interaction), violating SOP-QA-015’s ALCOA+ Contemporaneous principle and NABH Standard HIC.2 (Hospital Infection Control). 
Dr. Sharma instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming NABH audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the EMR data integrity audit findings and proposed improvements for NABH compliance.",https://drive.google.com/file/d/1xwt6RMBks6RCIJbPsmYwZKHeuCN1kqAI/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1s5xvidtTV_fTxU2C1-uarMw_HHQv0J5B/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-015 and EMR Access Log.
Compare SOP-QA-015 (requires contemporaneous EMR entries) to LOG-2025-032 (delayed timestamps).
Open “Fillable Document” (Compliance Verification Form).
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., delayed timestamps), detail deviation, and suggest improvements (e.g., retrain staff, implement real-time alerts).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_07,task_1_02_07_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,First Hospital Drill – Ward & Facility Compliance Sweep,Ward & Facility Compliance Sweep,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Anil Gupta, QA Manager. During a routine compliance sweep in Ward 9 (Orthopedic Unit), you review the Disinfection Compliance Log (LOG-2025-033) against SOP-QA-016 (Ward Hygiene and Disinfection Protocol). 

You find that 5 out of 10 daily disinfection logs lack staff signatures, classified as a major non-compliance issue violating NABH Standard HIC.3 (Hospital Infection Control). Dr. Gupta instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming NABH audit.

Deliverables
Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the compliance sweep findings and proposed improvements for NABH compliance.",https://drive.google.com/file/d/1XYrJRzUW0SnFBM3qRNqjBwbjIxBjcP19/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1TrFK-TDJNdMDE4BqDvPxncuhg25xqYhk/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-016 and Disinfection Compliance Log.
Compare SOP-QA-016 (requires signed disinfection logs per shift) to LOG-2025-033 (missing signatures).
Open “Fillable Document” (Audit & Inspection Form).
Fill the form: Check criteria (e.g., Documentation complete and accurate: NO), provide REMARKS (e.g., missing signatures), and recommend improvements in Others/Additional Observations (e.g., retrain staff, add digital logging).
Submit via “Answer Portal”.",10
course_1,ch_1_02,les_1_02_08,task_1_02_08_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Emergency Response Simulation – From Alarm to Action,Emergency Response Simulation,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Meera Nair, QA Lead. During a night shift in Ward 10 (Pathology Lab), a biohazard spill (chemical reagent) occurs due to a broken container during transport, classified as a high-severity incident. 

Dr. Nair instructs you to document the incident, classify its severity, and outline initial actions using the Deviation and Incident Report Form, following SOP-QA-017 (Biohazard Spill Response Protocol) to ensure compliance with NABH Standard FMS.4 (Facility Management and Safety).

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the biohazard spill, severity, immediate actions, and preliminary CAPA.",https://drive.google.com/file/d/18hDngVtD1yjQ9Z_SoMiZaVFnwN13arzA/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1py-8b79Qitl36u9Th1Polr11cvqMDiAP/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-017 and Biohazard Spill Log.
Compare SOP-QA-017 (requires immediate containment and reporting) to LOG-2025-034 (spill details).
Open “Fillable Document” (Deviation and Incident Report Form).
Fill the form: Describe the incident (biohazard spill), classify severity (high), note immediate actions (e.g., isolate area, deploy PPE), provide preliminary RCA (e.g., faulty container), and propose CAPA (e.g., replace containers, retrain staff).
Submit via “Answer Portal”",10
course_1,ch_1_02,les_1_02_09,task_1_02_09_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,The Grand Ward Game – Multi-Department QA/QC Coordination Challenge,Multi-Department QA/QC Coordination Challenge,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Anil Gupta, QA Manager. During a multi-department QA sweep, you identify two issues: (1) a Pharmacy dispensing error (wrong medication label for Batch MED-2025-101, risking ward errors) and (2) missing ICU hand hygiene logs (4/10 entries incomplete). 

Dr. Gupta instructs you to use the Crisis Tracker Dashboard to map and prioritize these issues, then the Deviation and Incident Report Form to detail the highest-priority issue (Pharmacy error) with RCA, ensuring NABH Standard COP.7 (Care of Patient) compliance.

Deliverables 

Crisis Tracker Dashboard (100–150 words across Issue Description, Containment Action Taken, Additional Comments) to map and prioritize issues.
Deviation and Incident Report Form (100–150 words across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) for the Pharmacy error.",https://drive.google.com/file/d/1nwk4AWRmAQbWIhxlQ5T3urlD4P_B3oBR/view?usp=sharing,https://tally.so/r/mYABqv | https://tally.so/r/3jVqb9,https://drive.google.com/file/d/11_yUF3-aZszRGV_j4taQsq90I-1s-Ce7/view?usp=sharing,"Click “Reference Documents” to review SOP-PH-001, SOP-QA-012, Pharmacy Dispensing Log, and Hand Hygiene Compliance Log.
Map issues: List Pharmacy error and ICU log issues, prioritize Pharmacy (higher risk).
Open “Fillable Document” (Crisis Tracker Dashboard).
Fill Dashboard: Describe issues, assign priorities (Pharmacy: High), note containment, link to Deviation IDs. Submit via “Answer Portal”.
Detail priority issue (Pharmacy error): Use Dashboard output for RCA.
Open “Fillable Document” (Deviation and Incident Report Form).
Fill Deviation Form: Describe Pharmacy error, note immediate actions, perform RCA (5 Whys), propose preliminary CAPA. Submit via “Answer Portal”.
Tip: Prioritize Pharmacy issue for patient safety; link IDs across forms for traceability.",10
course_1,ch_1_02,les_1_02_10,task_1_02_10_1,Pro Training in QA/QC ,For pharma & healthcare with enterprise-level validation systems & AI-augmented audit intelligence,Hospital Quality Command Protocols,Command Debrief – Findings Review & Strategy Redesign,Full-Facility Compliance Debrief Simulation,"You are a Junior Quality Control Analyst at Zenith Hospital, reporting to Dr. Vikram Desai, QA Lead. During a full-facility audit debrief, you review two findings from Ward 5 (ICU) and Ward 9 (Orthopedic Unit): (1) a 3-minute oxygen supply interruption due to a faulty regulator (critical, risking patient safety), and (2) incomplete training records for SOP-QA-016 (4/10 entries missing). 

Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate and prioritize these findings, then the CAPA Command Template to detail corrective/preventive actions for the oxygen issue, ensuring NABH Standard CQI.3 (Continuous Quality Improvement) compliance.

Deliverables

Crisis Tracker Dashboard (100–150 words across Issue Description, Containment Action Taken, Additional Comments) to consolidate and prioritize findings.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for the oxygen issue.",https://drive.google.com/file/d/1gz1mwQnqatonQgca6UFpEAIpg58eYCqx/view?usp=sharing,https://tally.so/r/mYABqv | https://tally.so/r/mDGOYl ,https://drive.google.com/file/d/1pn2MquNMI-i43eKaHoHi_XJHkzbHik0p/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-019, SOP-QA-020, Oxygen Supply Log, and Training Record Log.
Consolidate findings: List oxygen interruption and training record issues, prioritize oxygen (critical risk).
Open “Fillable Document” (Crisis Tracker Dashboard).
Fill Dashboard: Describe issues, assign priorities (oxygen: High), note containment, link to Deviation IDs. Submit via “Answer Portal”.
Detail priority issue (oxygen interruption): Use Dashboard output for CAPA planning.
Open “Fillable Document” (CAPA Command Template).
Fill CAPA Template: Reference oxygen issue Deviation ID, perform RCA, propose corrective/preventive actions, plan verification. Submit via “Answer Portal”.
Tip: Prioritize oxygen issue for patient safety; link IDs for traceability.",10
,,,,,,,,,,,,,,
course_1,ch_1_03,les_1_03_01,task_1_03_01_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,"Blueprint of GMP – Principles, History & Core Requirements",GMP Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Priya Sharma, QA Manager. During a routine GMP audit in the Tablet Manufacturing Unit, you review the Batch Production Record (BPR-2025-045) against SOP-QA-022 (GMP Batch Documentation Protocol). You find that 4 out of 10 batch records lack operator signatures, violating GMP 21 CFR Part 211.186 (Master Production and Control Records) and risking audit failure. Dr. Sharma instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the GMP audit findings and proposed improvements for compliance.",https://drive.google.com/file/d/1r_-mNWosJv52XNHlFuGZZmPL8-6ud1sg/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1JCwShApxlZcdMauEp7uLYlAeT3Ft8tjd/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-022 and Batch Production Record
Compare SOP-QA-022 (requires operator signatures for all batch records) to BPR-2025-045 (missing signatures)
Open “Fillable Document” (Compliance Verification Form)
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing signatures), detail deviation, and suggest improvements (e.g., retrain operators, add digital signatures)
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_02,task_1_03_02_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,Facility Fortress – Cleanroom Classifications & Environmental Controls,Cleanroom Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Priya Sharma, QA Manager. During a routine cleanroom audit in the Sterile Injectable Unit (ISO 5), you review the Environmental Monitoring Log (LOG-2025-041) against SOP-QA-023 (Cleanroom Environmental Control Protocol). You find that particle counts in 3 out of 10 samples exceed ISO 5 limits (3,520 particles ≥0.5 μm/m³), violating GMP 21 CFR Part 211.42 and risking contamination. Dr. Sharma instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the cleanroom audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1wJGIz4yl7iQlmp6COlynOjxZMgjoCfJv/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1SWgM-HLD69pOjaqzYa3aCun1gJCRgiA3/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-023 and Environmental Monitoring Log  
Compare SOP-QA-023 (requires ISO 5 particle limits) to LOG-2025-041 (exceeding limits)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check criteria (e.g., Safety protocols followed: NO), provide REMARKS (e.g., excessive particle counts), recommend improvements in Others/Additional Observations (e.g., replace HEPA filters, retrain staff)  
Submit via “Answer Portal”
",10
course_1,ch_1_03,les_1_03_03,task_1_03_03_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,"Personnel in Command – Gowning, Hygiene & Cross-Contamination Barriers",Gowning and Hygiene Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Anil Gupta, QA Manager. During a routine GMP audit in the Sterile Injectable Unit (ISO 5 cleanroom), you review the Gowning Compliance Log (LOG-2025-042) against SOP-QA-024 (Gowning and Hygiene Protocol). You find that 3 out of 10 gowning entries lack verification of sterile glove donning, violating GMP 21 CFR Part 211.28 (Personnel Responsibilities) and risking contamination. Dr. Gupta instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the gowning and hygiene audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1X_6eRBhX3tzO8Fo4r4HtToVvCe1xQqTj/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1f_mtN4YNvFzIQ7WZWiDmj6jdGZFy1-RW/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-024 and Gowning Compliance Log  
Compare SOP-QA-024 (requires verification of sterile glove donning) to LOG-2025-042 (missing verifications)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check criteria (e.g., Safety protocols followed: NO), provide REMARKS (e.g., missing glove verifications), recommend improvements in Others/Additional Observations (e.g., retrain staff, add digital checks)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_04,task_1_03_04_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,"Documented Truth – Batch Records, Logbooks & Controlled Documentation",GMP Documentation Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Priya Sharma, QA Manager. During a routine GMP audit in the Capsule Manufacturing Unit, you review the Batch Production Record (BPR-2025-046) against SOP-QA-025 (GMP Controlled Documentation Protocol). You find that 3 out of 10 batch record entries lack real-time timestamps, violating GMP 21 CFR Part 211.186 (Master Production and Control Records) and risking audit failure. Dr. Sharma instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the GMP documentation audit findings and proposed improvements for compliance.",https://drive.google.com/file/d/1v9sWmJUxPkDzEQOFLlH55KFmKpJC1fy9/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1_DTJLJwyj2vaA3cmASmzuDeDjThDIVq2/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-025 and Batch Production Record  
Compare SOP-QA-025 (requires real-time timestamps for batch records) to BPR-2025-046 (missing timestamps)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing timestamps), detail deviation, and suggest improvements (e.g., retrain operators, implement eDMS)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_05,task_1_03_05_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,"Raw Material Gatekeeping – Sampling, Storage & Supplier Qualification",Raw Material Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Anil Gupta, QA Manager. During a routine GMP audit in the Raw Material Warehouse, you review the Raw Material Receipt Log (LOG-2025-043) against SOP-QA-026 (Raw Material Sampling and Storage Protocol). You find that 3 out of 10 API batches lack Certificates of Analysis (CoA), violating GMP 21 CFR Part 211.84 (Testing and Approval/Rejection of Components). Dr. Gupta instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the raw material audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1oeHleqIre5QG0cReDfMNUGi1L75ArF_H/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1sLnxT-CLvw9BKenaMJfFctRmxT2XOTL4/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-026 and Raw Material Receipt Log  
Compare SOP-QA-026 (requires CoA for all API batches) to LOG-2025-043 (missing CoAs)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check criteria (e.g., Documentation complete and accurate: NO), provide REMARKS (e.g., missing CoAs), recommend improvements in Others/Additional Observations (e.g., retrain staff, update supplier agreements)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_06,task_1_03_06_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,"Line of Defense – Equipment Validation, Cleaning & Maintenance Cycles",Equipment Validation and Maintenance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Priya Sharma, QA Manager. During a routine GMP audit in the Tablet Manufacturing Unit, you review the Equipment Calibration Log (LOG-2025-044) against SOP-QA-027 (Equipment Validation and Maintenance Protocol). You find that 3 out of 10 calibration entries for a tablet press (Equipment ID: COMP-02) lack verification signatures, violating GMP 21 CFR Part 211.67 (Equipment Cleaning and Maintenance). Dr. Sharma instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the equipment audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1V9PSBy_OxFF54iozx0geLdIFTOdI5F-1/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1zAe6G9vXYfSEQnqEwe7Tzu0JJAtYR1cX/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-027 and Equipment Calibration Log  
Compare SOP-QA-027 (requires signed calibration verifications) to LOG-2025-044 (missing signatures)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check criteria (e.g., Equipment status verified: NO), provide REMARKS (e.g., missing signatures), recommend improvements in Others/Additional Observations (e.g., retrain technicians, add digital logging)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_07,task_1_03_07_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,The Critical Path – Process Validation & Change Control Systems,Process Validation and Change Control Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Priya Sharma, QA Manager. During a routine GMP audit in the Capsule Manufacturing Unit, you review the Change Control Log (LOG-2025-045) against SOP-QA-028 (Process Validation and Change Control Protocol). You find that 2 out of 10 change control entries for a new mixing blade lack validation data, violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Sharma instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the change control audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1qKPULKut67nQXAiL22maAezfAoAR7HAM/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1EDQ9XLVyJD79qXhZQlRf7O2P7WiXq4CS/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-028 and Change Control Log  
Compare SOP-QA-028 (requires validation data for all changes) to LOG-2025-045 (missing validation data)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing validation data), detail deviation, and suggest improvements (e.g., retrain staff, update SOP)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_08,task_1_03_08_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,Quality on the Floor – In-Process Controls & Batch Release Protocols,In-Process Controls and Batch Release Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Anil Gupta, QA Manager. During a routine GMP audit in the Tablet Manufacturing Unit, you review the In-Process Control Log (LOG-2025-046) against SOP-QA-029 (In-Process Controls and Batch Release Protocol). You find that 3 out of 10 in-process tablet weight checks lack recorded results, violating GMP 21 CFR Part 211.110 (Sampling and Testing of In-Process Materials). Dr. Gupta instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the in-process control audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1hvvgXr40dDyaqtP3Np2V5SQK5tgf2Eg4/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1RBSaiQZJ1EDXBggrUdaCqzQZ5vY3wY_r/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-029 and In-Process Control Log  
Compare SOP-QA-029 (requires recorded in-process weight checks) to LOG-2025-046 (missing results)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing weight checks), detail deviation, and suggest improvements (e.g., retrain operators, implement digital logging)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_09,task_1_03_09_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,"Regulatory Battlefield – WHO, USFDA, EU vs Indian GMP Codes",GMP Regulatory Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Priya Sharma, QA Manager. During a routine GMP audit in the Sterile Injectable Unit (ISO 5 cleanroom), you review the Data Integrity Log (LOG-2025-047) against SOP-QA-030 (GMP Documentation Compliance Protocol). You find that 3 out of 10 batch record entries lack audit trail documentation, violating USFDA GMP 21 CFR Part 211.188 (Batch Production and Control Records) and risking export market compliance. Dr. Sharma instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the GMP regulatory audit findings and proposed improvements for compliance.",https://drive.google.com/file/d/1mdTzcJSDJKCy5OEFXwYaDR6_Mtelc81y/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1_WEV0_m6h0dTEbqRLMOdnhcqB2AiHZ3W/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-030 and Data Integrity Log  
Compare SOP-QA-030 (requires audit trail for batch records) to LOG-2025-047 (missing audit trails)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing audit trails), detail deviation, and suggest improvements (e.g., retrain staff, implement eDMS)  
Submit via “Answer Portal”",10
course_1,ch_1_03,les_1_03_10,task_1_03_10_1,Pro Training in QA/QC ,,Pharma GMP Compliance Playbook,GMP War Game – Full-Scale Production Floor Compliance Simulation,Full-Scale GMP Compliance Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a full-scale GMP war game in the Sterile Injectable Unit (ISO 5 cleanroom), you identify two issues: (1) incomplete batch record entries (3/10 lack audit trails, critical for USFDA compliance), and (2) unverified equipment cleaning for a filling machine (FILL-01). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate and prioritize these issues, then the CAPA Command Template to detail corrective/preventive actions for the batch record issue, ensuring USFDA GMP 21 CFR Part 211.188 compliance for a mock audit.

Deliverables

Crisis Tracker Dashboard (100–150 words across Issue Description, Containment Action Taken, Additional Comments) to consolidate and prioritize issues.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for the batch record issue.",https://drive.google.com/file/d/1oo9XSJoudJdtZdHUaTeCkt3WP58dB34u/view?usp=sharing,https://tally.so/r/mYABqv | https://tally.so/r/mDGOYl ,https://drive.google.com/file/d/1ovm7Yl4TTrE3n09H57LLLLODF8qR6JL-/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-030, SOP-QA-027, Data Integrity Log, and Equipment Calibration Log  
Consolidate findings: List batch record and equipment cleaning issues, prioritize batch records (critical risk)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill Dashboard: Describe issues, assign priorities (batch records: High), note containment, link to Deviation IDs. Submit via “Answer Portal”  
Detail priority issue (batch records): Use Dashboard output for CAPA planning  
Open “Fillable Document” (CAPA Command Template)  
Fill CAPA Template: Reference batch record Deviation ID, perform RCA, propose corrective/preventive actions, plan verification. Submit via “Answer Portal”  
Tip: Prioritize batch records for USFDA compliance; link IDs for traceability",10
,,,,,,,,,,,,,,
course_1,ch_1_04,les_1_04_01,task_1_04_01_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"The SOP Arsenal – Structure, Scope & Regulatory Mandates",SOP Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Tablet Manufacturing Unit, you review the SOP Registry Log (LOG-2025-049) against SOP-QA-031 (SOP Management Protocol). You find that 2 out of 10 SOPs lack a defined scope section, violating GMP 21 CFR Part 211.22 (Quality Control Unit Responsibilities) and risking audit failure. Dr. Desai instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the SOP audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1Mk8OIDOd4CHpwAuQP4TIk7Exa4oorig7/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1oNgeaSSZ8Z2-Ju2Cy1DVulzo4jzqG5f1/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-031 and SOP Registry Log  
Compare SOP-QA-031 (requires defined scope for all SOPs) to LOG-2025-049 (missing scope sections)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Documentation complete and accurate: B - FAIL), provide REMARKS (e.g., missing scope sections), detail deviation, and suggest improvements (e.g., revise SOPs, retrain staff)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_02,task_1_04_02_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"Writing That Commands – Clarity, Precision & Zero-Ambiguity Rules",SOP Writing Quality Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Capsule Manufacturing Unit, you review SOP-QA-040 (Capsule Mixing Protocol) against SOP-QA-032 (SOP Writing and Review Protocol). You find that 3 out of 10 procedural steps in SOP-QA-040 use vague terms (e.g., “mix thoroughly” instead of “mix at 500 rpm for 10 minutes”), violating GMP 21 CFR Part 211.22 (Quality Control Unit Responsibilities). Dr. Desai instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the SOP writing audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1ooKhEjFxxgbDdiE2yQmCdvwZM55p0YJY/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1oZuQ3bNpawSPG-xJdwmuZQFt9qs1uDSI/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-032 and SOP-QA-040  
Compare SOP-QA-032 (requires precise, clear SOP language) to SOP-QA-040 (vague terms)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., SOP followed: B - FAIL), provide REMARKS (e.g., vague procedural steps), detail deviation, and suggest improvements (e.g., revise SOP, retrain staff)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_03,task_1_04_03_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"Controlled Evolution – Version Control, Review Cycles & Change Logs",SOP Version Control CAPA Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP audit in the Tablet Manufacturing Unit, you identify that 2 out of 10 entries in the Change Log (LOG-2025-050) for SOP-QA-041 (Tablet Compression Protocol) lack approval signatures, violating GMP 21 CFR Part 211.22 (Quality Control Unit Responsibilities). Dr. Desai instructs you to use the CAPA Command Template to outline corrective and preventive actions to address this deviation (DEV-2025-109) and ensure audit-readiness for an upcoming USFDA audit.

Deliverables 

Completed CAPA Command Template (100–150 words total across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) documenting corrective/preventive actions for the SOP change log deviation.",https://drive.google.com/file/d/1qPIO-bVqj6_IPhl8DaW_WPMMokcZ3IJ6/view?usp=sharing,https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1VXhREjw3pOKGR1LgM3jiFcMEWKzUNWp_/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-033 and Change Log  
Review SOP-QA-033 (requires approval signatures for change log entries) and LOG-2025-050 (missing signatures)  
Open “Fillable Document” (CAPA Command Template)  
Fill the form: Reference DEV-2025-109, perform RCA, propose corrective actions (e.g., complete signatures), preventive actions (e.g., digital approval system), and verification plan  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_04,task_1_04_04_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"Validation Warfare – IQ, OQ, PQ & System Qualification Essentials",Validation Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Sterile Injectable Unit, you review the Validation Report Log (LOG-2025-051) against SOP-QA-034 (Equipment Validation Protocol). You find that 2 out of 10 OQ entries for a filling machine (FILL-02) lack test result documentation, violating GMP 21 CFR Part 211.68 (Automatic, Mechanical, and Electronic Equipment). Dr. Desai instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the validation audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1ftiOX_94lI8H7NkOl3JcemN0_D6Hhb2A/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1dInxgd5l1C0Q5CKq2wvXHuvhedM93L1M/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-034 and Validation Report Log  
Compare SOP-QA-034 (requires documented OQ test results) to LOG-2025-051 (missing results)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check criteria (e.g., Documentation complete: NO), provide REMARKS (e.g., missing OQ results), recommend improvements in Others/Additional Observations (e.g., complete OQ records, retrain staff)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_05,task_1_04_05_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"Critical Protocols – Cleaning, Equipment & Safety SOPs in Action",Cleaning SOP Deviation Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Sterile Injectable Unit (ISO 5 cleanroom), you review the Cleaning Validation Log (LOG-2025-052) against SOP-QA-035 (Cleaning Validation Protocol). You find that 3 out of 10 cleaning entries for a filling machine (FILL-03) lack swab test results, violating GMP 21 CFR Part 211.67 (Equipment Cleaning and Maintenance). Dr. Desai instructs you to document the deviation and propose corrective actions using the Deviation and Incident Report Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the cleaning SOP deviation and proposed actions for GMP compliance.",https://drive.google.com/file/d/1AvsL5ah82zDH_EvR55ahudMkfM6-ljl7/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1p4Dt489QWhS1MZt7XhivV7JlguYMrkkS/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-035 and Cleaning Validation Log  
Compare SOP-QA-035 (requires swab test results for cleaning validation) to LOG-2025-052 (missing results)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill the form: Describe deviation, note immediate actions (e.g., re-clean equipment), perform RCA (e.g., 5 Whys), propose preliminary CAPA (e.g., retrain staff)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_06,task_1_04_06_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"Human Factor – Training, Compliance Tracking & Competency Records",Training and Competency Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Sterile Injectable Unit, you review the Competency Record Log (LOG-2025-053) against SOP-QA-036 (Training and Competency Protocol). You find that 3 out of 10 training entries for cleanroom operators lack completion signatures, violating GMP 21 CFR Part 211.25 (Personnel Qualifications). Dr. Desai instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the training audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1_TqiORroRxoEmUikhwhmf7Bai36ugrbA/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1RbEcSJ2etjI7W0oXKPxizuR7-lOQxqvj/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-036 and Competency Record Log  
Compare SOP-QA-036 (requires signed training completions) to LOG-2025-053 (missing signatures)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Training/competency verified: B - FAIL), provide REMARKS (e.g., missing signatures), detail deviation, and suggest improvements (e.g., retrain staff, update records)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_07,task_1_04_07_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,Gaps & Breaches – SOP Deviation Handling & Escalation Models,SOP Deviation Handling Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Tablet Manufacturing Unit, you review the Batch Production Record (BPR-2025-048) against SOP-QA-037 (Tablet Compression Protocol). You find that 3 out of 10 compression steps skipped in-process weight checks, violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to document the deviation and propose corrective actions using the Deviation and Incident Report Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the SOP deviation and proposed actions for GMP compliance.",https://drive.google.com/file/d/1UFCNJ4J648Ftw9sCo5O-dq_w9PUXdIOP/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/17hhSpYGpnc68VIyLkaZnLyTCMLOFAgcH/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-037 and Batch Production Record  
Compare SOP-QA-037 (requires in-process weight checks) to BPR-2025-048 (missing checks)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill the form: Describe deviation, note immediate actions (e.g., quarantine batches), perform RCA (e.g., 5 Whys), propose preliminary CAPA (e.g., retrain operators)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_08,task_1_04_08_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,"Digital Command – eSOP Systems, Access Hierarchies & 21 CFR Part 11",eSOP System Compliance Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Sterile Injectable Unit, you review the eSOP Audit Trail Log (LOG-2025-054) against SOP-QA-038 (eSOP System Management Protocol). You find that 3 out of 10 eSOP access entries lack audit trail documentation, violating 21 CFR Part 11 (Electronic Records; Electronic Signatures). Dr. Desai instructs you to document the findings and recommend improvements using the Compliance Verification Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Compliance Verification Form (100–150 words total across REMARKS, Deviation Details, Suggested Improvements) documenting the eSOP audit findings and proposed improvements for GMP and 21 CFR Part 11 compliance.",https://drive.google.com/file/d/1oXtOFYXpmPjOGn0x7vecZIpe-WXJ-0s5/view?usp=sharing,https://tally.so/r/m6Bzeo,https://drive.google.com/file/d/1PpW-viYKU-NxckKglTGTSerxxcEdyHZp/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-038 and eSOP Audit Trail Log  
Compare SOP-QA-038 (requires audit trail for all eSOP actions) to LOG-2025-054 (missing audit trails)  
Open “Fillable Document” (Compliance Verification Form)  
Fill the form: Check criteria (e.g., Documentation complete: B - FAIL), provide REMARKS (e.g., missing audit trails), detail deviation, and suggest improvements (e.g., retrain staff, update system)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_09,task_1_04_09_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,Audit Crossfire – SOP Review Under Regulatory Inspection Pressure,SOP Audit Simulation Under Regulatory Pressure,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a mock USFDA audit in the Tablet Manufacturing Unit, you review the SOP Registry Log (LOG-2025-055) against SOP-QA-039 (SOP Management and Audit Protocol). You find that 2 out of 10 SOPs are outdated (using v1.0 instead of v2.0), violating GMP 21 CFR Part 211.22 (Quality Control Unit Responsibilities). Dr. Desai instructs you to document the findings and recommend improvements using the Audit & Inspection Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) documenting the SOP audit findings and proposed improvements for GMP compliance.",https://drive.google.com/file/d/1AKlzmsrvG24BPdOnsM-Tn2cSbaFeku4R/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1JXr4XPPqFwwPnBFVIj6OlCXurXGiO52P/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-039 and SOP Registry Log  
Compare SOP-QA-039 (requires current SOP versions) to LOG-2025-055 (outdated versions)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check criteria (e.g., SOP followed: NO), provide REMARKS (e.g., outdated SOPs), recommend improvements in Others/Additional Observations (e.g., update SOPs, retrain staff)  
Submit via “Answer Portal”",10
course_1,ch_1_04,les_1_04_10,task_1_04_10_1,Pro Training in QA/QC ,,SOP Authoring and Validation Systems,The Validation Gauntlet – Full-Scale SOP Creation & Enforcement Drill,Full-Scale SOP Creation and Enforcement Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a full-scale GMP validation gauntlet in the Sterile Injectable Unit (ISO 5 cleanroom), you identify two issues: (1) vague steps in SOP-QA-042 (Sterile Filling Protocol, violating clarity rules), and (2) missing training signatures in Competency Record Log (LOG-2025-056). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate and prioritize these issues, then the CAPA Command Template to detail corrective/preventive actions for the vague SOP issue, ensuring USFDA GMP 21 CFR Part 211.22 compliance for a mock audit.

Deliverables 

Crisis Tracker Dashboard (100–150 words across Issue Description, Containment Action Taken, Additional Comments) to consolidate and prioritize issues.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for the vague SOP issue.",https://drive.google.com/file/d/1Rr7_Ns1eS6buIaDiApzQHCR4QMJtPm4y/view?usp=sharing,https://tally.so/r/mYABqv | https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1sZCsNmsuvtbNIz4k2oy63Asar-wszzkh/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-032, SOP-QA-042, and Competency Record Log  
Consolidate findings: List vague SOP steps and missing training signatures, prioritize SOP issue (critical for compliance)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill Dashboard: Describe issues, assign priorities (SOP: High), note containment, link to Deviation IDs. Submit via “Answer Portal”  
Detail priority issue (vague SOP): Use Dashboard output for CAPA planning  
Open “Fillable Document” (CAPA Command Template)  
Fill CAPA Template: Reference SOP Deviation ID, perform RCA, propose corrective/preventive actions, plan verification. Submit via “Answer Portal”  
Tip: Prioritize SOP issue for audit-readiness; link IDs for traceability",10
,,,,,,,,,,,,,,
course_1,ch_1_05,les_1_05_01,task_1_05_01_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,Breach Point – Types of Deviations & First-Response Protocols,Deviation Response Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP audit in the Tablet Manufacturing Unit, you review the Batch Production Record (BPR-2025-050) against SOP-QA-043 (Tablet Mixing Protocol). You find that 3 out of 10 mixing log entries lack operator signatures, a minor deviation violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to document the deviation and propose first-response actions using the Deviation and Incident Report Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the deviation and proposed actions for GMP compliance.",https://drive.google.com/file/d/16n6rUKfQnSSJVhrzzn5awluPIeW3dTRO/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1P92_i_qu7nKD--Lj5eGg06UJSRjKzcLv/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-043 and Batch Production Record  
Compare SOP-QA-043 (requires signed mixing log entries) to BPR-2025-050 (missing signatures)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill the form: Describe deviation, note immediate actions (e.g., correct logs), perform RCA (e.g., 5 Whys), propose preliminary CAPA (e.g., retrain operators)  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_02,task_1_05_02_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,Rapid Fire – Immediate Containment & Impact Assessment Tactics,Deviation Containment and Impact Assessment Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP check in the Sterile Injectable Unit, you review the In-Process Control Log (LOG-2025-057) against SOP-QA-044 (Sterile Filling Protocol). You find that 3 out of 10 fill volume checks show out-of-spec results (beyond ±2%), a major deviation violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to document the deviation, containment actions, and impact assessment using the Deviation and Incident Report Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the deviation, containment, and impact assessment for GMP compliance.",https://drive.google.com/file/d/19k6otYwsdackdB6CoWdSk_dINLjzF9u0/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1N1xrjtBYYVJeGIeOM7xzELcdl-_WiaPw/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-044 and In-Process Control Log  
Compare SOP-QA-044 (requires fill volume within ±2%) to LOG-2025-057 (out-of-spec results)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill the form: Describe deviation, note immediate actions (e.g., quarantine batches), perform RCA (e.g., 5 Whys), propose preliminary CAPA (e.g., recalibrate equipment)  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_03,task_1_05_03_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,"Data Drill – Deviation Registers, Logs & Trending Analysis",Deviation Tracking and Trending Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a routine GMP review in the Tablet Manufacturing Unit, you analyze the Deviation Register (REG-2025-058) against SOP-QA-045 (Deviation Management Protocol). You identify two recurring deviations: (1) missing operator signatures in 3/10 mixing logs (minor), and (2) out-of-spec pH in 2/10 mixing batches (major). Dr. Desai instructs you to consolidate and prioritize these deviations using the Crisis Tracker Dashboard, initiating trending analysis to prepare for an upcoming USFDA audit.

Deliverables 

Completed Crisis Tracker Dashboard (100–150 words total across Issue Description, Containment Action Taken, Additional Comments) consolidating and prioritizing deviations for GMP compliance and trending analysis.",https://drive.google.com/file/d/1d5o_sDVYIt3-4CXPNMsbAR2MuyQbeB-1/view?usp=sharing,https://tally.so/r/mYABqv,https://drive.google.com/file/d/1i4-64Gc_txXNepc250LmsVRIYdZyGU9t/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-045 and Deviation Register  
Compare SOP-QA-045 (requires complete deviation logs) to REG-2025-058 (missing signatures, out-of-spec pH)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill the form: Describe deviations, assign priorities (pH: High, signatures: Medium), note containment actions, and plan trending analysis in Additional Comments  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_04,task_1_05_04_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,"Mapping the Chaos – Fishbone, 5 Whys & Fault Tree Tools",Root Cause Analysis and CAPA Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Tablet Manufacturing Unit, you identify a recurring deviation in the In-Process Control Log (LOG-2025-059) against SOP-QA-046 (Tablet Compression Protocol): 3 out of 10 tablet weight checks are out-of-spec (beyond ±5%), violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to perform RCA using the 5 Whys technique and document corrective/preventive actions using the CAPA Command Template to prepare for an upcoming USFDA audit.

Deliverables 

Completed CAPA Command Template (100–150 words total across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) documenting RCA findings and CAPA for the deviation.",https://drive.google.com/file/d/1pWM6U90gfyWTkQ2mFupVyr9KauWdjdVX/view?usp=sharing,https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1DCPBGZG7R1rH61l3_-iRVCvEMI_KA7_-/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-046 and In-Process Control Log  
Review SOP-QA-046 (requires weight checks within ±5%) and LOG-2025-059 (out-of-spec weights)  
Perform RCA using 5 Whys to identify the root cause  
Open “Fillable Document” (CAPA Command Template)  
Fill the form: Reference DEV-2025-126, document RCA in Additional Comments, propose corrective/preventive actions, and plan verification  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_05,task_1_05_05_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,Root Cause Warfare – From Symptom to True Origin,Root Cause Analysis and CAPA Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, you identify a recurring deviation in the In-Process Control Log (LOG-2025-060) against SOP-QA-047 (Sterile Filling Protocol): 3 out of 10 sterility tests show contamination (positive results), a critical deviation violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to perform RCA using the 5 Whys technique and document corrective/preventive actions using the CAPA Command Template to prepare for an upcoming USFDA audit.

Deliverables 

Completed CAPA Command Template (100–150 words total across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) documenting RCA findings and CAPA for the critical deviation.",https://drive.google.com/file/d/1BTm6sv8NQdphaTaQWCKWsj3cM2KRrR_6/view?usp=sharing,https://tally.so/r/mDGOYl,https://drive.google.com/file/d/10NSyLWFknQCvh3pzAlETjW7CR4zew7Sg/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-047 and In-Process Control Log  
Review SOP-QA-047 (requires negative sterility test results) and LOG-2025-060 (positive results)  
Perform RCA using 5 Whys to identify the root cause  
Open “Fillable Document” (CAPA Command Template)  
Fill the form: Reference DEV-2025-127, document RCA in Additional Comments, propose corrective/preventive actions, and plan verification  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_06,task_1_05_06_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,Crossfire Controls – Human Error vs Systemic Failure Distinction,Human Error vs Systemic Failure RCA Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, you identify a deviation in the In-Process Control Log (LOG-2025-061) against SOP-QA-048 (Sterile Mixing Protocol): 3 out of 10 mixing batches show incorrect API dosing (beyond ±3%), violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to perform RCA using the 5 Whys technique to distinguish human error from systemic failure and document corrective/preventive actions using the CAPA Command Template for an upcoming USFDA audit.

Deliverables 

Completed CAPA Command Template (100–150 words total across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) documenting RCA findings and CAPA for the deviation.",https://drive.google.com/file/d/1GHjnStYiEqGVIeCx7P4EF449GVYizsGE/view?usp=sharing,https://tally.so/r/mDGOYl,https://drive.google.com/file/d/1vrItHi9L6QLD8EuowvqtcZ9IBIo8XTNi/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-048 and In-Process Control Log  
Review SOP-QA-048 (requires API dosing within ±3%) and LOG-2025-061 (incorrect dosing)  
Perform RCA using 5 Whys to distinguish human error vs. systemic failure  
Open “Fillable Document” (CAPA Command Template)  
Fill the form: Reference DEV-2025-128, document RCA in Additional Comments, propose corrective/preventive actions, and plan verification  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_07,task_1_05_07_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,"Evidence Arsenal – Documentation, Witness Reports & Proof Trails",Deviation Evidence Documentation Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, you identify a deviation in the Batch Production Record (BPR-2025-051) against SOP-QA-049 (Sterile Packaging Protocol): 3 out of 10 packaging steps skipped label verification checks, violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). An operator’s witness report confirms the oversight. Dr. Desai instructs you to document the deviation, witness details, and initial proof trail using the Deviation and Incident Report Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the deviation, witness report, and proof trail elements for GMP compliance.",https://drive.google.com/file/d/10Gw839UNpm41pLdmTHa4041XwzlMuJpm/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1HsDn__PaVqlpuWZFvZvz9zuL7Ggk4dsq/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-049 and Batch Production Record  
Compare SOP-QA-049 (requires label verification checks) to BPR-2025-051 (skipped checks) and include witness report details  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill the form: Describe deviation, note immediate actions (e.g., quarantine batch), include witness report in RCA, propose preliminary CAPA (e.g., retrain operators)  
Submit via “Answer Portal”",10
course_1,ch_1_05,les_1_05_08,task_1_05_08_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,"The Escalation Ladder – Minor, Major, Critical Deviation Handling",Deviation Escalation Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, you identify a critical deviation in the Sterility Test Log (LOG-2025-062) against SOP-QA-050 (Sterile Filling Protocol): 3 out of 10 sterility tests show contamination, violating GMP 21 CFR Part 211.100 (Written Procedures; Deviations). Dr. Desai instructs you to document the deviation, containment actions, and escalation to QA/management using the Deviation and Incident Report Form to prepare for an upcoming USFDA audit.

Deliverables 

Completed Deviation and Incident Report Form (100–150 words total across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) documenting the critical deviation, containment, and escalation for GMP compliance.",https://drive.google.com/file/d/1TESeIQsU0XJsDrmxNGjVOrsFOlhe_vKa/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1MjmKKwBG6uwNPBKZ1H4WcMLGancVnIDx/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-050 and Sterility Test Log  
Compare SOP-QA-050 (requires negative sterility tests) to LOG-2025-062 (positive results)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill the form: Describe deviation, note immediate actions (e.g., halt production), perform RCA (e.g., 5 Whys), note escalation to QA/management in CAPA Details  
Submit via “Answer Portal”
",10
course_1,ch_1_05,les_1_05_09,task_1_05_09_1,Pro Training in QA/QC ,,Deviation Tracking and Root Cause Engines,Simulation Siege – End-to-End Deviation Case Battle,End-to-End Deviation Case Battle Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP deviation case battle simulation in the Sterile Injectable Unit, you identify two deviations in the Batch Production Record (BPR-2025-052) against SOP-QA-051 (Sterile Filling Protocol): (1) 3/10 fill volume checks are out-of-spec (beyond ±2%, major deviation), and (2) 2/10 sterility tests show contamination (critical deviation). Dr. Desai instructs you to use the Deviation and Incident Report Form to document the critical sterility deviation, containment, and RCA, then the CAPA Command Template to detail corrective/preventive actions, ensuring USFDA GMP 21 CFR Part 211.100 compliance for a mock audit.

Deliverables

Deviation and Incident Report Form (100–150 words across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) for the sterility deviation.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for corrective/preventive actions.",https://drive.google.com/file/d/1JfB6Q6f5Tw343IEcA8_3pwEUvWcPay1W/view?usp=sharing,https://tally.so/r/3jVqb9 | https://tally.so/r/mDGOYl ,https://drive.google.com/file/d/1nljSjl_3BIs4x5202ilOV7ccwYUXlflx/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-051 and Batch Production Record  
Identify critical sterility deviation in BPR-2025-052 against SOP-QA-051 (negative sterility tests required)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill Deviation Form: Describe sterility deviation, note containment (e.g., halt production), perform RCA (5 Whys), note escalation to QA/management. Submit via “Answer Portal”  
Use Deviation Form output for CAPA planning  
Open “Fillable Document” (CAPA Command Template)  
Fill CAPA Template: Reference DEV-2025-131, detail corrective/preventive actions, plan verification. Submit via “Answer Portal”  
Tip: Prioritize critical sterility deviation for audit-readiness; link IDs for traceability",10
,,,,,,,,,,,,,,
course_1,ch_1_06,les_1_06_01,task_1_06_01_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,CAPA Command – Core Concepts & Regulatory Expectations,GMP Deviation Management and CAPA Implementation for Sterile Injectable Manufacturing,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, you identify two deviations in the In-Process Control Log (LOG-2025-063) against SOP-QA-052 (Sterile Mixing Protocol): (1) 3/10 API dosing checks are out-of-spec (beyond ±3%, major deviation), and (2) 2/10 sterility tests show contamination (critical deviation). Dr. Desai instructs you to use the Deviation and Incident Report Form to document the critical sterility deviation, RCA, and containment, then the CAPA Command Template to detail corrective/preventive actions and effectiveness checks, ensuring USFDA GMP 21 CFR Part 211.100 compliance for a mock audit.

Deliverables

Deviation and Incident Report Form (100–150 words across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) for the sterility deviation.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for corrective/preventive actions.",https://drive.google.com/file/d/1MU-Ov7vnPDkD0jd1u_iB8xFsmyqoo3YB/view?usp=sharing,https://tally.so/r/3jVqb9 | https://tally.so/r/mDGOYl ,https://drive.google.com/file/d/1VyG0u8YZ3YB1P5RB5XR_LmI1RhmLNVNu/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-052 and In-Process Control Log  
Identify critical sterility deviation in LOG-2025-063 against SOP-QA-052 (negative sterility tests required)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill Deviation Form: Describe sterility deviation, note containment (e.g., halt production), perform RCA (5 Whys), note escalation to QA/management. Submit via “Answer Portal”  
Use Deviation Form output for CAPA planning  
Open “Fillable Document” (CAPA Command Template)  
Fill CAPA Template: Reference DEV-2025-132, detail corrective/preventive actions, plan effectiveness checks. Submit via “Answer Portal”  
Tip: Prioritize critical sterility deviation for audit-readiness; link IDs for traceability",10
course_1,ch_1_06,les_1_06_02,task_1_06_02_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,From Firefight to Framework – CAPA Lifecycle Stages Explained,CAPA Lifecycle Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Tablet Manufacturing Unit, you identify two deviations in the In-Process Control Log (LOG-2025-064) against SOP-QA-053 (Tablet Mixing Protocol): (1) 3/10 pH checks are out-of-spec (beyond 6.8–7.2, major deviation), and (2) 2/10 mixing logs lack operator signatures (minor deviation). Dr. Desai instructs you to use the Deviation and Incident Report Form to document the major pH deviation, containment, and RCA, then the CAPA Command Template to detail corrective/preventive actions and effectiveness checks, ensuring USFDA GMP 21 CFR Part 211.100 compliance for a mock audit.

Deliverables
Deviation and Incident Report Form (100–150 words across Incident Description, Immediate Action Taken, Root Cause Analysis, CAPA Details) for the pH deviation.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for corrective/preventive actions.",https://drive.google.com/file/d/1pVGT0NQWYMy1IPxBGfknR4pw-fyUvgA0/view?usp=sharing,https://tally.so/r/3jVqb9 | https://tally.so/r/mDGOYl ,https://drive.google.com/file/d/1YUm1rUYNA-1F5XgHxhYs6Ryzv6biY9gm/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-053 and In-Process Control Log  
Identify major pH deviation in LOG-2025-064 against SOP-QA-053 (pH 6.8–7.2 required)  
Open “Fillable Document” (Deviation and Incident Report Form)  
Fill Deviation Form: Describe pH deviation, note containment (e.g., quarantine batch), perform RCA (5 Whys), note initial CAPA. Submit via “Answer Portal”  
Use Deviation Form output for CAPA planning  
Open “Fillable Document” (CAPA Command Template)  
Fill CAPA Template: Reference DEV-2025-134, detail corrective/preventive actions, plan effectiveness checks. Submit via “Answer Portal”  
Tip: Prioritize pH deviation for audit-readiness; link IDs for traceability",10
course_1,ch_1_06,les_1_06_03,task_1_06_03_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,AI at the Frontline – Machine Learning for Deviation Pattern Detection,ML-Driven Deviation Detection Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Tablet Manufacturing Unit, an ML model (validated per GAMP 5) analyzing the In-Process Control Log (LOG-2025-065) against SOP-QA-054 (Tablet Mixing Protocol) flags two recurring deviations: (1) 3/10 pH checks out-of-spec (beyond 6.8–7.2, major deviation), and (2) 2/10 mixing logs lack operator signatures (minor deviation). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate these ML-detected deviations, prioritize actions, and document validation for an upcoming USFDA audit, ensuring 21 CFR Part 211.100 compliance.

Deliverables 

Completed Crisis Tracker Dashboard (100–150 words total across Issue Description, Containment Action Taken, Additional Comments) consolidating ML-detected deviations and prioritizing actions for GMP compliance.",https://drive.google.com/file/d/1h-u8Y2FGmc04pCW1S5bmV5KSzPxW3zAa/view?usp=sharing,https://tally.so/r/mYABqv,https://drive.google.com/file/d/1ByayLIhL3xQrpmwojJz327bXxzl626Y7/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-054 and In-Process Control Log  
Review SOP-QA-054 (requires pH 6.8–7.2, signed logs) and LOG-2025-065 (ML-flagged deviations)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill the form: Describe ML-detected deviations, assign priorities (pH: High, signatures: Medium), note containment actions, and document ML validation in Additional Comments  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_04,task_1_06_04_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,"Smart Triggers – Automated Alerts, Dashboards & Risk Prioritization",Automated Deviation Detection Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, a validated QMS-integrated alert system (GAMP 5-compliant) analyzing the In-Process Control Log (LOG-2025-066) against SOP-QA-055 (Sterile Filling Protocol) flags two deviations: (1) 3/10 fill volume checks out-of-spec (beyond ±2%, major deviation), and (2) 2/10 sterility tests show contamination (critical deviation). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate these alert-detected deviations, prioritize risks, and document system validation for an upcoming USFDA audit, ensuring 21 CFR Part 211.100 and Annex 11 compliance.

Deliverables 

Completed Crisis Tracker Dashboard (100–150 words total across Issue Description, Containment Action Taken, Additional Comments) consolidating alert-detected deviations and prioritizing actions for GMP compliance.",https://drive.google.com/file/d/1KahGErjsx2AMGMmm-_hFxp7kaeFIAKLB/view?usp=sharing,https://tally.so/r/mYABqv,https://drive.google.com/file/d/1s8wviio5BVpmqp-6wu2kS7kMSGsVojab/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-055 and In-Process Control Log  
Review SOP-QA-055 (requires fill volume ±2%, negative sterility tests) and LOG-2025-066 (alert-flagged deviations)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill the form: Describe alert-detected deviations, assign priorities (sterility: High, volume: Medium), note containment actions, document QMS validation in Additional Comments  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_05,task_1_06_05_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,Escalation Pathways – Local vs Global CAPA Decision Chains,CAPA Escalation Pathway Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, a QMS-integrated system analyzing the In-Process Control Log (LOG-2025-067) against SOP-QA-056 (Sterile Filling Protocol) flags two deviations: (1) 3/10 fill volume checks out-of-spec (beyond ±2%, major deviation, local CAPA), and (2) 2/10 sterility tests show contamination (critical deviation, global CAPA). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate these deviations, assign local/global CAPA pathways, and document escalation for an upcoming USFDA audit, ensuring 21 CFR Part 211.100 and Annex 11 compliance.

Deliverables 
Completed Crisis Tracker Dashboard (100–150 words total across Issue Description, Containment Action Taken, Additional Comments) consolidating deviations and assigning CAPA pathways for GMP compliance.",https://drive.google.com/file/d/1J2OwUXU31FwH8IuC4s5AHKcnmkxAnO5-/view?usp=sharing,https://tally.so/r/mYABqv,https://drive.google.com/file/d/1nE86fNuSGdG-bXuc1e7Jy1GbJTE5XdPH/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-056 and In-Process Control Log  
Review SOP-QA-056 (requires fill volume ±2%, negative sterility tests) and LOG-2025-067 (flagged deviations)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill the form: Describe deviations, assign priorities (sterility: High, global CAPA; volume: Medium, local CAPA), note containment, document escalation in Additional Comments  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_06,task_1_06_06_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,Precision Counterstrikes – Corrective vs Preventive Action Differentiation,Corrective vs Preventive Action Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Tablet Manufacturing Unit, a QMS-integrated alert flags a deviation in the In-Process Control Log (LOG-2025-068) against SOP-QA-057 (Tablet Compression Protocol): 3 out of 10 tablet weight checks are out-of-spec (beyond ±5%), a major deviation violating GMP 21 CFR Part 211.100. Dr. Desai instructs you to perform RCA using 5 Whys and document corrective and preventive actions using the CAPA Command Template, ensuring clear differentiation for an upcoming USFDA audit.

Deliverables 
Completed CAPA Command Template (100–150 words total across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) documenting RCA findings, corrective, and preventive actions for GMP compliance.",https://drive.google.com/file/d/1XVVJ2rxTDEFZr7Au1tQtv1PXD2lBnDuA/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1EGWy-664OrCDwboMPaZfRtXowk5oyA0e/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-057 and In-Process Control Log  
Review SOP-QA-057 (requires weight checks within ±5%) and LOG-2025-068 (out-of-spec weights)  
Perform RCA using 5 Whys to identify the root cause  
Open “Fillable Document” (CAPA Command Template)  
Fill the form: Reference DEV-2025-142, document RCA in Additional Comments, detail corrective/preventive actions, plan verification  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_07,task_1_06_07_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,Evidence Intelligence – AI-Supported Root Cause Verification,AI-Supported RCA and CAPA Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, a GAMP 5-validated AI model analyzing the In-Process Control Log (LOG-2025-069) against SOP-QA-058 (Sterile Filling Protocol) flags a recurring deviation: 3 out of 10 sterility tests show contamination, a critical deviation violating GMP 21 CFR Part 211.100. The AI confirms a root cause tied to a faulty cleanroom filter. Dr. Desai instructs you to document the AI-verified root cause and corrective/preventive actions using the CAPA Command Template for an upcoming USFDA audit, ensuring 21 CFR Part 211.100 and Annex 11 compliance.

Deliverables 

Completed CAPA Command Template (100–150 words total across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) documenting AI-verified RCA findings and CAPA for the deviation.",https://drive.google.com/file/d/1l5nMH-a_CKfx1Y0kZP-DJn7zu4h3jLWa/view?usp=sharing,https://tally.so/r/3jVqb9,https://drive.google.com/file/d/1MD9y2RfHuAzhkPTr6ekMZwt_I4GeDHYZ/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-058 and In-Process Control Log  
Review SOP-QA-058 (requires negative sterility tests) and LOG-2025-069 (AI-flagged contamination)  
Perform RCA using AI model output to verify the root cause  
Open “Fillable Document” (CAPA Command Template)  
Fill the form: Reference DEV-2025-143, document AI-verified RCA in Additional Comments, detail corrective/preventive actions, plan verification  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_08,task_1_06_08_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,"System Defense – Integrating CAPA with QMS, LIMS & eTMF Platforms",CAPA System Integration Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a GMP review in the Sterile Injectable Unit, a QMS-integrated system (GAMP 5-validated) analyzing data from QMS, LIMS, and eTMF against SOP-QA-059 (Sterile Filling Protocol) flags two deviations in the In-Process Control Log (LOG-2025-070): (1) 3/10 fill volume checks out-of-spec (beyond ±2%, major deviation), and (2) 2/10 sterility tests show contamination (critical deviation). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate these deviations, document system integration details, and prioritize actions for an upcoming USFDA audit, ensuring 21 CFR Part 211.100 and Annex 11 compliance.

Deliverables 

Completed Crisis Tracker Dashboard (100–150 words total across Issue Description, Containment Action Taken, Additional Comments) consolidating deviations and documenting system integration for GMP compliance.",https://drive.google.com/file/d/1mcHDTZjcp3bSeNYx8vJErlCRjI6Fk8cI/view?usp=sharing,https://tally.so/r/mYABqv,https://drive.google.com/file/d/17Vus6vUdRONpKRmYgqDZNZYEgm0fyVU-/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-059 and In-Process Control Log  
Review SOP-QA-059 (requires fill volume ±2%, negative sterility tests) and LOG-2025-070 (QMS/LIMS/eTMF-flagged deviations)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill the form: Describe deviations, assign priorities (sterility: High, volume: Medium), note containment actions, document QMS/LIMS/eTMF integration in Additional Comments  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_09,task_1_06_09_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,Audit Heat – CAPA Case Studies Under FDA/WHO Inspection Pressure,CAPA Audit Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. During a mock USFDA audit in the Sterile Injectable Unit, you review a CAPA (CAPA-2025-028) for a critical deviation in the In-Process Control Log (LOG-2025-071) against SOP-QA-060 (Sterile Filling Protocol): 3 out of 10 sterility tests show contamination (DEV-2025-146). You must evaluate the CAPA’s RCA, actions, and documentation using the Audit & Inspection Form to ensure 21 CFR Part 211.100 and Annex 11 compliance for the audit.

Deliverables 

Completed Audit & Inspection Form (100–150 words total across REMARKS and Others/Additional Observations) evaluating the CAPA for GMP compliance and audit-readiness.",https://drive.google.com/file/d/1gOeP3_v4kK_f-3FTffSebs5knjvPMJgi/view?usp=sharing,https://tally.so/r/mV6BGl,https://drive.google.com/file/d/1KA4UY85eymZQ3_zWsCMkzECrdVpHVEHr/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-060, In-Process Control Log, and CAPA Report  
Review SOP-QA-060 (requires negative sterility tests) and LOG-2025-071 (contaminated tests)  
Open “Fillable Document” (Audit & Inspection Form)  
Fill the form: Check CAPA criteria (e.g., RCA quality, documentation), provide REMARKS, recommend improvements in Others/Additional Observations  
Submit via “Answer Portal”",10
course_1,ch_1_06,les_1_06_10,task_1_06_10_1,Pro Training in QA/QC ,,AI-Augmented CAPA & Escalation Tactics,The CAPA War Room – AI-Simulated Escalation & Full CAPA Closure Drill,CAPA War Room Simulation,"You are a Junior Quality Control Analyst at Zenith Pharma Labs, reporting to Dr. Vikram Desai, QA Lead. In a CAPA War Room drill in the Sterile Injectable Unit, a GAMP 5-validated AI model simulating multi-site deviations flags two issues in the In-Process Control Log (LOG-2025-072) against SOP-QA-061 (Sterile Filling Protocol): (1) 3/10 fill volume checks out-of-spec (beyond ±2%, major deviation, local CAPA), and (2) 2/10 sterility tests show contamination (critical deviation, global CAPA). Dr. Desai instructs you to use the Crisis Tracker Dashboard to consolidate deviations and document escalation, then the CAPA Command Template for the critical sterility deviation’s actions and closure, ensuring 21 CFR Part 211.100 and Annex 11 compliance for a mock USFDA audit.

Deliverables 

Crisis Tracker Dashboard (100–150 words across Issue Description, Containment Action Taken, Additional Comments) consolidating deviations and escalation.
CAPA Command Template (100–150 words across Corrective Actions, Preventive Actions, Verification of Effectiveness, Additional Comments) for the sterility deviation.",https://drive.google.com/file/d/1WcjEslzQT6MwTIV9ZQQe5s838UKoKLGc/view?usp=sharing,https://tally.so/r/mYABqv | https://tally.so/r/mDGOYl ,https://drive.google.com/file/d/1iOeSUL0MHq3aXZu-XmWI9FLvFKaOB8Q6/view?usp=sharing,"Click “Reference Documents” to review SOP-QA-061 and In-Process Control Log  
Identify AI-simulated deviations in LOG-2025-072 against SOP-QA-061 (fill volume ±2%, negative sterility tests)  
Open “Fillable Document” (Crisis Tracker Dashboard)  
Fill Dashboard: Describe deviations, assign priorities (sterility: High, global CAPA; volume: Medium, local CAPA), note containment, document escalation/AI validation. Submit via “Answer Portal”  
Use Dashboard output for CAPA planning  
Open “Fillable Document” (CAPA Command Template)  
Fill CAPA Template: Reference DEV-2025-148, detail corrective/preventive actions, plan verification/closure. Submit via “Answer Portal”  
Tip: Prioritize sterility for global CAPA; link IDs for traceability",10
,,,,,,,,,,,,,,
course_1,ch_1_07,les_1_07_01,task_1_07_01_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks",The QC Arsenal – Core Instruments & Lab Infrastructure Mastery,,,,,,,10
course_1,ch_1_07,les_1_07_02,task_1_07_02_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks","Calibration Warfare – Principles, Schedules & Tolerance Limits",,,,,,,10
course_1,ch_1_07,les_1_07_03,task_1_07_03_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks","Weapons Check – Balances, pH Meters & Pipette Accuracy Control",,,,,,,10
course_1,ch_1_07,les_1_07_04,task_1_07_04_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks","Spectral Command – UV-Vis, IR & HPLC Basics for QC Ops",,,,,,,10
course_1,ch_1_07,les_1_07_05,task_1_07_05_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks",Chromatography Frontline – HPLC/GC System Suitability & Validation,,,,,,,10
course_1,ch_1_07,les_1_07_06,task_1_07_06_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks","Microbial Patrol – Sterility, Endotoxin & Environmental Monitoring Tools",,,,,,,10
course_1,ch_1_07,les_1_07_07,task_1_07_07_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks","Wet Lab Combat – Titrations, Dissolution & Stability Testing in Practice",,,,,,,10
course_1,ch_1_07,les_1_07_08,task_1_07_08_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks",Break the System – Handling Out-of-Calibration & OOT Data,,,,,,,10
course_1,ch_1_07,les_1_07_09,task_1_07_09_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks","The QC Audit Zone – Equipment Logs, Calibration Certificates & Compliance",,,,,,,10
course_1,ch_1_07,les_1_07_10,task_1_07_10_1,Pro Training in QA/QC ,,"QC Instrumentation, Calibration & Wet Lab Checks",The Ultimate Lab Drill – Full-Scale QC Instrumentation & Wet Lab Simulation,,,,,,,10
,,,,,,,,,,,,,,
course_1,ch_1_08,les_1_08_01,task_1_08_01_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,"Digital Battlefield – eQMS, eTMF & LIMS Foundations",,,,,,,10
course_1,ch_1_08,les_1_08_02,task_1_08_02_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,Data Armor – ALCOA+ in Digital Records & Part 11 Compliance,,,,,,,10
course_1,ch_1_08,les_1_08_03,task_1_08_03_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,"Chain of Truth – Metadata, Audit Trails & System Logs",,,,,,,10
course_1,ch_1_08,les_1_08_04,task_1_08_04_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,"Secure the Vault – Access Control, Authentication & Cybersecurity in QA",,,,,,,10
course_1,ch_1_08,les_1_08_05,task_1_08_05_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,Real-Time Intel – Electronic Batch Records & Live Data Monitoring,,,,,,,10
course_1,ch_1_08,les_1_08_06,task_1_08_06_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,"Document Crossfire – Versioning, Archiving & Retrieval in Digital Systems",,,,,,,10
course_1,ch_1_08,les_1_08_07,task_1_08_07_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,"Audit Shockwaves – Regulatory Expectations for eDocs (FDA, EMA, WHO)",,,,,,,10
course_1,ch_1_08,les_1_08_08,task_1_08_08_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,Inspection Readiness – Mock Digital Audits & Surprise Drill Tactics,,,,,,,10
course_1,ch_1_08,les_1_08_09,task_1_08_09_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,The Paperless War Game – Transitioning from Paper to Digital QA/QC,,,,,,,10
course_1,ch_1_08,les_1_08_10,task_1_08_10_1,Pro Training in QA/QC ,,Digital Documentation & Audit Readiness,Digital Siege Simulation – Full-Scale Audit in a Virtual QMS Environment,,,,,,,10
,,,,,,,,,,,,,,
course_1,ch_1_09,les_1_09_01,task_1_09_01_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO",Regulatory Battlefield – Global vs Local Quality Standards Overview,,,,,,,10
course_1,ch_1_09,les_1_09_02,task_1_09_02_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO","FDA Frontline – 21 CFR Parts 210, 211 & Inspection Focus Points",,,,,,,10
course_1,ch_1_09,les_1_09_03,task_1_09_03_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO","WHO Watchtower – GMP, GCP & Global Prequalification Standards",,,,,,,10
course_1,ch_1_09,les_1_09_04,task_1_09_04_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO","ISO Arsenal – ISO 9001, 13485 & Risk-Based Quality Systems",,,,,,,10
course_1,ch_1_09,les_1_09_05,task_1_09_05_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO",NABH Command – Hospital Accreditation Standards & Compliance Protocols,,,,,,,10
course_1,ch_1_09,les_1_09_06,task_1_09_06_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO","Regulatory Crossfire – Gap Analysis Across FDA, WHO, ISO, NABH",,,,,,,10
course_1,ch_1_09,les_1_09_07,task_1_09_07_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO",Survival Drills – Mock FDA Audit with CAPA Response,,,,,,,10
course_1,ch_1_09,les_1_09_08,task_1_09_08_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO",Hospital Heat – NABH Inspection Simulation & Corrective Actions,,,,,,,10
course_1,ch_1_09,les_1_09_09,task_1_09_09_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO",Multi-Front Combat – Parallel Audit Simulation (FDA + NABH + ISO),,,,,,,10
course_1,ch_1_09,les_1_09_10,task_1_09_10_1,Pro Training in QA/QC ,,"Regulatory Simulations: FDA, WHO, NABH, ISO","Mentor War Council – Oral Defense, Regulatory Simulation Feedback (Mentorship)",,,,,,,10
,,,,,,,,,,,,,,
course_1,ch_1_10,les_1_10_01,task_1_10_01_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,Audit Arsenal – Internal Audit Mastery & SOP Playbook,,,,,,,10
course_1,ch_1_10,les_1_10_02,task_1_10_02_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,Audit Triggers – Risk-Based Planning & Pre-Audit Prep,,,,,,,10
course_1,ch_1_10,les_1_10_03,task_1_10_03_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,"Audit Evidence – Document Tracing, Data Integrity & Records Mastery",,,,,,,10
course_1,ch_1_10,les_1_10_04,task_1_10_04_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,Interview Shield – Staff Q&A Handling Under Pressure,,,,,,,10
course_1,ch_1_10,les_1_10_05,task_1_10_05_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,Simulation 1 – Mock Internal Audit of Pharma Manufacturing Line,,,,,,,10
course_1,ch_1_10,les_1_10_06,task_1_10_06_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,"Hospital Audit Core – Patient Records, Pharmacy & ICU Quality Checks",,,,,,,10
course_1,ch_1_10,les_1_10_07,task_1_10_07_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,"Digital Audits – eTMF, CTMS & Audit Trails in Electronic Systems",,,,,,,10
course_1,ch_1_10,les_1_10_08,task_1_10_08_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,Simulation 2 – Surprise Hospital Internal Audit with Red Flag Detection,,,,,,,10
course_1,ch_1_10,les_1_10_09,task_1_10_09_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,Survival Drill – Crisis Management During a Failing Audit Scenario,,,,,,,10
course_1,ch_1_10,les_1_10_10,task_1_10_10_1,Pro Training in QA/QC ,,Internal Audit Drills and Inspection Survival,"Mentor Tribunal – Full Audit Review, Feedback & Re-Audit Defense",,,,,,,10
,,,,,,,,,,,,,,
course_1,ch_1_11,les_1_11_01,task_1_11_01_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,CAPA Command – Foundations of Corrective & Preventive Action,,,,,,,10
course_1,ch_1_11,les_1_11_02,task_1_11_02_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,"Root Cause Warfare – Fishbone, 5 Whys & Advanced RCA Tools",,,,,,,10
course_1,ch_1_11,les_1_11_03,task_1_11_03_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,CAPA Documentation – Industry-Grade Templates & Compliance Writing,,,,,,,10
course_1,ch_1_11,les_1_11_04,task_1_11_04_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,"Risk Radar – FMEA, HACCP & Pharma/Hospital Risk Matrices",,,,,,,10
course_1,ch_1_11,les_1_11_05,task_1_11_05_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,Simulation 1 – Root Cause Analysis & CAPA Drafting for a Pharma Deviation,,,,,,,10
course_1,ch_1_11,les_1_11_06,task_1_11_06_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,Hospital CAPA Combat – Handling Sentinel Events & Near-Misses,,,,,,,10
course_1,ch_1_11,les_1_11_07,task_1_11_07_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,"CAPA Systems – Digital CAPA, TrackWise & AI-Powered Risk Prediction",,,,,,,10
course_1,ch_1_11,les_1_11_08,task_1_11_08_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,Simulation 2 – End-to-End CAPA Lifecycle Execution (Pharma + Hospital),,,,,,,10
course_1,ch_1_11,les_1_11_09,task_1_11_09_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,Audit-Ready CAPA – How Inspectors Grill CAPA & Risk Logs,,,,,,,10
course_1,ch_1_11,les_1_11_10,task_1_11_10_1,Pro Training in QA/QC ,,Smart Quality Systems & Predictive Analytics,"Mentor Tribunal – CAPA Review, Feedback & Risk Defense Drill",,,,,,,10
,,,,,,,,,,,,,,
course_1,ch_1_12,les_1_12_01,task_1_12_01_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,"Global QA/QC Landscape – FDA, EMA, WHO, NABH, ISO & Beyond",,,,,,,10
course_1,ch_1_12,les_1_12_02,task_1_12_02_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,"Pharma Regulatory Codes – GMP, GLP, GCP Deep Dive",,,,,,,10
course_1,ch_1_12,les_1_12_03,task_1_12_03_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,"Hospital Accreditation Standards – NABH, JCI & Global Best Practices",,,,,,,10
course_1,ch_1_12,les_1_12_04,task_1_12_04_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,Data Integrity & 21 CFR Part 11 – The Digital Compliance Battlefield,,,,,,,10
course_1,ch_1_12,les_1_12_05,task_1_12_05_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,Simulation 1 – Regulatory Mock Inspection (FDA Style for Pharma),,,,,,,10
course_1,ch_1_12,les_1_12_06,task_1_12_06_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,Simulation 2 – Hospital Accreditation Audit Drill (NABH/JCI),,,,,,,10
course_1,ch_1_12,les_1_12_07,task_1_12_07_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,"International QA/QC Trends – AI, Automation & Smart Quality Systems",,,,,,,10
course_1,ch_1_12,les_1_12_08,task_1_12_08_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,"Future of QA/QC – Predictive Compliance, Digital Twins & Global Workforce Skills",,,,,,,10
course_1,ch_1_12,les_1_12_09,task_1_12_09_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,Final Audit Simulation – Pharma + Hospital Integrated Compliance War Game,,,,,,,10
course_1,ch_1_12,les_1_12_10,task_1_12_10_1,Pro Training in QA/QC ,,Full-Scale QA/QC Simulation Project,"Capstone Mentorship – Career Readiness, Interview Defense & QA/QC Leadership",,,,,,,10
,,,,,,,,,,,,,,10
,,,,,,,,,,,,,,10
course_2,ch_2_01,les_2_01_01,task_2_01_01_1,Pro Training in Pharmacovigilance ,"Monitor, evaluate, and manage drug safety to protect patients and ensure regulatory compliance.",Foundations of Pharmacovigilance,What is Pharmacovigilance?,ADR Case Documentation,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a report from a healthcare professional (HCP). A 40-year-old female patient developed a severe rash three days after starting paracetamol (500 mg, oral, three times daily) for a headache. She was hospitalized for one day and recovered. The HCP suspects paracetamol caused the rash. You must document the case within a 24-hour deadline.


Deliverables

Completed ADR Report Form: Fill the ICH-compliant ADR Report Form in ZANE Omega with patient details, drug information, adverse event, seriousness, expectedness, causality, and narrative (200-300 characters). 
Use the case sheet and safety information provided.
Submission Method: Submit via the ADR Report Form in ZANE Omega, or paste the data (including narrative) into Omega Word, or upload a PDF.",https://drive.google.com/file/d/161Pww4Z4n42LVUaZYKnt1-jegExk5Sry/view?usp=sharing,https://tally.so/r/w20Wjg,https://drive.google.com/file/d/1KrSe4335DRApfkmDQ5lK_5FqUyXpZlej/view?usp=sharing,"Check Case Details : Confirm patient (40-year-old female), drug (paracetamol, 500 mg), adverse event (severe rash, hospitalized), and reporter (HCP). Use case ID PV-2025-001, receipt date September 29, 2025.
Classify Seriousness : Mark as serious due to hospitalization.
Assess Expectedness : Check paracetamol safety information (Reference Document). Severe rash is not listed, so mark unexpected.
Assess Causality : Select “Probable” based on HCP suspicion and timing.
Fill ADR Report Form : Enter in ZANE Omega:
Reporter: Dr. Emily Wong, email: emily.wong@clinic.com.
Drug: Paracetamol, 500 mg, oral, three times daily.
Onset Date: September 26, 2025.
Event: Severe rash, hospitalized, recovered.
Seriousness: Serious.
Expectedness: Unexpected.
Causality: Probable.
Narrative: Summarize case (e.g., “40-year-old female had severe rash 3 days after paracetamol 500 mg. Hospitalized; recovered. Serious, unexpected, probable causality.”).
Submit : Complete all fields and submit",10
course_2,ch_2_01,les_2_01_02,task_2_01_02_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,History & Evolution of PV,Regulatory Query Response,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a mock regulatory query from the WHO regarding an ADR report for amoxicillin (500 mg, oral, twice daily). The report details a 45-year-old male patient who experienced anaphylaxis, requiring hospitalization, two days after starting the drug (Case ID: PV-2025-004). The WHO asks how historical PV milestones ensure proper handling of such cases. You must respond within a 24-hour deadline.

Deliverables

Completed Regulatory Query Response Form: Fill the Regulatory Query Response Form in ZANE Omega with query details, case ID, and a response (200-300 words) summarizing key PV historical milestones and their role in managing the amoxicillin ADR case. 
Use the provided reference data.
Submission Method: Submit via the Regulatory Query Response Form in ZANE Omega.",https://drive.google.com/file/d/1l1RzAJncteSmOySu0--Wzp8McrWNWR7X/view?usp=sharing,https://tally.so/r/mRpNoQ,https://drive.google.com/file/d/1vFuaqD6NYU6Fi-sYcG-qZurNfBVLG3xe/view?usp=sharing,"Review Query Details: Confirm the WHO query (ID: WHO-Query-2025-002) and case (PV-2025-004, anaphylaxis, hospitalized).
Identify Key Milestones: Use the reference document to select historical PV events (e.g., Thalidomide, ICH guidelines) relevant to ADR reporting.
Link to Case: Connect milestones to the amoxicillin case (e.g., expedited reporting for serious ADRs).
Fill Query Response Form: In ZANE Omega, enter:
Query ID: WHO-Query-2025-002.
Query Type: Data Clarification.
Case ID: PV-2025-004.
Response: Summarize Thalidomide’s impact, WHO PIDM, and ICH guidelines’ role in ADR management (200-300 words).
Supporting Docs: Not required.
Escalation: No.
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_03,task_2_01_03_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,Global PV Regulatory Bodies,Regulatory Query Response – FDA Inquiry on Metformin Lactic Acidosis,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a mock regulatory query from the FDA regarding an ADR report for metformin (500 mg, oral, twice daily). The report details a 60-year-old female patient who experienced severe lactic acidosis, requiring hospitalization, five days after starting the drug (Case ID: PV-2025-005). The FDA asks which global regulatory bodies oversee such ADR reporting and their roles. You must respond within a 24-hour deadline.

Deliverables

Completed Regulatory Query Response Form: Fill the Regulatory Query Response Form in ZANE Omega with query details, case ID, and a response (200-300 words) summarizing the roles of FDA, EMA, and WHO and their databases in managing the metformin ADR case. 
Use the provided reference data.
Submission Method: Submit via the Regulatory Query Response Form in ZANE Omega, or paste the response into Omega Word, or upload a PDF.",https://drive.google.com/file/d/1IbeO7Y1ulrMcaiKEpzzBq-kaJ6ZSjZU6/view?usp=sharing,https://tally.so/r/mRpNoQ,https://drive.google.com/file/d/1Z13tSqgyg7OAuvQaoXcwTHZd5ZI20sc-/view?usp=sharing,"Review Query Details: Confirm the FDA query (ID: FDA-Query-2025-001) and case (PV-2025-005, lactic acidosis, hospitalized).
Identify Regulatory Roles: Use the reference document to outline FDA, EMA, and WHO roles and databases (FAERS, EudraVigilance, VigiBase).
Link to Case: Connect the metformin case to each body’s oversight (e.g., FDA’s FAERS for U.S. reporting).
Fill Query Response Form: In ZANE Omega, enter:
Query ID: FDA-Query-2025-001.
Query Type: Data Clarification.
Case ID: PV-2025-005.
Response: Summarize FDA, EMA, WHO roles and databases for the ADR case (200-300 words).
Supporting Docs: Not required.
Escalation: No.
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_04,task_2_01_04_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,Adverse Event (AE) Basics,ADR Case Documentation,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a report from a healthcare professional (HCP). A 35-year-old male patient developed a severe allergic reaction two days after starting penicillin (500 mg, oral, twice daily) for a throat infection. He was hospitalized for one day and recovered. The HCP suspects penicillin caused the reaction. You must document the case within a 24-hour deadline.

Deliverables

Completed ADR Report Form: Fill the ICH-compliant ADR Report Form in ZANE Omega with reporter details, drug information, adverse event, seriousness, expectedness, outcome, expedited reporting status, and narrative (200-300 characters). 
Use the provided case sheet and safety information.
Submission Method: Submit via the ADR Report Form in ZANE Omega.",https://drive.google.com/file/d/1-uzq1yBbnBAliOI_X8dFIuTPGxiB0gUP/view?usp=sharing,https://tally.so/r/w20Wjg,https://drive.google.com/file/d/1A3py3ckufNrJQAyDHLLff4P9QiIzFVxs/view?usp=sharing,"Check Case Details: Confirm patient (35-year-old male), drug (penicillin, 500 mg), event (severe allergic reaction, hospitalized), and reporter (HCP). Use case ID PV-2025-006, receipt date September 29, 2025.
Classify Event: Identify as SAE (hospitalization) and ADR (HCP suspects drug causality).
Assess Seriousness: Mark as serious due to hospitalization.
Check Expectedness: Review penicillin safety information. Severe allergic reaction is a known rare side effect, so mark expected.
Assess Causality: Select “Probable” based on HCP suspicion and timing.
Fill ADR Report Form: Enter in ZANE Omega:
Reporter Details: Dr. Michael Patel, email: michael.patel@clinic.com.
Suspect Drug: Penicillin, 500 mg, oral, twice daily.
Reaction Onset Date: September 27, 2025.
AE Details: Severe allergic reaction, hospitalized, recovered.
Expectedness: Expected.
Outcome: Recovered.
Expedited Reporting: Yes.
Narrative Summary: Summarize case (e.g., “35-year-old male had severe allergic reaction 2 days after penicillin 500 mg. Hospitalized; recovered. Serious, expected, probable causality.”).
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_05,task_2_01_05_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,Good Pharmacovigilance Practices (GVP),Regulatory Query Response – EMA Inquiry on Lisinopril Hypotension,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a mock regulatory query from the EMA regarding an ADR report for lisinopril (10 mg, oral, once daily). The report details a 50-year-old male patient who experienced severe hypotension, requiring hospitalization, three days after starting the drug (Case ID: PV-2025-007). The EMA asks how GVP principles ensure proper handling of this ADR. You must respond within a 24-hour deadline.

Deliverables

Completed Regulatory Query Response Form: Fill the Regulatory Query Response Form in ZANE Omega with query details, case ID, and a response (200-300 words) summarizing GVP principles and their role in managing the lisinopril ADR case. 
Use the provided reference data.
Submission Method: Submit via the Regulatory Query Response Form in ZANE Omega.",https://drive.google.com/file/d/1vNntA1LAJcwuai5zhOfsgAqkcHV3ouWX/view?usp=sharing,https://tally.so/r/mRpNoQ,https://drive.google.com/file/d/1TqdUkGvnKiaGwojaHSfeL2sdDw7ys86l/view?usp=sharing,"Review Query Details: Confirm the EMA query (ID: EMA-Query-2025-002) and case (PV-2025-007, severe hypotension, hospitalized).
Identify GVP Principles: Use the reference document to select key GVP principles (e.g., ADR reporting, risk management) relevant to ADR handling.
Link to Case: Connect principles to the lisinopril case (e.g., expedited reporting for serious ADRs).
Fill Query Response Form: Enter in ZANE Omega:
Query ID: EMA-Query-2025-002.
Query Type: Data Clarification.
Original Case ID: PV-2025-007.
Response: Summarize GVP principles (ADR reporting, risk management, Module VI) and their role (200-300 words).
Supporting Docs: Not required.
Escalation Needed: No.
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_06,task_2_01_06_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,AI in PV Research,Aggregate Signal Assessment – Omeprazole Severe Diarrhea,"As a Drug Safety Associate at Apex Pharmaceuticals, you are analyzing adverse event reports for omeprazole (20 mg, oral, once daily) used for acid reflux. Recent data shows 15 cases of severe diarrhea over three months (July 1–September 30, 2025), with a disproportionality metric (PRR) of 2.5, indicating a potential safety signal. You must use Claude to summarize the signal and recommend actions for an aggregate report within a 24-hour deadline.

Deliverables

Completed Aggregate Reporting Dashboard Form: Fill the Aggregate Reporting Dashboard Form in ZANE Omega with reporting period, case count, signal details, risk level, recommendations, and Claude usage note (200-300 characters). 
Use the provided case data and Claude AI to generate the signal summary.
Submission Method: Submit via the Aggregate Reporting Dashboard Form in ZANE Omega.",https://drive.google.com/file/d/1ilL2re_x9RhmxejmB6VK4oW2Y3VyKH7B/view?usp=sharing,https://tally.so/r/wkqoZe,https://drive.google.com/file/d/1HBqhLi_8iLseElzBmL_HZ90o-sfRVyYV/view?usp=sharing,"Review Case Data: Confirm 15 cases of severe diarrhea for omeprazole, PRR 2.5, from July 1–September 30, 2025 (Reference Document).
Generate Signal Summary with Claude: Access Claude’s  via Tools section . Input: “Summarize: 15 cases of severe diarrhea with omeprazole, PRR 2.5, July–September 2025, potential signal, recommend actions.” Copy Claude’s output (200-300 characters) for the signal summary.
Assess Risk Level: Select “Medium” risk based on PRR >2.0 and hospitalization data.
Draft Recommendations: Suggest further monitoring or label updates based on Claude’s output.
Fill Aggregate Reporting Dashboard Form: Enter in ZANE Omega:
Reporting Period: July 1–September 30, 2025.
Total Cases: 15.
Key Signals Identified: Severe diarrhea, PRR 2.5 (from Claude summary).
Risk Level: Medium.
Risk Mitigation Plan: Monitor signal, consider label update.
Tool/AI Used: Claude.
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_07,task_2_01_07_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,PV Roles & Responsibilities,Regulatory Query Response – EMA Inquiry on Fluoxetine Insomnia,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a regulatory query from the EMA regarding an adverse drug reaction (ADR) report for fluoxetine (20 mg, oral, once daily). The report details a 45-year-old female patient who experienced severe insomnia, requiring hospitalization, four days after starting the drug (Case ID: PV-2025-009). The EMA asks which PV roles are involved in processing and reviewing this ADR and their responsibilities. You must respond within a 24-hour deadline.

Deliverables

Completed Regulatory Query Response Form: Fill the Regulatory Query Response Form in ZANE Omega with query details, case ID, and a response (200-300 words) summarizing the PV roles involved in the fluoxetine ADR case and their responsibilities. 
Use the provided reference data.
Submission Method: Submit via the Regulatory Query Response Form in ZANE Omega.",https://drive.google.com/file/d/1rUnwV3GxZm_NvmA8J3WjRR5EfkXWJyUh/view?usp=sharing,https://tally.so/r/mRpNoQ,https://drive.google.com/file/d/1IzEhEdk2MzdOYngUXvDG5EMoDjwQuTX1/view?usp=sharing,"Review Query Details: Confirm the EMA query (ID: EMA-Query-2025-003) and case (PV-2025-009, severe insomnia, hospitalized).
Identify PV Roles: Use the reference document to select roles (e.g., Drug Safety Associate, PV Medical Reviewer) and their responsibilities for ADR processing.
Link to Case: Connect roles to the fluoxetine case (e.g., case processing, medical review).
Fill Query Response Form: Enter in ZANE Omega:
Query ID: EMA-Query-2025-003.
Query Type: Data Clarification.
Original Case ID: PV-2025-009.
Response: Summarize roles and responsibilities for the ADR case (200-300 words).
Supporting Docs: Not required.
Escalation Needed: No.
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_08,task_2_01_08_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,Introduction to MedDRA,ICSR Data Entry – Warfarin-Induced Gingival Bleeding,"Today, as a Drug Safety Associate at Apex Pharmaceuticals, you receive a report from a healthcare professional (HCP). A 70-year-old male patient developed severe bleeding gums two days after starting warfarin (5 mg, oral, once daily) for atrial fibrillation. He was hospitalized for one day and recovered. The HCP suspects warfarin caused the bleeding. You must document the case in an ICSR Data Entry Form by tomorrow.

Deliverables

Completed ICSR Data Entry Form: Fill the ICSR Data Entry Form in ZANE Omega with patient details, drug information, adverse event, MedDRA PT code, seriousness, causality, submission date, and narrative (200-300 characters). 
Use the provided case sheet and safety information.
Submission Method: Submit via the ICSR Data Entry Form in ZANE Omega.",https://drive.google.com/file/d/1eC4i7YA5khwUnByJS8pEspprZE7e_v34/view?usp=sharing,https://tally.so/r/wvkldv,https://drive.google.com/file/d/1tRhW5o9EPaIQk3D_juwCodqDFBkhQ94_/view?usp=sharing,"Check Case Details: Confirm patient (70-year-old male), drug (warfarin, 5 mg), event (severe bleeding gums, hospitalized), and reporter (HCP). Use case ID PV-001, receipt date today.
Classify Seriousness: Mark as serious due to hospitalization.
Assess Causality: Select “Probable” based on HCP suspicion and timing.
Use MedDRA PT Code: Apply code “10018939” (Gingival bleeding) from the reference document.
Fill ICSR Data Entry Form: Enter in ZANE Omega:
Patient ID: PV-001.
Age: 70.
Gender: Male.
Adverse Event Description: Severe bleeding gums, hospitalized, recovered.
MedDRA PT Code: 10018939.
Seriousness: Hospitalized.
Causality Assessment: Probable.
Submission Date: Today.
Follow-Up Notes: Not required.
Submit: Complete all fields and submit.",10
course_2,ch_2_01,les_2_01_09,task_2_01_09_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,PV Documentation Essentials,ICSR Data Entry – Levothyroxine-Induced Palpitations,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a report from a healthcare professional (HCP). A 55-year-old female patient developed severe palpitations three days after starting levothyroxine (100 mcg, oral, once daily) for hypothyroidism. She was hospitalized for one day and recovered. The HCP suspects levothyroxine caused the palpitations. You must document the case in an ICSR Data Entry Form asap.

Deliverables

Completed ICSR Data Entry Form: Fill the ICSR Data Entry Form in ZANE Omega with patient details, drug information, adverse event, seriousness, causality, submission date, and narrative (200-300 characters). 
Use the provided case sheet and safety information.
Submission Method: Submit via the ICSR Data Entry Form in ZANE Omega.",https://drive.google.com/file/d/1bH27XJdTE_onhr7TXwi1WKY8QXfrdLrA/view?usp=sharing,https://tally.so/r/wvkldv,https://drive.google.com/file/d/1BDrIuvNc2Wrp-h6TLbRKB6SB0UHxsP26/view?usp=sharing,"Check Case Details: Confirm patient (55-year-old female), drug (levothyroxine, 100 mcg), event (severe palpitations, hospitalized), and reporter (HCP). Use case ID PV-002, receipt date today.
Classify Seriousness: Mark as serious due to hospitalization.
Assess Causality: Select “Probable” based on HCP suspicion and timing.
Draft Narrative: Summarize the case using provided data (200-300 characters).
Fill ICSR Data Entry Form: Enter in ZANE Omega:
Patient ID: PV-002.
Age: 55.
Gender: Female.
Adverse Event Description: Severe palpitations, hospitalized, recovered.
Seriousness: Hospitalized.
Causality Assessment: Probable.
Submission Date: Today.
Follow-Up Notes: Not required.
Submit: Complete all fields and submit by tomorrow.",10
course_2,ch_2_01,les_2_01_10,task_2_01_10_1,Pro Training in Pharmacovigilance,,Foundations of Pharmacovigilance,Recap,Omegamentorship,,,,,,
course_2,ch_2_02,les_2_02_01,task_2_02_01_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),ICSR Overview & Structure,ICSR Data Entry – Cetirizine-Induced Dizziness,"As a Drug Safety Associate at Apex Pharmaceuticals, you receive a spontaneous report from a healthcare professional (HCP). A 30-year-old female patient developed severe dizziness two days after starting cetirizine (10 mg, oral, once daily) for allergies. She was hospitalized for one day and recovered. The HCP suspects cetirizine caused the dizziness. You must document the case in an ICSR Data Entry Form by tomorrow.

Deliverables

Completed ICSR Data Entry Form: Fill the ICSR Data Entry Form in ZANE Omega with patient details, drug information, adverse event, seriousness, causality, submission date, and narrative (200-300 characters). 
Use the provided case sheet and safety information.
Submission Method: Submit via the ICSR Data Entry Form in ZANE Omega.",https://drive.google.com/file/d/1hQGnFYGhmVOTD7szLY7LVwlHBhvZUR3w/view?usp=sharing,https://tally.so/r/wvkldv,https://drive.google.com/file/d/1P8YqNm8nw7kaNS5eQhODanTwtTQ7c5-p/view?usp=sharing,"Check Case Details: Confirm patient (30-year-old female), drug (cetirizine, 10 mg), event (severe dizziness, hospitalized), and reporter (HCP). Use case ID PV-003, receipt date today.
Classify Seriousness: Mark as serious due to hospitalization.
Assess Causality: Select “Probable” based on HCP suspicion and timing.
Draft Narrative: Summarize the case using provided data (200-300 characters).
Fill ICSR Data Entry Form: Enter in ZANE Omega:
Patient ID: PV-003.
Age: 30.
Gender: Female.
Adverse Event Description: Severe dizziness, hospitalized, recovered.
Seriousness: Hospitalized.
Causality Assessment: Probable.
Submission Date: Today.
Follow-Up Notes: Not required.
Submit: Complete all fields and submit.",10
course_2,ch_2_02,les_2_02_02,task_2_02_02_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),Adverse Event (AE) Case Intake Process,ICSR Data Entry – Metformin-Induced Nausea,"As a Pharmacovigilance Associate at Zenith Pharma, you receive an email report of an adverse event from Dr. Sarah Patel, a physician at City Hospital. The report concerns a patient experiencing an adverse event while using metformin for type 2 diabetes. Your responsibility is to review the provided reference document, validate the information, and accurately complete the ICSR Data Entry Form.

Deliverables
A completed ICSR Data Entry Form based on the validated data from the reference document.",https://drive.google.com/file/d/1caUYQ2-5lSzfSvrJ1DQYIAYOwezQSUBw/view?usp=sharing,https://tally.so/r/wvkldv,https://drive.google.com/file/d/1tGFTsaI0sGblZfqllWNM-COdXW64a35g/view?usp=sharing,"Review the Reference Document to extract key details regarding the patient, suspected drug, adverse event, concomitant medications, and reporter.
Validate the data for completeness, confirming that all mandatory fields (e.g., patient demographics, drug details, AE description, reporter information) are present and accurate.
Assign a unique Case ID to the report (e.g., ZP-2025-001).
Enter the validated information into the ICSR Data Entry Form, using the specified MedDRA code ""10028813"" for nausea.
Verify the seriousness classification (non-serious in this case) and ensure compliance with regulatory timelines (submission within 15 calendar days for non-serious AEs).
Maintain confidentiality of patient and reporter data in accordance with GDPR and HIPAA regulations.",10
course_2,ch_2_02,les_2_02_03,task_2_02_03_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),Source Document Review,Source Document Review – Metformin ICSR Verification,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in India. You are reviewing an ICSR for a patient who experienced an adverse event while taking metformin for type 2 diabetes, reported by a clinic in Australia. Your task is to compare the ICSR data with the source document (a clinic note) and fill out a simplified Source Document Review Form, noting any mistakes or missing information. The task ensures compliance with global standards and is designed to be quick and clear for beginners.

Deliverables
A completed Source Document Review Form, checking patient, drug, AE, and reporter details against the source document.
A brief note of any errors or missing data, with a simple follow-up suggestion.
Submit the form to your supervisor via Horizon Pharma’s PV system, ensuring an audit trail per ICH E6(R3).
",https://drive.google.com/file/d/1ckhCXwhk8LODojv8xebe7gJcA-BWyutH/view?usp=sharing,https://tally.so/r/wvkldv,https://drive.google.com/file/d/1kzfS8NUfdg1y-Zip0qb8fKzf95cR6da2/view?usp=sharing,"Read the Reference Document (clinic note) to find details about the patient, metformin, adverse event, and reporter.
Compare these details with the ICSR Data to check if they match.
Fill out the Source Document Review Form by marking each field as “Correct” or “Incorrect/Missing.”
In the “Notes/Follow-Up” section, write one sentence about any errors or missing information and suggest a simple action (e.g., call the doctor).
Use MedDRA code ""10028813"" for nausea, as required by global standards.
Keep patient and reporter information private per GDPR (EU), HIPAA (USA), UK Data Protection Act, and India’s DPDP Act.
Submit the form within 24 hours.",10
course_2,ch_2_02,les_2_02_04,task_2_02_04_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),Narrative Writing Basics,AE Narrative Writing – Metformin-Induced Nausea,"You are a Pharmacovigilance Trainee at Unity Pharma, a company based in Canada. You are tasked with writing an AE narrative for an ICSR based on a spontaneous report from a clinic in Brazil. The report details a patient experiencing nausea while taking metformin for type 2 diabetes. Your role is to use the provided source document (a clinic note) to write a concise narrative, ensuring it is accurate, clear, and compliant with global standards, suitable for submission to regulatory authorities like Health Canada, ANVISA (Brazil), FDA, MHRA, EMA, and CDSCO.

Deliverables

A completed AE Narrative, summarizing the patient’s adverse event in a clear, chronological format.
The narrative should include all required components (patient details, drug information, AE details, outcome) and use standard terminology (MedDRA code ""10028813"" for nausea).
Submit the narrative to your supervisor via Unity Pharma’s PV system, ensuring an audit trail per ICH E2B(R3).
",https://drive.google.com/file/d/17fI1icNt2fGUMCmrkYD9IeObPB7ntzjQ/view?usp=sharing,omegaword,https://drive.google.com/file/d/1P2qdDKVZNEgdSbKV6MZg1bsSHPSgy5Rb/view?usp=sharing,"Read the Reference Document (clinic note) to gather details about the patient, metformin, adverse event, and reporter.
Organize the information in chronological order, starting with the patient’s baseline condition, drug administration, AE onset, and outcome.
Write a concise AE Narrative (3-5 sentences) including
Patient details (age, sex, medical history)
Suspected drug (name, dose, start date, indication)
AE description (onset, seriousness, MedDRA code, outcome)
Any relevant actions or follow-up plans
Use clear, factual language in past tense, avoiding assumptions or abbreviations.
Apply MedDRA code ""10028813"" for nausea, as required by global standards.
Ensure confidentiality by using the patient ID instead of the full name, per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Brazil’s LGPD.
Submit the narrative within 24 hours, reflecting a beginner-friendly timeline for global pharmacovigilance reporting into OMEGA WORD.",10
course_2,ch_2_02,les_2_02_05,task_2_02_05_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),AI for ICSR Triage,AI for ICSR Triage,"You are a Pharmacovigilance Trainee at Stellar Pharma, a company based in Singapore. You are tasked with performing a causality assessment for an ICSR based on a spontaneous AE report from a clinic in Malaysia. The report describes a patient experiencing nausea while taking metformin for type 2 diabetes. Your role is to review the provided source document (clinic note), assess the causality using a simplified WHO-UMC framework, and complete a Causality Assessment Form, ensuring compliance with global standards for submission to regulatory authorities like HSA (Singapore), NPRA (Malaysia), FDA, MHRA, EMA, and CDSCO.

Deliverables
A completed Causality Assessment Form, indicating the causality category (Certain, Probable, Possible, Unlikely) and supporting rationale.
A brief note explaining the chosen category based on key factors like temporal relationship and alternative causes.
Submit the form to your supervisor via Stellar Pharma’s PV system, ensuring an audit trail per ICH E2B(R3).",https://drive.google.com/file/d/1gCKoBg5qS0LFNwj7Usf6Dsnd000CLUQA/view?usp=sharing,https://tally.so/r/wb0ob6,https://drive.google.com/file/d/1mdd8raV7nvHU-GRZbL3Awse_tF6Mfnl7/view?usp=sharing,"Read the Reference Document (clinic note) to gather details about the patient, metformin, adverse event, and relevant clinical information.
Review the Simplified WHO-UMC Causality Categories (provided below) to understand the criteria for assessing causality.
Evaluate the AE based on:

Temporal relationship: Did nausea occur after starting metformin?
Alternative explanations: Are there other drugs or conditions that could cause nausea?
Dechallenge: Did nausea improve after stopping or continuing metformin (if applicable)?

Complete the Causality Assessment Form by selecting the appropriate causality category (Certain, Probable, Possible, Unlikely) and providing a one-sentence rationale.
Use MedDRA code ""10028813"" for nausea, as required by global standards.
Ensure confidentiality per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Malaysia’s PDPA.
Submit the form within 24 hours, reflecting a beginner-friendly timeline for global pharmacovigilance operations.",10
course_2,ch_2_02,les_2_02_06,task_2_02_06_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),Causality Assessment Intro,ICSR Causality Assessment – Metformin-Induced Nausea,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with performing an AI-enhanced Naranjo scoring simulation for an ICSR based on a spontaneous AE report from a clinic in Singapore. The report details a patient who developed nausea after starting metformin for type 2 diabetes. Using Grok (grok.com), you will analyze the provided structured fields, score each of the 10 Naranjo questions, calculate the total score, classify the causality, and justify your scoring. Enter the results in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A basic scoring entry in OMEGA Word, including scores for each Naranjo question, total score, causality classification (Definite >9, Probable 5-8, Possible 1-4, Doubtful <1), and a short justification.
A brief follow-up suggestion.",https://drive.google.com/file/d/1LK3Bv3uKG0ZVDOQNnbTJxCgo5G0Ku9W3/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1nRuZFkwNWiJJTOSATxSOQHiS7aRdo8aT/view?usp=drive_link,"Access Grok at Tools Section and input this prompt:
    
  *""Analyze the following adverse event data using the Naranjo algorithm: A 55-year-old male with type 2 diabetes started metformin 500 mg orally twice daily on June 15, 2025, and reported nausea starting July 10, 2025. No other medications or gastrointestinal conditions reported, no dechallenge or rechallenge performed, nausea is a known side effect of metformin per literature, no toxic levels or placebo test. Suggest scores for each of the 10 Naranjo questions (Yes/No/Don't Know with corresponding points) and explain key factors.""*
    
Review the  Reference Document  (structured fields below) to confirm details.
Score each of the 10 Naranjo questions based on Grok’s output and your evaluation (Yes = +points, No = -points, Don't Know = 0, per the Naranjo framework below).
Calculate the total score and classify the causality.
Provide a short justification (1-2 sentences) explaining how the scores were determined.
Open  OMEGA Word  and create a new document titled ""Naranjo Scoring Entry - Case ID HP-2025-SG-001"".
Enter the question scores, total, classification, justification, and follow-up in OMEGA Word.
Use MedDRA code ""10028813"" for nausea.
Ensure confidentiality per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Singapore’s PDPA.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_02,les_2_02_07,task_2_02_07_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),MedDRA Type Coding for ICSRs,MedDRA Coding – Metformin AE,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with coding an AE from an ICSR based on a spontaneous report from a clinic in Singapore. The report includes a verbatim description of the patient's symptom after taking metformin for type 2 diabetes. Using Grok (grok.com), you will code the verbatim term to the appropriate Lowest Level Term (LLT), Preferred Term (PT), and System Organ Class (SOC), justify your coding, and enter it in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.


Deliverables

A basic coding entry in OMEGA Word, including the verbatim term, LLT, PT, SOC, and a short justification for the coding choice.
A brief follow-up suggestion if more information is needed.
",https://drive.google.com/file/d/1b0Q7IcYMYYwuzxAhWGzqPj87Q7pT_t-N/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/15AUISoXUb09aPE5iJ5lPql9K_uu51zhj/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
""Code the following verbatim adverse event description using MedDRA: 'Patient experienced severe burning pain in the stomach after taking the drug.' Suggest the appropriate Lowest Level Term (LLT), Preferred Term (PT), and System Organ Class (SOC), and explain why this coding fits.""
Review the Reference Document (ICSR details below) to confirm the verbatim description and context.
Code the verbatim term based on Grok’s output and your evaluation:

Select the LLT that matches the description closely.
Map to the corresponding PT.
Assign the SOC.

Justify the coding in 1-2 sentences, explaining why it fits (e.g., specificity, hierarchy).
Open OMEGA Word and create a new document titled ""MedDRA Coding Entry - Case ID HP-2025-SG-001"".
Enter the verbatim term, LLT, PT, SOC, justification, and follow-up in OMEGA Word.
Use MedDRA code for the PT if known, or note it from Grok.
Ensure confidentiality per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Singapore’s PDPA.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_02,les_2_02_08,task_2_02_08_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),ICSR Quality Checks,ICSR Quality Check – Metformin AE,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. 
You are tasked with performing a quality check on an ICSR based on a spontaneous AE report from a clinic in Singapore. The report details a patient who experienced nausea after taking metformin for type 2 diabetes. Using Grok (grok.com), you will review the provided ICSR data for errors, identify 3-5 issues, suggest corrections, and enter a short QC note in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A simple QC note in OMEGA Word, listing 3-5 identified errors from the ICSR and suggested corrections.
A brief follow-up suggestion for resolving any ambiguities.
",https://drive.google.com/file/d/1RTlYJREElYPDr3LKeU2Kmy6XJkeRHpQg/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1dHzMAlo3osOOCu65ZiUCqyLLd0Phxjil/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
""Review this ICSR data for quality check errors in patient info, drug details, AE details, narrative, seriousness, and coding: Patient: Male, 55 years, type 2 diabetes. Drug: Metformin 500 mg oral twice daily, started June 15, 2025. AE: Nausea onset July 10, 2025, non-serious, ongoing. Narrative: Patient reported stomach pain. No concomitant drugs. Suggest 3-5 errors and corrections.""
Review the Reference Document (ICSR data below) to confirm potential errors (e.g., mismatch in narrative, missing details).
Identify 3-5 errors based on Grok’s output and your evaluation, such as inconsistencies in narrative vs AE description or missing seriousness validation.
Suggest corrections for each error (e.g., update narrative to match AE).
Open OMEGA Word and create a new document titled ""ICSR QC Note - Case ID HP-2025-SG-001"".
Enter the list of 3-5 errors, corrections, and follow-up in OMEGA Word.
Use MedDRA code ""10028813"" for nausea if relevant.
Ensure confidentiality per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Singapore’s PDPA.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_02,les_2_02_09,task_2_02_09_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),Submission Timelines and Rules,iCSR Timeline Entry,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with mapping submission timelines for an ICSR based on a spontaneous AE report from a clinic in Singapore. The report details a patient who experienced a serious AE after taking metformin for type 2 diabetes. Using Grok (grok.com), you will calculate the 15-day submission deadline from Day 0, identify any follow-up deadlines, map them to a calendar (e.g., due dates), and enter a simple timeline entry in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A basic timeline entry in OMEGA Word, including Day 0, submission deadline, follow-up deadline (if applicable), and a short note on compliance.
",https://drive.google.com/file/d/1yZvTNUgUQGf0Etev7-l1G4KPc2FNLrf8/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/10cTxA7IWx2WzIOZVRI27qjnOCRJS1XWk/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
""Calculate ICSR submission timelines for this case: Day 0 is September 20, 2025, for a serious non-fatal AE. Provide the 15-day submission deadline and any follow-up deadline, mapping them to a simple calendar format with dates.""
Review the Reference Document (ICSR details below) to confirm Day 0 and seriousness.
Calculate deadlines based on Grok’s output:
Submission deadline: 15 days from Day 0 for serious non-fatal.
Follow-up: Note if any 8-day follow-up applies (only for fatal/life-threatening).
Map the deadlines to a simple calendar (e.g., Day 0: Sep 20; Deadline: Oct 5).
Open OMEGA Word and create a new document titled ""ICSR Timeline Entry - Case ID HP-2025-SG-001"".
Enter the timeline, note, and reminder in OMEGA Word.
Ensure confidentiality per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Singapore’s PDPA.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_02,les_2_02_10,task_2_02_10_1,Pro Training in Pharmacovigilance,,Individual Case Safety Reports (ICSR),Individual Case Safety Report (ICSR) Case Closure,Individual Case Safety Report (ICSR) Case Closure,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with checking an ICSR for closure based on a spontaneous AE report from a clinic in Singapore. The report details a patient who experienced nausea after taking metformin for type 2 diabetes. Using Grok (grok.com), you will evaluate the provided ICSR data against the closure checklist, determine if it's ready for closure or list 2-3 missing items, and enter a basic closure status in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A basic closure status entry in OMEGA Word, stating if the case is ready for closure, listing 2-3 missing items if not, and a short follow-up suggestion.
Submit the entry in OMEGA Word to your supervisor, ensuring an audit trail per ICH E2B(R3).
",https://drive.google.com/file/d/1NB9YTJSNzp2UdYL4hnXyAsUa9yzkPEuj/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1IOPMDb6bAdH2l0-CHsPzPNi9J0hhMOqR/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
""Evaluate this ICSR data for closure readiness based on pharmacovigilance checklist: Patient: Male, 55 years, type 2 diabetes. Drug: Metformin 500 mg oral twice daily, started June 15, 2025. AE: Nausea onset July 10, 2025, non-serious, ongoing. Narrative complete, MedDRA coded, causality possible. Submission done, ACK received. Suggest if ready for closure or 2-3 missing items.""
Review the Reference Document (ICSR data below) to confirm checklist items (e.g., submission ACK, coding, narrative).
Determine closure readiness based on Grok’s output and your evaluation: Ready (yes/no), and list 2-3 missing items if no.
Suggest a follow-up action (e.g., obtain missing ACK).
Open OMEGA Word and create a new document titled ""ICSR Closure Status Entry - Case ID HP-2025-SG-001"".
Enter the readiness status, missing items (if any), and follow-up in OMEGA Word.
Ensure confidentiality per GDPR (EU), HIPAA (USA), UK Data Protection Act, India’s DPDP Act, and Singapore’s PDPA.
Submit in OMEGA Word within 24 hours.",10
,,,,,,,,,,,,,,
course_2,ch_2_03,les_2_03_01,task_2_03_01_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,Global PV Databases Overview,ICSR Closure Status Entry ICSR Closure Status Entry ,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with querying global PV databases for an AE from an ICSR based on a spontaneous report from a clinic in Singapore. The report details a patient who experienced nausea after taking metformin for type 2 diabetes. Using the VigiBase simulator and Grok (grok.com), you will query VigiBase for metformin-nausea data, reconcile with FAERS/EudraVigilance summaries from Grok, analyze 3-5 trends, and enter a simple signal summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A basic signal summary entry in OMEGA Word, listing 3-5 trends from VigiBase query and reconciliation with FAERS/EudraVigilance.
A brief follow-up suggestion for career application or further analysis.",https://drive.google.com/file/d/1TRg4jZek0iTup8whU0a9Q3uQMrJPWaGX/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1Tf8IxG9fSZrDICcgoZxxSXwEKdqvLo86/view?usp=drive_link,"Access the ZANE VigiBase and input queries like ""metformin nausea reports"" and ""metformin nausea trends"" to retrieve data.
Access Grok at Tools Section and input this prompt:
    
 ""Summarize FAERS and EudraVigilance data on metformin-related nausea, including report counts, demographics, and trends.""
   
Review the Reference Document (ICSR details below) to confirm the AE context.
Combine ZANE VigiBase outputs with Grok's FAERS/EudraVigilance summaries, analyzing 3-5 trends (e.g., report count, demographics).
Suggest a follow-up action either manually or using AI (e.g., draft a signal observation for PSUR).
Open OMEGA Word
Enter the 3-5 trends and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_03,les_2_03_02,task_2_03_02_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,E2B R3 Standards,E2B R3 Standards,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with filling out an ICSR form using E2B(R3) standards for an ICSR based on a spontaneous AE report from a clinic in Singapore. The report details a patient who experienced nausea after taking metformin for type 2 diabetes. Using the E2B R3 simulator, you will fill out the key E2B(R3) fields, validate the form with Grok (grok.com), and enter the completed form in OMEGA. Ensure compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A completed ICSR form in OMEGA.",https://drive.google.com/file/d/1SF1URWgZgyjLtqwjiTo7GxrRrcazc_bL/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1TQXGcPzOn4KMI8cICs_YxI8zhwmlxexE/view?usp=drive_link,"Access the ICSR form in forms section and  fill in the form fields based on the reference document. (e.g., patient age, sex, AE description, drug name).
Access Grok at tools section and input this prompt:
      ""Validate this filled E2B(R3) ICSR form for completeness: Patient: Male, 55 years. Suspected Drug: Metformin, dose 500 mg oral twice daily, start June 15, 2025. AE: Nausea, onset July 10, 2025, non-serious. Confirm if mandatory fields are filled.""
    
Review the Reference Document (ICSR details below) to ensure accurate filling.
Fill out the E2B(R3) key fields in ICSR form: Case ID, Patient Info, Suspected Drug, AE Details, Reporter Info.
Note the validation from Grok (e.g., all mandatory fields complete).
Enter the filled form and validation note in OMEGA & submit.",10
course_2,ch_2_03,les_2_03_03,task_2_03_03_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,VigiBase Navigation,VigiBase Navigation,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with navigating VigiBase for an AE from an ICSR based on a spontaneous report from a clinic in Singapore. The report details a patient who experienced bleeding after taking warfarin for atrial fibrillation. Using the VigiBase simulator, you will search for similar ICSRs, review 3-5 key case details (e.g., seriousness, demographics), and enter a simple case search summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.


Deliverables

A basic case search summary entry in OMEGA Word, listing 3-5 key details from the VigiBase search on warfarin-bleeding ICSRs.
A brief follow-up suggestion for case review.",https://drive.google.com/file/d/1gOOjCokke5riHvTdlQwmXrf7iP_5hECy/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1aGtpE3M_3iJdssK6SVbNEdsXtaMEGJQ_/view?usp=sharing,"Access the ZANE VigiBase and input queries like ""warfarin bleeding reports"" and ""warfarin bleeding trends"" to retrieve ICSR data.
Review the Reference Document (ICSR details below) to confirm the AE context.
Summarize 3-5 key details from the simulator's output (e.g., number of cases, seriousness levels).
Suggest a follow-up action (e.g., export for signal detection).
Open OMEGA Word and create a new document titled ZANE VigiBase Search Summary Entry - Case ID HP-2025-SG-001.
Enter the 3-5 details and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.
",10
course_2,ch_2_03,les_2_03_04,task_2_03_04_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,FAERS Data Reconciliation,FAERS Data Reconciliation,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in New Zealand. You are tasked with reconciling FAERS data for an ICSR based on a spontaneous report from a clinic in Singapore. The report details a patient who experienced bleeding after taking warfarin for atrial fibrillation. Using the FAERS Reconciliation simulator, you will compare internal and FAERS data, identify 3-5 discrepancies, suggest corrections, and enter a simple reconciliation summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like Medsafe (New Zealand), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.


Deliverables

A basic reconciliation summary entry in OMEGA Word, listing 3-5 discrepancies and suggested corrections.
A brief follow-up suggestion for resolution.",https://drive.google.com/file/d/1sSk2D2DCdLgHBtVMeVEx8mnn-iRoU2vT/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/18I6pcQXA73m3KkPm4lVWajoI9xEOxDiG/view?usp=sharing,"Access the ZANE FAERS and Navigate to ICSR Database  input drug name ""warfarin"" to retrieve discrepancies.
Review the Reference Document (internal ICSR and simulated FAERS data below) to confirm discrepancies.
Identify 3-5 discrepancies from the simulator's output (e.g., seriousness mismatch, missing fields).
Suggest corrections for each (e.g., update FAERS with correct seriousness).
Open OMEGA Word and create a new document titled ""FAERS Reconciliation Summary Entry - Case ID HP-2025-SG-001"".
Enter the 3-5 discrepancies, corrections, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours. ",10
course_2,ch_2_03,les_2_03_05,task_2_03_05_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,AI for Database Queries,AI for Database Queries,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the USA. You are tasked with querying global PV databases for an AE from an ICSR based on a spontaneous report from a clinic in Singapore. The report details a patient who experienced tinnitus after taking aspirin for headache. Using the VigiBase and EudraVigilance, you will query VigiBase for aspirin-tinnitus data, reconcile with FAERS/EudraVigilance, analyze 3-5 trends, and enter a simple signal summary in OMEGA Word for submission using AI (Grok or ChatGPT), ensuring compliance with regulatory authorities like FDA (USA), HSA (Singapore), MHRA, EMA, and CDSCO.


Deliverables

A basic signal summary entry in OMEGA Word, listing 3-5 trends from the VigiBase query and reconciliation with FAERS/EudraVigilance.
A brief follow-up suggestion for further analysis.",https://drive.google.com/file/d/1oNiPgyiFmOpWFP8Np4xezAF7mB5n6Vd2/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1rxvhdLlRJk6ObaUfOrGo3JEWPZVqf5UB/view?usp=sharing,"Access the ZANE VigiBase and input queries like ""aspirin tinnitus reports"" and ""aspirin tinnitus trends"" to retrieve data. Do the same with EudraVigilance.
Access Grok at Tools Section and reconcile.
Review the Reference Document (ICSR details below) to confirm the AE context.
Combine ZANE VigiBase outputs & FAERS/EudraVigilance summaries, analyzing 3-5 trends (e.g., report count, demographics).
Suggest a follow-up action (e.g., generate automated report for signal detection).
Open OMEGA Word and create a new document titled ""PV Signal Summary Entry - Case ID HP-2025-SG-001"".
Enter the 3-5 trends and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_03,les_2_03_06,task_2_03_06_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,Argus Safety System Intro,Argus Safety System Intro,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Ireland. You are tasked with entering an ICSR into Argus for an AE from a spontaneous report from a clinic in Singapore. The report details a patient who experienced rash after taking amoxicillin for infection. Using the Argus simulator, you will enter key case details, validate the entry with Grok (grok.com), and enter a simple case entry summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like HPRA (Ireland), HSA (Singapore), FDA, MHRA, EMA, and CDSCO.

Deliverables

A basic case entry summary entry in OMEGA Word, including the validated ICSR fields from the Argus simulator.
A brief follow-up suggestion for medical review.",https://drive.google.com/file/d/1PToIFl-_EVWUcJZBe1evyA-QOfggKMjI/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1v4aP-Yfjv3eYrWYJnKxRO-hAIVQCVaLe/view?usp=sharing,"Access the ZANE Argus and fill the ICSR. (Use reference document)
After entering all the information from the reference document and clicking “Create Case,” copy the case details and verify them using Grok.
Access Grok at Tools Section and input this prompt:
    
""Validate this Argus case entry for completeness: {input copied case details from ZANE Argus} Confirm if key fields are complete.""
    
Review the Reference Document (ICSR details below) to ensure accurate entry.
Summarize the validated fields from the simulator and Grok (e.g., patient info, drug, AE).
Suggest a follow-up action (e.g., perform causality assessment).
Submit in OMEGA within 24 hours.",10
course_2,ch_2_03,les_2_03_07,task_2_03_07_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,ARISg System Basics,ARISg System Basics,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Europe. You are tasked with entering an ICSR into ARISg for an AE from a spontaneous report from a clinic in Singapore. The report details a patient who experienced myalgia after taking atorvastatin for hypercholesterolemia. Using the ARISg simulator, you will enter key case details, validate the entry with Grok (grok.com), and enter a simple case entry summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), HSA (Singapore), FDA, MHRA, and CDSCO.

Deliverables

A basic case entry summary entry in OMEGA Word, including the validated ICSR fields from the ARISg simulator.
A brief follow-up suggestion for medical review.",https://drive.google.com/file/d/1-wDxJY_9UfFHyoI4zx4nzGFOt9IH4AHb/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/14F_nD6i8WwuRACyJlUyO2hmxq-2TNH_P/view?usp=sharing,"Access the ZANE ARISg and navigate to  Case Intake in sidebar then enter case fields like ""patient age: 60, sex: male, AE: myalgia, drug: atorvastatin, onset: September 20, 2025, seriousness: non-serious"".
After entering all the information from the reference document and clicking “Create Case,” copy the case details and verify them using Grok.
Access Grok at Tools Section and input this prompt:
    
""Validate this ARISg case entry for completeness:{input copied case details from ZANE ARISg} Confirm if key fields are complete.""
    
Review the Reference Document (ICSR details below) to ensure accurate entry.
Summarize the validated fields from the simulator and Grok (e.g., patient info, drug, AE).
Suggest a follow-up action (e.g., perform causality assessment).
Submit in OMEGA within 24 hours.",10
course_2,ch_2_03,les_2_03_08,task_2_03_08_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,Data Privacy in PV (GDPR/HIPAA),Data Privacy in PV (GDPR/HIPAA),"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in India. You are tasked with checking data privacy compliance for an ICSR based on a spontaneous report from a clinic in the USA. The report details a patient who experienced dizziness after taking enalapril for hypertension. Using Grok (grok.com), you will analyze the ICSR for GDPR/HIPAA issues, identify 3-5 privacy risks, suggest corrections, and enter a simple privacy check summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like CDSCO (India), FDA (USA), MHRA, EMA.

Deliverables

A basic privacy check summary entry in OMEGA Word, listing 3-5 privacy risks and suggested corrections.
A brief follow-up suggestion for compliance.",https://drive.google.com/file/d/1bcQ6Br4YHPevNgqofRBiunq-YFd8D-1G/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1ejUXUYYUXy65qbO4zmhaa5WqWYur3cV0/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
    
""Analyze this ICSR for GDPR/HIPAA privacy risks: Patient: Male, 50 years, hypertension, full name John Doe. Drug: Enalapril 10 mg oral daily, start September 15, 2025. AE: Dizziness, onset September 20, 2025, non-serious. Reporter: Dr. Jane Smith, phone +1-555-123-4567, email jane.smith@email.com. Suggest 3-5 risks and corrections.""
    
Review the Reference Document (ICSR details below) to confirm potential risks (e.g., non-anonymized data).
Identify 3-5 risks from Grok's output (e.g., visible identifiers, unprotected PHI).
Suggest corrections for each (e.g., pseudonymize patient name).
Open OMEGA Word and create a new document titled ""Privacy Check Summary Entry - Case ID HP-2025-US-001"".
Enter the 3-5 risks, corrections, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_03,les_2_03_09,task_2_03_09_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,Database Error Handling,Database Error Handling,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Europe. You are tasked with handling database errors for an ICSR based on a spontaneous report from a clinic in the USA. The report details a patient who experienced bleeding after taking clopidogrel for cardiovascular disease. Using Grok (grok.com), you will analyze the ICSR for errors, identify 3-5 issues, suggest corrections, and enter a simple error handling summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), FDA (USA), MHRA, CDSCO.

Deliverables

A basic error handling summary entry in OMEGA Word, listing 3-5 errors and suggested corrections.
A brief follow-up suggestion for prevention.",https://drive.google.com/file/d/1hI4DRHUxIdEGMQ3_YmbyyV3Vay0jBIEO/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1UExpnMj3aXS5QmRdH75Lx1s3gSaa7c-8/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Analyze this ICSR data for database errors like missing fields or incorrect formats:  Patient: Male, 70 years (age missing unit). Drug: Clopidogrel 75 mg oral daily, start September 15, 2025 (end date missing). AE: Bleeding, onset September 20, 2025, non-serious (MedDRA code missing).Narrative: Patient reported bleeding. No concomitant drugs.Suggest 3-5 errors and corrections.
Review the Reference Document (ICSR details below) to confirm potential errors (e.g. missing codes, formats).
Identify 3-5 errors from Grok's output (e.g., missing MedDRA code, incorrect age format).
Suggest corrections for each (e.g., add MedDRA code 10005329 for bleeding).
Open OMEGA Word and paste it. Hit submit.",10
course_2,ch_2_03,les_2_03_10,task_2_03_10_1,Pro Training in Pharmacovigilance,,Global PV Systems & Databases,PV System Integration,no-task,,,,,,
course_2,ch_2_04,les_2_04_01,task_2_04_01_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Signal Detection Overview,Signal Detection Overview,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Europe. You are tasked with querying global PV databases for an AE from an ICSR based on a spontaneous report from a clinic in India. The report details a patient who experienced hepatotoxicity after taking paracetamol for fever. Using the official VigiAccess website (vigiaccess.org) from WHO, you will query for paracetamol-hepatotoxicity data and enter a simple signal summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), CDSCO (India), FDA, MHRA.

Deliverables

A basic signal summary entry in OMEGA Word, listing 3-5 trends from the VigiAccess query and reconciliation with FAERS.
A brief follow-up suggestion for further analysis.",https://drive.google.com/file/d/1h2dALsdDrO0WjO24Fn-kJ0evOf2co89p/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1CyrUwSTeH7pOGFkyXcIQG146PkJ0UNLV/view?usp=drive_link,"Access the official VigiAccess website at vigiaccess.org and search for ""paracetamol"" (or ""acetaminophen"" if needed), then navigate to hepatotoxicity-related ADRs to retrieve data (e.g., report count, categories).
Review the Reference Document (ICSR details below) to confirm the AE context.
Open OMEGA Word & Enter the 3-5 trends and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_02,task_2_04_02_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Quantitative Signal Detection,Quantitative Signal Detection,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in India. You are tasked with performing quantitative signal detection for an AE from an ICSR based on a spontaneous report from a clinic in Europe. The report details a patient who experienced rhabdomyolysis after taking rosuvastatin for hypercholesterolemia. Using Grok (grok.com), you will calculate PRR, ROR, and IC from the provided dataset, interpret 3-5 key points, and enter a simple signal analysis summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like CDSCO (India), EMA (Europe), FDA, MHRA.

Deliverables

A basic signal analysis summary entry in OMEGA Word, listing 3-5 key points from the PRR/ROR/IC calculations.
A brief follow-up suggestion for validation.",https://drive.google.com/file/d/16iYoUSG7HHwfRZzLl73anSheXD8UmmGK/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1nnVpPE9waHL38ubdEETE793pdstOKQkj/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Calculate PRR, ROR, and IC for this AE dataset: Drug A (rosuvastatin) with AE: 50 cases, without AE: 950; All other drugs with AE: 100 cases, without AE: 9000. Interpret the results for signal detection.
Review the Reference Document (dataset details below) to confirm the calculation context.
Analyze 3-5 key points from Grok's output (e.g., PRR value, signal strength).
Suggest a follow-up action (e.g., manual review of cases).
Open OMEGA Word and create a new document titled ""Quantitative SD Summary Entry - Case ID HP-2025-EU-001"".
Enter the 3-5 points and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_03,task_2_04_03_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Qualitative Signal Detection,Qualitative Signal Detection,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Europe. You are tasked with performing qualitative signal detection for an AE from an ICSR based on a spontaneous report from a clinic in India. The report details a patient who experienced hyperkalemia after taking losartan for hypertension. Using Grok (grok.com), you will analyze the narrative for qualitative signals, identify 3-5 key points, and enter a simple narrative review summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), CDSCO (India), FDA, MHRA.

Deliverables

A basic narrative review summary entry in OMEGA Word, listing 3-5 key qualitative points from the analysis.
A brief follow-up suggestion for validation.",https://drive.google.com/file/d/1Bmpm6-yP3E7LVmch9pOB4mOyRNPpQbZr/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1UrG_kLHzZ3YZywr3keAG-XwQ5hk8bat-/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Analyze this ICSR narrative qualitatively for signals: A 65-year-old male with hypertension started losartan 50 mg oral daily on September 15, 2025, and reported hyperkalemia on September 20, 2025, with potassium level 5.8 mEq/L, non-serious, ongoing. No concomitant drugs, no renal issues noted. Identify 3-5 key qualitative points like patterns or clinical relevance.
Review the Reference Document (ICSR details below) to confirm the narrative context.
Identify 3-5 key points from Grok's output (e.g., temporal pattern, lack of alternatives).
Suggest a follow-up action (e.g., integrate with quantitative data).
Open OMEGA Word 
Enter the 3-5 points and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_04,task_2_04_04_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,AI for Signal Noise Reduction,AI for Signal Noise Reduction,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in India. You are tasked with reducing noise in a signal dataset for an AE from an ICSR based on a spontaneous report from a clinic in Europe. The report details a patient who experienced edema after taking valsartan for hypertension. Using Grok (grok.com), you will process the noisy dataset, filter 3-5 duplicates/false positives, and enter a simple cleaned signal summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like CDSCO (India), EMA (Europe), FDA, MHRA.

Deliverables

A basic cleaned signal summary entry in OMEGA Word, listing 3-5 filtered items (duplicates/false positives) and the remaining signals.
A brief follow-up suggestion for further validation.",https://drive.google.com/file/d/1zsGco1ILxaJ1U0MImShkGqS4bts4yHe6/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1_ffCWX4YtVP156RyHM3ILBv2dWDNYFFS/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Process this noisy AE dataset for valsartan-related edema: Dataset: Report 1: Edema after valsartan, serious; Report 2: Duplicate of Report 1; Report 3: Non-related headache; Report 4: Edema after valsartan, non-serious; Report 5: Low-quality, missing data; Report 6: Edema after valsartan, serious; Report 7: False positive, unrelated to drug. Filter 3-5 duplicates/false positives and summarize remaining signals.
Review the Reference Document (ICSR details below) to confirm the AE context.
Filter 3-5 items from Grok's output (e.g., duplicates, false positives).
Summarize the remaining signals (e.g., valid reports, trends).
Suggest a follow-up action (e.g., integrate with quantitative analysis).
Open OMEGA Word and create a new document titled ""AI Noise Reduction Summary Entry - Case ID HP-2025-EU-001"".
Enter the filtered items, remaining summary, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_05,task_2_04_05_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Risk Management Plans (RMP),Risk Management Plans (RMP),"You are a Pharmacovigilance Trainee at Morizo Pharma, a company based in India. You are tasked with checking data privacy compliance for an ICSR based on a spontaneous report from a clinic in the USA. The report details a patient who experienced cough after taking lisinopril for hypertension. Using AI, you will review for GDPR/HIPAA issues, identify 3-5 privacy risks, suggest corrections, and enter a simple privacy check summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like CDSCO (India), FDA (USA), MHRA, EMA.

Deliverables

A basic privacy check summary entry in OMEGA Word, listing 3-5 privacy risks and suggested corrections.
A brief follow-up suggestion for compliance.",https://drive.google.com/file/d/1Mjk9-eisgKQBs22UqLeidVW9PZlvfKS6/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1e6DrHiTYcwbaAHOqvl_TnfcOLf6470DA/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Review this ICSR for GDPR/HIPAA privacy risks: Patient: Male, 50 years, hypertension. Drug: Lisinopril 10 mg oral daily, start September 15, 2025. AE: Cough, onset September 20, 2025, non-serious. Suggest 3-5 risks and corrections.
Review the Reference Document (ICSR details below) to confirm potential risks (e.g., non-anonymized data).
Identify 3-5 risks
Suggest corrections for each (e.g., pseudonymize patient ID).
Open OMEGA Word and create a new document titled ""Privacy Check Summary Entry - Case ID HP-2025-US-001"".
Enter the 3-5 risks, corrections, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_06,task_2_04_06_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Signal Validation Process,Signal Validation Process,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Ireland. You are tasked with validating a potential signal from an ICSR based on a spontaneous report from a clinic in the USA. The report details a patient who experienced dry cough after taking ramipril for hypertension. Using Grok (grok.com), you will evaluate the signal for confirmation, list 3-5 key reasons, and enter a simple signal validation summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like HPRA (Ireland), FDA (USA), MHRA, EMA, CDSCO.

Deliverables

A basic signal validation summary entry in OMEGA Word, stating if confirmed (yes/no) and listing 3-5 key reasons.
A brief follow-up suggestion for action.",https://drive.google.com/file/d/1L0I7FnfsL0AmB5VOOUOpYLU7_uuc9SBx/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1O_rrOYJuPYm49YgPqm8Wvjxa9HHAcoHd/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Evaluate this potential signal for confirmation: A 55-year-old male with hypertension started ramipril 5 mg oral daily on September 15, 2025, and reported dry cough on September 20, 2025, non-serious, ongoing. No concomitant drugs, no respiratory issues noted. Determine if confirmed (yes/no) and provide 3-5 key reasons based on temporal relationship, plausibility, and data quality.
Review the Reference Document (ICSR details below) to confirm the signal context.
Determine confirmation status and list 3-5 reasons from Grok's output (e.g., temporal pattern, known class effect).
Suggest a follow-up action (e.g., recommend further monitoring).
Open OMEGA Word and create a new document titled ""Signal Validation Summary Entry - Case ID HP-2025-US-001"".
Enter the status, 3-5 reasons, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_07,task_2_04_07_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Disproportionality Analysis,Disproportionality Analysis,"You are a Pharmacovigilance Trainee at Global Pharma, a company based in Europe. You are tasked with performing disproportionality analysis for an AE from an ICSR based on a spontaneous report from a clinic in India. The report details a patient who experienced angioedema after taking lisinopril for hypertension. Using Grok (grok.com), you will calculate PRR, ROR, and IC from the provided dataset, interpret 3-5 key points, and enter a simple DPA summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), CDSCO (India), FDA, MHRA.

Deliverables

A basic DPA summary entry in OMEGA Word, listing 3-5 key points from the PRR/ROR/IC calculations.
A brief follow-up suggestion for validation.",https://drive.google.com/file/d/1m99fUOBePRBhYKMjxW9dFR2WhmI4jpT0/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1__y6ZJvvo3J7VmeWBO-niLjENTzLhf2O/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Calculate PRR, ROR, and IC for this AE dataset: Drug A (lisinopril) with AE: 30 cases, without AE: 970; All other drugs with AE: 50 cases, without AE: 9500. Interpret the results for signal detection.
Review the Reference Document (ICSR details below) to confirm the calculation context.
Analyze 3-5 key points from Grok's output (e.g., PRR value, signal strength).
Suggest a follow-up action (e.g., clinical review of cases).
Open OMEGA Word and create a new document titled ""DPA Summary Entry - Case ID GP-2025-IN-001"".
Enter the 3-5 points and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_08,task_2_04_08_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Signal Reporting Standards,Signal Reporting Standards,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the USA. You are tasked with drafting a signal report for a potential safety issue from an ICSR based on a spontaneous report from a clinic in Europe. The report details a patient who experienced hepatotoxicity after taking atorvastatin for hypercholesterolemia. Using the official VigiAccess website (vigiaccess.org) from WHO, you will query for atorvastatin-hepatotoxicity data, draft a mock signal report with Grok (grok.com), and enter a simple signal report summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like FDA (USA), EMA (Europe), MHRA, CDSCO.

Deliverables

A basic signal report summary entry in OMEGA Word, including 3-5 key elements from the VigiAccess query and draft report.
A brief follow-up suggestion for regulatory action.",https://drive.google.com/file/d/1LqADSI28jM6FUXKt7VV7LEQjDJNHEjTY/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1VNynKLlWsFCy2lViYYn0Z2cwF-331SZZ/view?usp=sharing,"Access the official VigiAccess website at vigiaccess.org and search for ""atorvastatin"" (or ""statin"" if needed), then navigate to hepatotoxicity-related ADRs to retrieve data (e.g., report count, categories) – take screenshots or note key stats creatively to build your report.
Access Grok at Tools Section and input this prompt:
Draft a mock signal report for atorvastatin-related hepatotoxicity: Include signal description, data sources (VigiBase stats), assessment (seriousness, causality), and recommendations (e.g., RMP update). Summarize in 3-5 key points.
Review the Reference Document (ICSR details below) to confirm the AE context.
Combine VigiAccess data with Grok's draft, listing 3-5 key elements (e.g., report count, recommendations).
Suggest a follow-up action (e.g., submit to EMA).
Open OMEGA Word and create a new document titled ""Signal Report Summary Entry - Case ID HP-2025-EU-001"".
Enter the 3-5 elements and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_09,task_2_04_09_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Risk Minimization Strategies,Risk Minimization Strategies,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in India. You are tasked with designing an RMS for a potential risk from an ICSR based on a spontaneous report from a clinic in Europe. The report details a patient who experienced hepatotoxicity after taking terbinafine for fungal infection. Using the official VigiAccess website (vigiaccess.org) from WHO, you will query for terbinafine-hepatotoxicity data (e.g., report count, seriousness), then use Grok (grok.com) to design a creative RMS intervention (e.g., a patient education app or HCP monitoring toolkit), and enter a simple RMS design summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like CDSCO (India), EMA (Europe), FDA, MHRA.

Deliverables

A basic RMS design summary entry in OMEGA Word, describing the creative intervention and 3 key data points from VigiAccess that justify it.
A brief follow-up suggestion for effectiveness measurement.",https://drive.google.com/file/d/1qv0Arw4w46Ynr5aTHm4L7yucaFfl38zh/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1TTHryW1_JxIZq6F52e19JjIBVQyHIM5T/view?usp=sharing,"Access the official VigiAccess website at vigiaccess.org and search for ""terbinafine"" (or ""lamisil"" if needed), then navigate to hepatotoxicity-related ADRs to retrieve data (e.g., report count, categories) – note 3 key points creatively to inform your design.
Access Grok at Tools Section and input this prompt:
Design a creative RMS intervention (e.g., patient app or HCP toolkit) for terbinafine-related hepatotoxicity based on this data: [paste your 3 VigiAccess points]. Make it practical and engaging.
Review the Reference Document (ICSR details below) to confirm the AE context.
Describe the creative intervention from Grok's output, linking to your 3 VigiAccess points.
Suggest a follow-up action (e.g., measure via patient feedback surveys).
Open OMEGA Word and create a new document titled ""RMS Design Summary Entry - Case ID HP-2025-EU-001"".
Enter the description, 3 points, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_04,les_2_04_10,task_2_04_10_1,Pro Training in Pharmacovigilance,,Signal Detection & Risk Management,Signal Dashboards,Omegamentorship,,,,,,
course_2,ch_2_05,les_2_05_01,task_2_05_01_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,PSUR Overview & Requirements,PSUR Overview & Requirements,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in India. You are tasked with preparing a PSUR overview for a potential safety issue from an ICSR based on a spontaneous report from a clinic in Europe. The report details a patient who experienced gastrointestinal bleeding after taking ibuprofen for pain. Using the official VigiAccess website (vigiaccess.org) from WHO, you will query for ibuprofen-gastrointestinal bleeding data (e.g., report count, trends), then use Grok (grok.com) to generate a creative mini-PSUR storyboard (e.g., a text-based ""comic strip"" narrative of safety summary and benefit-risk), and enter a simple PSUR storyboard summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like CDSCO (India), EMA (Europe), FDA, MHRA.

Deliverables

A basic PSUR storyboard summary entry in OMEGA Word, including 3 key data points from VigiAccess and the creative storyboard text from Grok.
A brief follow-up suggestion for full PSUR submission.",https://drive.google.com/file/d/1WGttyR9Vfvx0eJ1EKhKi8t5jcdDT5vNS/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1Ajof6vizWRt8RLoS5jcHTZWfDCZcED4r/view?usp=sharing,"Access the official VigiAccess website at vigiaccess.org and search for ""ibuprofen"" (or ""NSAID"" if needed), then navigate to gastrointestinal bleeding-related ADRs to retrieve data (e.g., report count, categories) – note 3 key points to inform your storyboard.
Access Grok at Tools Section and input this prompt:
Generate a creative mini-PSUR storyboard in text form (like a comic strip narrative) for ibuprofen-related gastrointestinal bleeding: Include sections for safety summary, benefit-risk assessment, and conclusions, based on this data: [paste your 3 VigiAccess points]. Make it engaging and story-like.
Review the Reference Document (ICSR details below) to confirm the AE context.
Combine VigiAccess data with Grok's storyboard, listing the 3 points and storyboard text.
Suggest a follow-up action (e.g., submit to CDSCO for review).
Open OMEGA Word and create a new document titled ""PSUR Storyboard Summary Entry - Case ID HP-2025-EU-001"".
Enter the 3 points, storyboard text, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_02,task_2_05_02_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,DSUR Basics & Timelines,DSUR Basics & Timelines,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Europe. You are tasked with preparing DSUR timelines for an ongoing clinical trial from an ICSR based on a report from a clinic in India. The report details a patient who experienced fatigue after taking sofosbuvir for hepatitis C. Using Grok (grok.com), you will calculate the annual submission timeline from IND approval date, generate a creative text-based DSUR infographic (e.g., a described timeline graphic), and enter a simple DSUR timeline summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), CDSCO (India), FDA, MHRA.

Deliverables

A basic DSUR timeline summary entry in OMEGA Word, including the calculated timeline and creative infographic text from Grok.
A brief follow-up suggestion for data inclusion.",https://drive.google.com/file/d/1329IQ-VkcYWx1_LjOaai2LwRE4-aSVR6/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1-x7lcirQSMQGSOCcZRdzootNToFSp5d0/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Calculate DSUR timelines for this clinical trial: IND approval date September 15, 2025, for sofosbuvir in hepatitis C trials. Provide annual submission deadlines and generate a creative text-based infographic (e.g., a visual timeline description) for the first 2 years.
Review the Reference Document (ICSR details below) to confirm the trial context.
Calculate timelines from Grok's output (e.g., first DSUR due November 15, 2026).
Include the creative infographic text (e.g., a described graphic timeline).
Suggest a follow-up action (e.g., include interval safety data).
Open OMEGA Word
Enter the timeline, infographic text, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_03,task_2_05_03_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,Data Aggregation for Reports,Data Aggregation for Reports,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in Europe. You are tasked with aggregating data for a PSUR from a batch of ICSRs based on spontaneous reports from clinics in the USA. The reports detail patients who experienced myalgia after taking atorvastatin for hypercholesterolemia. Using Grok (grok.com), you will clean the dataset (e.g., remove duplicates, fix missing fields), tabulate AE frequencies (e.g., by seriousness, age), and enter a simple aggregated data summary in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (Europe), FDA (USA), MHRA, CDSCO.

Deliverables

A basic aggregated data summary entry in OMEGA Word, including a tabulated AE frequency summary (e.g., table of seriousness counts) and 3 key trends.
A brief follow-up suggestion for PSUR inclusion.",https://drive.google.com/file/d/1XPYAcis1MVPhNgN5liB6UedN6NPax9ta/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1vKesT01VER71-q2NcqKoVF9XkG9y0nLo/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Clean this ICSR dataset for aggregation: [paste the full Reference Document dataset]. Remove duplicates, fix missing fields (e.g., assume seriousness 'Non-serious' if missing), standardize MedDRA codes, then tabulate AE frequencies by seriousness and age group. Summarize 3 key trends.
Review the Reference Document (dataset below) to confirm the data context.
Clean and tabulate based on Grok's output (e.g., table of myalgia cases by seriousness).
Analyze 3 key trends (e.g., higher in elderly, mostly non-serious).
Suggest a follow-up action (e.g., include in PSUR risk evaluation).
Open OMEGA Word and create a new document titled ""Data Aggregation Summary Entry - Case ID HP-2025-US-001"".
Enter the tabulated summary, 3 trends, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_04,task_2_05_04_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,AI for PSUR Drafting,AI for PSUR Drafting,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. You are tasked with drafting a PSUR section for a potential safety issue from an ICSR based on a spontaneous report from a clinic in the USA. The report details a patient who experienced angioedema after taking valsartan for hypertension. Using Grok (grok.com) as an NLP tool, you will draft the ""Summary of Safety Concerns"" section, edit it for clinical accuracy, and enter the revised section in OMEGA Word for submission, ensuring compliance with regulatory authorities like MHRA (UK), FDA (USA), EMA, CDSCO.

Deliverables

A revised PSUR section entry in OMEGA Word, including the AI-drafted text and 1-2 human edits with explanations.
A brief follow-up suggestion for quality review.",https://drive.google.com/file/d/1EMuqyO0pCzlbNM0Y6bjIwhgCbD4f9VUj/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1OfpYt5XG5WtAVjqd5dgMwPuymbwG1IWE/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Draft a PSUR 'Summary of Safety Concerns' section for valsartan-related angioedema: Include known risks, potential risks, and missing information, based on this data: 300 reports, 70% serious, onset average 2 weeks, higher in females. Make it concise and regulatory-style.
Review the Reference Document (ICSR details below) to confirm the AE context.
Edit the Grok draft by adding 1-2 refinements (e.g., add a clinical note or correct a detail for accuracy).
Explain your edits briefly (e.g., ""Added female predominance emphasis for precision"").
Suggest a follow-up action (e.g., submit for medical review).
Open OMEGA Word and create a new document titled ""PSUR Draft Section Entry - Case ID HP-2025-US-001"".
Enter the revised section, edits explanation, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_05,task_2_05_05_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,Line Listings & Summary Tabulations,Line Listings & Summary Tabulations,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. You are tasked with creating a summary tabulation from a line listing derived from aggregated ICSRs reported to databases like EudraVigilance and FAERS, focusing on ibuprofen-related gastrointestinal bleeding. Using Grok (grok.com) as an NLP tool, you will draft the ""Summary Tabulation"" section, edit it for clinical and regulatory accuracy, and enter the revised section in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India).

Deliverables

A revised Summary Tabulation entry in OMEGA Word, including the AI-drafted text and 1-2 human edits with explanations.
A brief follow-up suggestion for quality review.",https://drive.google.com/file/d/1dp2god4RLsTzQcbscszDHxCjedmApp51/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1BO-SkiQtd20KBiqwfWfegD9m3o-6zhyK/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Draft a Summary Tabulation section for ibuprofen-related gastrointestinal bleeding: Include counts and percentages by seriousness, age groups, sex, outcomes, and trends, based on this data: 200 reports, 60% serious, age distribution (20% under 18, 50% 18-65, 30% over 65), 55% female, outcomes (70% recovered, 20% ongoing, 10% fatal). Make it concise and regulatory-style, using MedDRA terminology.
Review the Reference Document (sample line listing details below) to confirm the AE context and aggregation.
Edit the Grok draft by adding 1-2 refinements (e.g., add a note on MedDRA coding or adjust for demographic trends for accuracy).
Explain your edits briefly (e.g., ""Added emphasis on elderly risk for precision based on age distribution"").
Suggest a follow-up action (e.g., recommend signal evaluation for high-risk groups).
Open OMEGA Word and create a new document titled ""Summary Tabulation Draft Section - Case ID HP-2025-EU-US-001"".
Enter the revised section, edits explanation, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_06,task_2_05_06_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,PSUR Quality Checks,PSUR Quality Checks,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. You are tasked with performing quality checks on a draft PSUR section derived from aggregated ICSRs reported to databases like FAERS and EudraVigilance, focusing on atorvastatin-related myopathy. Using Grok (grok.com) as an NLP tool, you will draft the ""PSUR Quality Check Summary"" section, edit it for compliance and accuracy, and enter the revised section in OMEGA Word for submission, ensuring compliance with regulatory authorities like FDA (USA), EMA (EU), MHRA (UK), and CDSCO (India).

Deliverables

A revised PSUR Quality Check Summary entry in OMEGA Word, including the AI-drafted text and 1-2 human edits with explanations.
A brief follow-up suggestion for quality review.",https://drive.google.com/file/d/1g_ZIz1wZbvYQq6LKe6SqK_RSBEFKXxbW/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/14AhGYHS1a_OKKV4qWwEYaKlH2wiDy3q4/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Draft a PSUR Quality Check Summary for atorvastatin-related myopathy: Include verification of data accuracy, completeness, consistency, regulatory compliance, and key trends, based on this data: 150 reports, 65% serious, age distribution (15% under 18, 55% 18-65, 30% over 65), 60% male, outcomes (75% recovered, 15% ongoing, 10% fatal). Make it concise and regulatory-style, referencing MedDRA coding.
Review the Reference Document (sample PSUR details below) to confirm the quality check context.
Edit the Grok draft by adding 1-2 refinements (e.g., add a note on duplicate detection or adjust for consistency in terminology for accuracy).
Explain your edits briefly (e.g., ""Added reference to ICH E2C(R2) for regulatory compliance emphasis"").
Suggest a follow-up action (e.g., schedule an independent review).
Open OMEGA Word and create a new document titled ""PSUR Quality Check Draft Summary - Case ID HP-2025-US-EU-001"".
Enter the revised section, edits explanation, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_07,task_2_05_07_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,DSUR Case Study Analysis,DSUR Case Study Analysis,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. You are tasked with analyzing a DSUR section from aggregated clinical trial data (Phase II/III) reported to databases like ClinicalTrials.gov and EudraCT, focusing on Cardiostimab-related elevated liver enzymes in chronic heart failure trials. Using Grok (grok.com) as an NLP tool, you will draft the ""Signal Detection and Risk Evaluation"" section, edit it for clinical and regulatory accuracy, and enter the revised section in OMEGA Word for submission, ensuring compliance with regulatory authorities like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India).

Deliverables

A revised Signal Detection and Risk Evaluation entry in OMEGA Word, including the AI-drafted text and 1-2 human edits with explanations.
A brief follow-up suggestion for quality review.",https://drive.google.com/file/d/1r1-S4_g7WYzEFcK6GGHoENUBxbPfyaUD/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1-Jp2n_taiKr9qQb9XOW_ZEHnReH6BnvK/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Draft a DSUR 'Signal Detection and Risk Evaluation' section for Cardiostimab-related elevated liver enzymes: Include signal identification, causality assessment, risk evaluation, and recommendations, based on this data: 100 reports, 50% serious, incidence rate 5 per 100 patient-years, higher in Phase III, temporal association average 4 weeks, dose-response observed. Make it concise and regulatory-style, using MedDRA terminology.
Review the Reference Document (sample DSUR case details below) to confirm the analysis context.
Edit the Grok draft by adding 1-2 refinements (e.g., add a note on benefit-risk implications or adjust for confounding factors for accuracy).
Explain your edits briefly (e.g., ""Added comparison to preclinical data for comprehensive risk evaluation"").
Suggest a follow-up action (e.g., escalate to Safety Review Committee).
Open OMEGA Word and create a new document titled ""DSUR Draft Section Entry - Case ID HP-2025-UK-EU-001"".
Enter the revised section, edits explanation, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_08,task_2_05_08_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,Regulatory Submission of Reports,Regulatory Submission of Reports,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. You are tasked with preparing a section for regulatory submission from aggregated ICSRs reported to databases like FAERS and EudraVigilance, focusing on metformin-related lactic acidosis. Using Grok (grok.com) as an NLP tool, you will draft the ""Key Considerations for Submission"" section, edit it for compliance and accuracy, and enter the revised section in OMEGA Word for submission, ensuring compliance with regulatory authorities like FDA (USA), EMA (EU), MHRA (UK), and CDSCO (India).

Deliverables

A revised Key Considerations for Submission entry in OMEGA Word, including the AI-drafted text and 1-2 human edits with explanations.
A brief follow-up suggestion for quality review.",https://drive.google.com/file/d/1TFlcNSXy5TYhQbr1Jo8idNtp0lsr7kPH/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1Fs0IP2lkAuBGjM30C-qzM6qRmzE0IDB6/view?usp=sharing,"Access Grok at Tools Section and input this prompt:
Draft a 'Key Considerations for Submission' section for a regulatory report on metformin-related lactic acidosis: Include data quality, compliance, traceability, and recommendations, based on this data: 120 reports, 70% serious, age distribution (10% under 18, 60% 18-65, 30% over 65), 50% female, outcomes (65% recovered, 25% ongoing, 10% fatal). Make it concise and regulatory-style, referencing MedDRA coding.
Review the Reference Document (sample regulatory report details below) to confirm the submission context.
Edit the Grok draft by adding 1-2 refinements (e.g., add a note on data privacy compliance or adjust for regional variations for accuracy).
Explain your edits briefly (e.g., ""Added GDPR/HIPAA reference for data privacy emphasis"").
Suggest a follow-up action (e.g., monitor regulatory acknowledgment).
Open OMEGA Word and create a new document titled ""Regulatory Submission Draft Section - Case ID HP-2025-US-EU-002"".
Enter the revised section, edits explanation, and follow-up in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_09,task_2_05_09_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,Handling PSUR Queries,Handling PSUR Queries,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. You've received a batch of PSUR queries from various regulators (e.g., EMA, FDA) about a report on clopidogrel-related thrombocytopenia. Your challenge is to act as a ""Query Detective"" by matching each query to the most appropriate handling strategy and rationale from a provided list, ensuring accurate, timely responses that maintain compliance with authorities like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India).

Deliverables

A completed Query Matching Table in OMEGA Word, showing matched queries, strategies, and rationales.
A brief explanation of one ""aha"" moment from the puzzle (e.g., why a certain match was tricky or insightful).",https://drive.google.com/file/d/1FEMuWP1hLn8hlVOjeOf6fVXtqRYHWUHQ/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1xRK493g2qjJGht2BDRpzM60oW1xeZPGv/view?usp=sharing,"Review the Reference Document (sample queries and options below) to familiarize yourself with the puzzle elements.
Analyze each query: Identify its focus (e.g., discrepancy, missing data) based on the study document's guidance on query nature.
Match to strategies: Select the best handling strategy (A-E) and rationale (1-5) from the lists provided.
Build the table: Use a simple table format in OMEGA Word with columns for Query Number, Matched Strategy (letter), Matched Rationale (number), and Brief Justification.
Add your insight: Note one interesting takeaway from the matching process.
Open OMEGA Word and create a new document titled ""PSUR Query Matching Puzzle - Case ID HP-2025-UK-US-001"".
Enter the table and insight in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_05,les_2_05_10,task_2_05_10_1,Pro Training in Pharmacovigilance,,Aggregate Safety Reporting,Periodic Report Automation,omegamentorship,,,,,,
course_2,ch_2_06,les_2_06_01,task_2_06_01_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,MedDRA Hierarchy Overview,MedDRA Hierarchy Overview,"You are a Pharmacovigilance Trainee at Horizon Pharma, a company based in the UK. Your team is preparing a PSUR for paracetamol-related adverse events. In this ""Quick Code Quest,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code three simple patient-reported adverse events into MedDRA Preferred Terms (PTs). You’ll verify one PT for accuracy and write a brief note for the PSUR, ensuring compliance with authorities like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India).

Deliverables

A MedDRA Coding Note in OMEGA Word, listing the three descriptions, their PTs, one verification note, and a brief PSUR comment.
A one-sentence reflection on using the tool.",https://drive.google.com/file/d/1YKkljzQjj33BzHYbyNPUGokHsv5I4eqh/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1YXkVQ4SgContbfF_kOdkMX7tmdhM3icF/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (three adverse event descriptions below) for input.
Input each description into the tool’s “Adverse Event Coder” field, using the latest MedDRA version (e.g., 27.0), to generate the PT.
Verify one PT: Check if the tool’s PT for the first description makes sense (e.g., matches the symptom logically).
Write the note: In OMEGA Word, list the descriptions, PTs, a verification note for the first PT, and a one-sentence PSUR comment on how these codes help.
Add reflection: Note one thing you learned about the tool or MedDRA.
Open OMEGA Word and create a document titled ""Quick Code Quest Note - Case ID HP-2025-UK-EU-004"".
Enter the note and reflection in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_02,task_2_06_02_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,"LLT, PT, and SOC Coding","LLT, PT, and SOC Coding","You are a Pharmacovigilance Trainee at Horizon Pharma, a UK-based company, on a mission as a ""Safety Code Explorer."" Your team is preparing a PSUR for omeprazole-related adverse events from spontaneous reports. In this ""Adverse Event Coding Adventure,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code four patient-reported adverse events into LLTs, PTs, and SOCs. You’ll log your findings in a vibrant summary for the PSUR, ensuring compliance with authorities like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as decoding clues to keep the safety map clear!

Deliverables

An Adventure Log in OMEGA Word, listing the four adverse event descriptions, their LLT, PT, and SOC codes from the tool, and a one-sentence PSUR note on their value.
A one-sentence ""Explorer’s Insight"" on what made the coding fun or clear.",https://drive.google.com/file/d/1W-N3ZdkQKTV1CFZET_aSLdWezCeMJ--R/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1Wt5Y3Ee1Fuwir0iXtjwzGkdQbU6Za9Bc/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (four adverse event descriptions below) to prepare your inputs.
Input each description: Enter the exact text into the tool's ""Adverse Event Coder"" field, select MedDRA version 27.0, and generate the LLT, PT, and SOC.
Log the codes: Record the tool's output for each description (LLT, PT, SOC) in a table.
Write the PSUR note: Add a one-sentence comment on how these codes help the PSUR (e.g., spotting trends).
Add your insight: Note one fun or clear aspect of using the tool or MedDRA.
Open OMEGA Word and create a document titled ""Adverse Event Coding Adventure Log - Case ID HP-2025-UK-EU-005"".
Enter the log table, PSUR note, and insight in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_03,task_2_06_03_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,AI for MedDRA Auto-Coding,AI for MedDRA Auto-Coding,"You are an AI Safety Coder at Horizon Pharma, a UK-based company, working on a PSUR for a new antihypertensive drug, Novacard, in a Phase III clinical trial. In this ""AI Code Quest,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to auto-code four colorful adverse event descriptions into LLTs, PTs, and SOCs. You’ll validate one code for accuracy and create a brief report for the PSUR, ensuring compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as a high-tech adventure to turn messy patient reports into clear, regulatory-ready codes!

Deliverables

An AI Code Quest Report in OMEGA Word, listing the four descriptions, their auto-generated LLT, PT, and SOC codes, a validation note for one code, and a one-sentence PSUR note.
A one-sentence ""Coder’s Spark"" on what made the AI coding process exciting or clear.",https://drive.google.com/file/d/1PGMkUSLQ550iU-UtM-vdOhrbY3rp8KD3/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/16yv_N_bgWOABGKAZQSusvwXuB9vkf2fK/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (four adverse event descriptions below) to prepare inputs.
Input each description: Enter the exact text into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate LLT, PT, and SOC codes.
Validate one code: For the first description, check if the tool’s LLT and PT match the reported symptom (e.g., does “tummy upset” map to “Abdominal discomfort” logically?).
Create the report: In OMEGA Word, list the descriptions, their codes, a validation note for the first description, and a one-sentence PSUR note on how these codes help.
Add your spark: Note one exciting or clear aspect of using the AI tool.
Open OMEGA Word and create a document titled ""AI Code Quest Report - Case ID HP-2025-UK-EU-006"".
Enter the report and spark in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_04,task_2_06_04_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,Coding Accuracy Checks,Coding Accuracy Checks,"You are a Code Check Agent at Horizon Pharma, a UK-based company, working on a PSUR for ibuprofen-related adverse events from spontaneous reports. In this ""Code Check Challenge,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to auto-code three patient-reported adverse events into LLTs, PTs, and SOCs. You’ll verify the accuracy of one code against its source description and compile a brief report for the PSUR, ensuring compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as a mission to catch any coding slip-ups and keep the safety data crystal clear!

Deliverables

A Code Check Agent’s Report in OMEGA Word, listing the three descriptions, their LLT, PT, and SOC codes, an accuracy check note for one code, and a one-sentence PSUR comment.
A one-sentence ""Agent’s Clue"" on what made the accuracy check interesting or useful.",https://drive.google.com/file/d/1lW3e4gG42a7JXPVQDt6v7jb7wYkb3oub/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1lpqLPjP-WKdkED2LHndwiptWZD6Qcul0/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (three adverse event descriptions below) to prepare inputs.
Input each description: Enter the exact text into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate LLT, PT, and SOC codes.
Perform accuracy check: For the first description, verify if the tool’s LLT and PT match the reported symptom (e.g., does “bad tummy pain” align with “Abdominal pain”?) and note any issues.
Create the report: In OMEGA Word, list the descriptions, their codes, an accuracy check note for the first description, and a one-sentence PSUR comment on how these codes help.
Add your clue: Note one interesting or useful aspect of the accuracy check process.
Open OMEGA Word and create a document titled ""Code Check Challenge Report - Case ID HP-2025-UK-EU-007"".
Enter the report and clue in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_05,task_2_06_05_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,Complex Case Coding,Complex Case Coding,"You are a Safety Coding Detective at Horizon Pharma, a UK-based company, working on a PSUR for atorvastatin-related adverse events from spontaneous reports. In this ""Complex Case Coding Mystery,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code two complex patient-reported adverse events, each involving multiple symptoms, into LLTs, PTs, and SOCs. You’ll verify the coding accuracy for one case and create a concise Case File for the PSUR, ensuring compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as solving a mystery to untangle tricky patient reports into clear, regulatory-ready codes!

Deliverables

A Complex Case Coding Case File in OMEGA Word, listing the two descriptions, their LLT, PT, and SOC codes, an accuracy check note for one case, and a one-sentence PSUR comment.
A one-sentence ""Detective’s Insight"" on what made the coding process interesting or clear.",https://drive.google.com/file/d/1G__hU4iatiZZT5BkHGUCSmU7E3i4gzKK/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1_PVykqwb_BEmunr5oWAzIw9oWG8c2SQ-/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (two complex adverse event descriptions below) to prepare inputs.
Input each description: Enter the exact text into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate LLT, PT, and SOC codes for each symptom.
Perform accuracy check: For the first description, verify if the tool’s LLTs and PTs logically match the reported symptoms (e.g., do “muscle soreness” and “tummy trouble” align with correct PTs?)
Create the Case File: In OMEGA Word, list the descriptions, their codes, an accuracy check note for the first description, and a one-sentence PSUR comment on how these codes help.
Add your insight: Note one interesting or clear aspect of the coding process.
Open OMEGA Word and create a document titled ""Complex Case Coding Case File - Case ID HP-2025-UK-EU-008"".
Enter the Case File and insight in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_06,task_2_06_06_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,Narrative Quality Standards,Narrative Quality Standards,"You are a Narrative Detective at Horizon Pharma, a UK-based company, preparing a PSUR for metformin-related adverse events from spontaneous reports. In this ""Narrative Detective Mission,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code adverse events from two simplified patient narratives, each with multiple details, into LLTs, PTs, and SOCs. You’ll then draft a concise Case Summary for the PSUR, ensuring clarity, completeness, and compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as solving a case to make patient stories crystal clear for regulators!

Deliverables

A Narrative Detective Case Summary in OMEGA Word, listing the two narratives, their LLT, PT, and SOC codes, a brief quality check note for one narrative, and a one-sentence PSUR comment.
A one-sentence ""Detective’s Discovery"" on what made the narrative coding or quality check fun or clear.",https://drive.google.com/file/d/1m8TsElYKtWcWyXQmEyU2qn1-upnI7OEQ/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1MYBEUnPtDaewaXZztXMlEd0CtJFZJAeG/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (two simplified patient narratives below) to prepare inputs.
Input adverse events: For each narrative, identify the adverse event(s), enter them into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate LLT, PT, and SOC codes.
Perform quality check: For the first narrative, verify if the coded terms and narrative details (e.g., outcome, causality) align with ICH E2B(R3) standards (e.g., clear, complete).
Create the Case Summary: In OMEGA Word, list the narratives, their codes, a quality check note for the first narrative, and a one-sentence PSUR comment on how these summaries help.
Add your discovery: Note one fun or clear aspect of the coding or quality check process.
Open OMEGA Word and create a document titled ""Narrative Detective Case Summary - Case ID HP-2025-UK-EU-009"".
Enter the Case Summary and discovery in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_07,task_2_06_07_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,Follow-Up Case Processing,Follow-Up Case Processing,"You are a Case Follow-Up Agent at Horizon Pharma, a UK-based company, working on a PSUR for amoxicillin-related adverse events from spontaneous reports. In this ""Follow-Up Case Quest,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code updated adverse event details from two simplified follow-up case reports, each with new information (e.g., outcomes, additional symptoms). You’ll verify the coding accuracy for one case and create a short Case Update Log for the PSUR, ensuring compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as piecing together the final clues to complete the safety case file!

Deliverables

A Case Update Log in OMEGA Word, listing the two follow-up case reports, their updated LLT, PT, and SOC codes, an accuracy check note for one case, and a one-sentence PSUR comment.
A one-sentence ""Agent’s Insight"" on what made the follow-up coding or verification process fun or clear.",https://drive.google.com/file/d/1M7HGggrtjveZu7WILunDMYCqx3cVkG0o/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1cYsmDzLVu0F9ycmUpsoXW9DOEMYCqlZ7/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (two follow-up case reports below) to identify new adverse event details for coding.
Input updated adverse events: For each report, enter the new or updated adverse event(s) into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate LLT, PT, and SOC codes.
Perform accuracy check: For the first case, verify if the coded terms and updated details (e.g., outcome, new symptom) align with ICH E2B(R3) standards (e.g., complete, accurate).
Create the Case Update Log: In OMEGA Word, list the follow-up reports, their updated codes, an accuracy check note for the first case, and a one-sentence PSUR comment on how these updates help.
Add your insight: Note one fun or clear aspect of the follow-up coding or verification process.
Open OMEGA Word and create a document titled ""Follow-Up Case Quest Log - Case ID HP-2025-UK-EU-010"".
Enter the Case Update Log and insight in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_08,task_2_06_08_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,Coding Error Resolution,Coding Error Resolution,"You are a Code Fix Agent at Horizon Pharma, a UK-based company, working on a PSUR for simvastatin-related adverse events from spontaneous reports. In this ""Code Fix Mission,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code three adverse event descriptions, identify one intentional coding error in the provided initial codes, correct it using the tool, and create a short Mission Report for the PSUR. This ensures compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as spotting and fixing a hidden mistake to keep the safety data spotless!

Deliverables

A Code Fix Mission Report in OMEGA Word, listing the three descriptions, their correct LLT, PT, and SOC codes, a correction note for the identified error, and a one-sentence PSUR comment.
A one-sentence ""Agent’s Breakthrough"" on what made spotting or fixing the error interesting or clear.",https://drive.google.com/file/d/1olyRp_tiTHRGPGSjwTr2YJizey5SxOJs/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1-Ik-Z3c_CimXan7P_4czeC-cWEYQrkmG/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (three adverse event descriptions and initial codes below) to identify the coding error.
Input each description: Enter the exact text into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate correct LLT, PT, and SOC codes.
Identify and correct error: Compare the tool’s output to the initial codes in the Reference Document; spot the error (one description has an incorrect PT) and note the correction.
Create the Mission Report: In OMEGA Word, list the descriptions, their correct codes, a correction note for the error, and a one-sentence PSUR comment on how the fix helps.
Add your breakthrough: Note one interesting or clear aspect of spotting or fixing the error.
Open OMEGA Word and create a document titled ""Code Fix Mission Report - Case ID HP-2025-UK-EU-011"".
Enter the Mission Report and breakthrough in OMEGA Word
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_09,task_2_06_09_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,MedDRA Version Updates,MedDRA Version Updates,"You are a Version Update Explorer at Horizon Pharma, a UK-based company, preparing a PSUR for losartan-related adverse events from spontaneous reports. In this ""Version Update Adventure,"" you’ll use the Zane MedDRA Simulation Tool (accessible at Tools Section ) to code three adverse event descriptions using MedDRA version 27.0. You’ll compare one code to a previous version (26.0) to identify a term update and create a short Update Log for the PSUR, ensuring compliance with regulators like EMA (EU), FDA (USA), MHRA (UK), and CDSCO (India). Think of it as exploring a new map to keep safety data up to date!

Deliverables

A Version Update Log in OMEGA Word, listing the three descriptions, their LLT, PT, and SOC codes from MedDRA 27.0, a comparison note for one code against version 26.0, and a one-sentence PSUR comment.
A one-sentence ""Explorer’s Insight"" on what made the version update process interesting or clear.",https://drive.google.com/file/d/1QMO7EEVsZoX4hKd703R62qVdkXllKA_0/view?usp=sharing,https://tally.so/r/n021q6,https://drive.google.com/file/d/1Fse7ZwpmevVtZ_g2Codtkdi0mCNOTpbW/view?usp=sharing,"Access the Zane MedDRA in tools section with your trainee credentials.
Review the Reference Document (three adverse event descriptions and version 26.0 codes below) to prepare inputs.
Input each description: Enter the exact text into the tool’s “Adverse Event Coder” field, select MedDRA version 27.0, and generate LLT, PT, and SOC codes.
Compare versions: For the first description, compare the tool’s version 27.0 PT to the version 26.0 PT provided in the Reference Document to identify any term update (e.g., a refined PT).
Create the Update Log: In OMEGA Word, list the descriptions, their version 27.0 codes, a comparison note for the first description, and a one-sentence PSUR comment on how the update helps.
Add your insight: Note one interesting or clear aspect of the version update process.
Open OMEGA Word and create a document titled ""Version Update Adventure Log - Case ID HP-2025-UK-EU-012"".
Enter the Update Log and insight in OMEGA Word.
Submit in OMEGA Word within 24 hours.",10
course_2,ch_2_06,les_2_06_10,task_2_06_10_1,Pro Training in Pharmacovigilance,,MedDRA Coding & Case Quality,MedDRA Version Updates,omegamentorship,,,,,,
,,,,,,,,,,,,,,
course_2,ch_2_07,les_2_07_01,task_2_07_01_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,PV Audit Overview,PV Audit Overview,,,,,,10
course_2,ch_2_07,les_2_07_02,task_2_07_02_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,Preparing for FDA PV Inspections,Preparing for FDA PV Inspections,,,,,,10
course_2,ch_2_07,les_2_07_03,task_2_07_03_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,EMA PV Audit Requirements,EMA PV Audit Requirements,,,,,,10
course_2,ch_2_07,les_2_07_04,task_2_07_04_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,CAPA for PV Findings,CAPA for PV Findings,,,,,,10
course_2,ch_2_07,les_2_07_05,task_2_07_05_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,AI for PV Audit Trails,AI for PV Audit Trails,,,,,,10
course_2,ch_2_07,les_2_07_06,task_2_07_06_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,Mock PV Audit Simulations,Mock PV Audit Simulations,,,,,,10
course_2,ch_2_07,les_2_07_07,task_2_07_07_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,Handling Inspection Queries,Handling Inspection Queries,,,,,,10
course_2,ch_2_07,les_2_07_08,task_2_07_08_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,Document Control for PV Audits,Document Control for PV Audits,,,,,,10
course_2,ch_2_07,les_2_07_09,task_2_07_09_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,Post-Audit Reporting,Post-Audit Reporting,,,,,,10
course_2,ch_2_07,les_2_07_10,task_2_07_10_1,Pro Training in Pharmacovigilance,,PV Audits & Inspections,Continuous PV Compliance,Continuous PV Compliance,,,,,,10
,,,,,,,,,,,,,,
course_2,ch_2_08,les_2_08_01,task_2_08_01_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Risk Communication Overview,Risk Communication Overview,,,,,,10
course_2,ch_2_08,les_2_08_02,task_2_08_02_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Dear Healthcare Professional Letters,Dear Healthcare Professional Letters,,,,,,10
course_2,ch_2_08,les_2_08_03,task_2_08_03_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,AI for Safety Communication,AI for Safety Communication,,,,,,10
course_2,ch_2_08,les_2_08_04,task_2_08_04_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,DSMB & Safety Committee Roles,DSMB & Safety Committee Roles,,,,,,10
course_2,ch_2_08,les_2_08_05,task_2_08_05_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Patient Safety Notifications,Patient Safety Notifications,,,,,,10
course_2,ch_2_08,les_2_08_06,task_2_08_06_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Stakeholder Engagement in PV,Stakeholder Engagement in PV,,,,,,10
course_2,ch_2_08,les_2_08_07,task_2_08_07_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Risk Communication Metrics,Risk Communication Metrics,,,,,,10
course_2,ch_2_08,les_2_08_08,task_2_08_08_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Handling Public Safety Queries,Handling Public Safety Queries,,,,,,10
course_2,ch_2_08,les_2_08_09,task_2_08_09_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Crisis Communication in PV,Crisis Communication in PV,,,,,,10
course_2,ch_2_08,les_2_08_10,task_2_08_10_1,Pro Training in Pharmacovigilance,,Risk Management & Safety Communication,Global Safety Communication,Global Safety Communication,,,,,,10
,,,,,,,,,,,,,,
course_2,ch_2_09,les_2_09_01,task_2_09_01_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Post-Marketing PV Overview,Post-Marketing PV Overview,,,,,,10
course_2,ch_2_09,les_2_09_02,task_2_09_02_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Real-World Evidence (RWE) in PV,Real-World Evidence (RWE) in PV,,,,,,10
course_2,ch_2_09,les_2_09_03,task_2_09_03_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,AI for Post-Market Signals,AI for Post-Market Signals,,,,,,10
course_2,ch_2_09,les_2_09_04,task_2_09_04_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Literature Monitoring for PV,Literature Monitoring for PV,,,,,,10
course_2,ch_2_09,les_2_09_05,task_2_09_05_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Social Media Safety Monitoring,Social Media Safety Monitoring,,,,,,10
course_2,ch_2_09,les_2_09_06,task_2_09_06_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Post-Market Query Handling,Post-Market Query Handling,,,,,,10
course_2,ch_2_09,les_2_09_07,task_2_09_07_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Label Updates for Safety,Label Updates for Safety,,,,,,10
course_2,ch_2_09,les_2_09_08,task_2_09_08_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Post-Market Report Compilation,Post-Market Report Compilation,,,,,,10
course_2,ch_2_09,les_2_09_09,task_2_09_09_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Global Post-Market Harmonization,Global Post-Market Harmonization,,,,,,10
course_2,ch_2_09,les_2_09_10,task_2_09_10_1,Pro Training in Pharmacovigilance,,Post-Marketing Surveillance,Post-Market Audit Prep,Post-Market Audit Prep,,,,,,10
,,,,,,,,,,,,,,
course_2,ch_2_10,les_2_10_01,task_2_10_01_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,AI for Automated Case Processing,AI for Automated Case Processing,,,,,,10
course_2,ch_2_10,les_2_10_02,task_2_10_02_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,NLP for AE Narrative Analysis,NLP for AE Narrative Analysis,,,,,,10
course_2,ch_2_10,les_2_10_03,task_2_10_03_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,Predictive Analytics in PV,Predictive Analytics in PV,,,,,,10
course_2,ch_2_10,les_2_10_04,task_2_10_04_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,AI for PV Workflow Automation,AI for PV Workflow Automation,,,,,,10
course_2,ch_2_10,les_2_10_05,task_2_10_05_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,Blockchain for PV Data Integrity,Blockchain for PV Data Integrity,,,,,,10
course_2,ch_2_10,les_2_10_06,task_2_10_06_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,AI Ethics in PV,AI Ethics in PV,,,,,,10
course_2,ch_2_10,les_2_10_07,task_2_10_07_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,AI in PV Dashboards,AI in PV Dashboards,,,,,,10
course_2,ch_2_10,les_2_10_08,task_2_10_08_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,AI for Global PV Integration,AI for Global PV Integration,,,,,,10
course_2,ch_2_10,les_2_10_09,task_2_10_09_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,Future PV Trends (Digital Twins),Future PV Trends (Digital Twins),,,,,,10
course_2,ch_2_10,les_2_10_10,task_2_10_10_1,Pro Training in Pharmacovigilance,,Advanced AI in Pharmacovigilance,Integrating AI with PV Systems,Integrating AI with PV Systems,,,,,,10
,,,,,,,,,,,,,,
course_2,ch_2_11,les_2_11_01,task_2_11_01_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,PV Operations Overview,PV Operations Overview,,,,,,10
course_2,ch_2_11,les_2_11_02,task_2_11_02_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,Argus Workflow Management,Argus Workflow Management,,,,,,10
course_2,ch_2_11,les_2_11_03,task_2_11_03_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,ARISg System Integration,ARISg System Integration,,,,,,10
course_2,ch_2_11,les_2_11_04,task_2_11_04_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,AI for PV Task Automation,AI for PV Task Automation,,,,,,10
course_2,ch_2_11,les_2_11_05,task_2_11_05_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,E2B R3/R4 XML Conversions,E2B R3/R4 XML Conversions,,,,,,10
course_2,ch_2_11,les_2_11_06,task_2_11_06_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,PV System Validation (21 CFR Part 11),PV System Validation (21 CFR Part 11),,,,,,10
course_2,ch_2_11,les_2_11_07,task_2_11_07_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,Multi-Site PV Coordination,Multi-Site PV Coordination,,,,,,10
course_2,ch_2_11,les_2_11_08,task_2_11_08_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,PV Metrics & Reporting,PV Metrics & Reporting,,,,,,10
course_2,ch_2_11,les_2_11_09,task_2_11_09_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,Troubleshooting PV Systems,Troubleshooting PV Systems,,,,,,10
course_2,ch_2_11,les_2_11_10,task_2_11_10_1,Pro Training in Pharmacovigilance,,PV Operations & Systems Integration,Scalability in PV Operations,Scalability in PV Operations,,,,,,10
,,,,,,,,,,,,,,
course_2,ch_2_12,les_2_12_01,task_2_12_01_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Full PV Lifecycle Review,Full PV Lifecycle Review,,,,,,10
course_2,ch_2_12,les_2_12_02,task_2_12_02_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Advanced PV Simulation Strategies,Advanced PV Simulation Strategies,,,,,,10
course_2,ch_2_12,les_2_12_03,task_2_12_03_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Building PV Portfolios with AI,Building PV Portfolios with AI,,,,,,
course_2,ch_2_12,les_2_12_04,task_2_12_04_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Interview Prep for PV Roles,Interview Prep for PV Roles,,,,,,
course_2,ch_2_12,les_2_12_05,task_2_12_05_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Networking in Pharmacovigilance,Networking in Pharmacovigilance,,,,,,10
course_2,ch_2_12,les_2_12_06,task_2_12_06_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,AI for PV Career Advancement,AI for PV Career Advancement,,,,,,10
course_2,ch_2_12,les_2_12_07,task_2_12_07_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Case Studies of PV Success,Case Studies of PV Success,,,,,,10
course_2,ch_2_12,les_2_12_08,task_2_12_08_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Handling PV Crises,Handling PV Crises,,,,,,10
course_2,ch_2_12,les_2_12_09,task_2_12_09_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Emerging PV Regulations,Emerging PV Regulations,,,,,,10
course_2,ch_2_12,les_2_12_10,task_2_12_10_1,Pro Training in Pharmacovigilance,,Capstone Integration & Career Prep,Final PV Capstone Sim,Final PV Capstone Sim,,,,,,10
,,,,,,,,,,,,,,
course_3,ch_3_01,les_3_01_01,task_3_01_01_1,Pro Training in Clinical Research,Understand and execute end-to-end clinical trial operations with scientific rigor and ethical precision.,Foundations of Clinical Research & GCP Basics,Introduction to Clinical Research.,Write a Study Synopsis for the AstmaClear Phase II Trial,"You've just received an email from your supervisor at the CRO: ""Hey team, we're gearing up for the AstmaClear Phase II Trial. This is a key step to evaluate the efficacy of AstmaClear—an oral anti-inflammatory tablet designed to reduce airway inflammation—in reducing asthma symptoms and its overall safety compared to a placebo. 

We'll target adults aged 18-65 with moderate asthma, who've been diagnosed for at least one year and have no recent hospitalizations. The intervention involves participants taking a 10 mg AstmaClear tablet daily for 12 weeks, or a matching placebo. Key stakeholders include ClearPharma as the sponsor, our Apex CRO team, the site investigators, and of course, the enrolled patients. We're expecting outcomes like reduced asthma symptoms (think less wheezing and shortness of breath) and decreased reliance on rescue inhalers, all with minimal side effects such as mild nausea. 

Prepare a Study Synopsis for the site investigator's review—keep it professional and concise.""

Instructions: Using the provided Study Synopsis Template, write a 150-200 word summary for the AstmaClear trial. Extract and organize the details from the supervisor's email to include the study’s phase, objective, target population, intervention, key stakeholders, and expected outcomes.

Deliverables

A completed Study Synopsis (150-200 words) submitted in OMEGA WORD.",https://drive.google.com/file/d/1TXmcFYMJnKbpa0wzSaODAQfIfsk7PXE6/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/12kMWdh7vkvzcxnskjEQK-MEoboQ2YQk1/view?usp=sharing,"Open the reference document & go through the template.
Use the content in the scenario (Mail) to fill in the details.
Paste the final draft in OMEGA & submit.",10
course_3,ch_3_01,les_3_01_02,task_3_01_02_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,History & Evolution of Clinical Trials.,Analyzing Historical Clinical Trial Impacts with Modern AI Tools,"You are a clinical research coordinator at MediTrial Solutions, a contract research organization (CRO). Your supervisor, Dr. Elena Carter, has tasked you with preparing a report for a new client, BioPharma Innovations, who is launching a Phase II trial for a novel diabetes drug, DiaCure. 

The client wants to understand how historical clinical trial milestones shape today’s ethical and regulatory standards, and how AI tools can ensure compliance with Good Clinical Practice (GCP). 

Your report will be used to educate the client’s trial team and ensure their study aligns with modern standards.


Deliverables

Write a concise report (300-400 words) in OMEGA WORD addressed to Dr. Elena Carter, summarizing your findings. Include:
A brief overview of each milestone and its influence on GCP.
A specific AI tool or approach (real or hypothetical) and how it addresses risks tied to these milestones.
A closing statement on why understanding trial history is critical for the DiaCure trial’s success.",,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1FDu6jUl3HrT5El-Z18OqrIRGNZMjd_bQ/view?usp=sharing,"Historical Analysis: Select two key historical milestones in clinical trials (e.g., Nuremberg Code, Thalidomide Tragedy, Tuskegee Syphilis Study, ICH-GCP establishment) and explain their impact on modern GCP principles, such as informed consent, participant safety, or standardized protocols.
AI Application: Propose how a modern AI tool could be used to prevent ethical or regulatory issues tied to your chosen milestones in the DiaCure trial. For example, how could AI ensure informed consent or monitor participant safety?
How to do this task?

Research using perplexity and other AI tools.  

Open OMEGA WORD and paste your content.",10
course_3,ch_3_01,les_3_01_03,task_3_01_03_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,Roles in a Clinical Trial Team.,Coordinating Roles in a Clinical Trial Team,"You are a junior Clinical Research Coordinator (CRC) at VitalCRO Solutions, a contract research organization (CRO) managing a Phase III trial for a new heart failure drug, CardioVita, sponsored by PharmaCore Innovations. The trial involves multiple hospital sites, and your supervisor, Dr. Sarah Nguyen, has asked you to prepare a task assignment plan to ensure smooth collaboration among the trial team. Your plan will clarify roles and assign specific tasks to team members to support the trial’s success and compliance with Good Clinical Practice (GCP).

Deliverables

Write a concise task assignment plan (300-400 words) addressed to Dr. Sarah Nguyen, summarizing your findings. Include:

A brief overview of the three roles and their responsibilities.
One task per role and its importance to the trial.
A collaboration plan with one challenge and solution.
A closing statement on the importance of clear role assignments for the CardioVita trial.",,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1GEd2ZiVqW_QI6o6_cFsERs3Jd4rkiSYB/view?usp=sharing,"Role Identification: Identify three key roles in the CardioVita trial team (e.g., Sponsor, Principal Investigator, Clinical Research Associate, etc.) and briefly describe their primary responsibilities based on the lesson content.
Task Assignment: Assign one specific task to each of the three roles that supports the trial’s operations (e.g., protocol design, patient recruitment, site monitoring). Explain how each task contributes to the trial’s success and GCP compliance.
Collaboration Plan: Describe how these roles collaborate between the CRO (VitalCRO Solutions), the sponsor (PharmaCore Innovations), and hospital sites to ensure effective trial execution. Provide one example of a potential challenge in this collaboration and how it could be addressed.
Go through the answer key if you need it.
Resources ;
 Internet verified info on clinical trial roles.
 GCP guidelines for role responsibilities (available via ICH-GCP website).
Submit the final draft in OMEGA WORD.",10
course_3,ch_3_01,les_3_01_04,task_3_01_04_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,Introduction to Good Clinical Practice (GCP).,Creating a GCP Checklist for a Clinical Trial,"You are a new Clinical Research Coordinator (CRC) at StarCRO, helping manage a Phase II trial for a new asthma drug, AstmaRelief, sponsored by HealthPharma. Your supervisor, Dr. Lisa Chen, wants you to create a simple GCP checklist to ensure the trial team follows Good Clinical Practice (GCP) standards. The checklist will guide the team in protecting participants and ensuring reliable data.

Deliverables

GCP checklist in OMEGA WORD.",,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1QogbLrls-iN4BWH3eyd6okTSE_va-CLY/view?usp=sharing,"You are a junior Clinical Research Coordinator (CRC) at EthiCRO Solutions, assisting with a Phase II trial for a new diabetes drug, DiaSafe, sponsored by MediPharm Inc. Your supervisor, Dr. Rachel Kim, has asked you to create an ethics checklist to ensure the trial follows Good Clinical Practice (GCP) and Belmont Report principles. The checklist will guide the trial team in protecting participants and maintaining ethical standards.

Deliverable:

Write a concise ethics checklist (200-300 words) addressed to Dr. Rachel Kim, formatted as a list with brief explanations. Include:

Two Belmont Report principles with their application to DiaSafe.
One potential ethical breach and a prevention method.
Three informed consent elements.
A brief closing on why ethics matter for DiaSafe.
Length: 200-300 words.
Deadline: Within 24 hrs
Resources ;
Lesson materials on the Belmont Report and GCP ethics.
EthiCRO’s trial ethics guide (hypothetical for this task).",10
course_3,ch_3_01,les_3_01_05,task_3_01_05_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,Ethical Considerations in Trials.,Applying Ethical Principles in a Clinical Trial.,"You are a junior Clinical Research Coordinator (CRC) at EthiCRO Solutions, assisting with a Phase II trial for a new diabetes drug, DiaSafe, sponsored by MediPharm Inc. Your supervisor, Dr. Rachel Kim, has asked you to create an ethics checklist to ensure the trial follows Good Clinical Practice (GCP) and Belmont Report principles. The checklist will guide the trial team in protecting participants and maintaining ethical standards.

Deliverables

Write a concise ethics checklist (200-300 words) addressed to Dr. Rachel Kim, formatted as a list with brief explanations. Include:

Two Belmont Report principles with their application to DiaSafe.
One potential ethical breach and a prevention method.
Three informed consent elements.
A brief closing on why ethics matter for DiaSafe.
Length: 200-300 words.
Deadline: Within 24 hrs
Resources ;
Lesson materials on the Belmont Report and GCP ethics.
EthiCRO’s trial ethics guide (hypothetical for this task).",,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1ADt0Z66sZD1xGEzaYtDEolDN3CfZlkpd/view?usp=sharing,"Ethical Principles: Select two Belmont Report principles (Respect for Persons, Beneficence, Justice) and explain how they will be applied in the DiaSafe trial to protect participants.
Ethical Breach: Identify one common ethical breach (e.g., lack of informed consent, neglecting safety, unfair participant selection) that could occur in the DiaSafe trial and suggest one way to prevent it.
Informed Consent: List three key elements that must be included in the DiaSafe trial’s informed consent form to ensure ethical compliance.",10
course_3,ch_3_01,les_3_01_06,task_3_01_06_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,"Regulatory Bodies Overview (FDA, EMA, etc.).",Summarizing Regulatory Guidelines for a Clinical Trial Protocol,"You are a Clinical Research Coordinator at Horizon Biotech, developing a new diabetes drug, GlucoVita. Your supervisor, Dr. Maria Lopez, needs a Clinical Trial Protocol Summary for a multinational Phase II trial (U.S., EU, Japan, UK). To align with regulatory expectations, you must summarize an FDA guidance document on clinical trial protocols and incorporate key points into the summary form.

Deliverables

A completed Clinical Trial Protocol Summary form, including the 200-word FDA guideline summary and 50-word AI summary comparison.",https://drive.google.com/file/d/1d3iAs9wh9XQ_8hLJBMWVzlNUri5ZuvQO/view?usp=sharing,https://tally.so/r/mR7VDJ,https://drive.google.com/file/d/1vzoD0Jkyk5smU25gBFxvUrOHv0PZpfws/view?usp=sharing,"Read the Reference Document: Review the mock FDA guidance document (see Reference Documents) on clinical trial protocol requirements (approx. 800 words).
Summarize the Guideline: Using an AI tool (e.g., Grok), summarize the FDA guidance into a 200-word digest. Focus on protocol elements like objectives, endpoints, safety monitoring, and regulatory compliance.
Complete the Protocol Summary Form: Fill out the Clinical Trial Protocol Summary form (template provided) for the GlucoVita trial, incorporating the summarized FDA guideline points. Include:
    - Trial name: GlucoVita Phase II Study
    - Indication: Type 2 diabetes
    - Study population: Adults aged 18-65
    - Primary endpoint: Reduction in HbA1c levels
    - Regulatory bodies involved: FDA, EMA, PMDA, MHRA
Compare Summaries: Note any gaps or differences between your AI-generated summary and the original FDA guidance.",10
course_3,ch_3_01,les_3_01_07,task_3_01_07_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,"Trial Types & Designs (RCTs, Observational).",Trial Design Classification,"You are a junior clinical research assistant at MediCore Labs, a company developing a new drug, DiabeSafe, for type 2 diabetes. Your team is designing a study to evaluate DiabeSafe and needs your help to classify the trial design and justify your reasoning. The study involves observing 1,500 patients already prescribed DiabeSafe by their doctors, tracking their blood sugar levels and side effects over 3 years, without assigning any patients to a placebo or control group.

Deliverables

An OMEGA WORD submission that contains,
The classification of the DiabeSafe trial design.
Two advantages and two limitations of the chosen design.
A 150-200-word justification explaining your classification and why the design suits the study.
Submission method: OMEGA SUBMISSION PORTAL

Estimated Time: 30-45 minutes",https://drive.google.com/file/d/1vTpdQGtJ5kmG-yfFtD4eJt7IoolbAula/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1cEaDVw_Hl5mqwZspZWFYQ9OB7JTbtqeQ/view?usp=sharing,"Review the Scenario and Reference Document:
    - Read the DiabeSafe trial scenario above and the attached DiabeSafe Trial Protocol Summary.
    - Use the Lesson 7 video content to compare the study’s methodology to RCTs and Observational Studies.
Classify the Trial Design:
    - Determine if the DiabeSafe study is an RCT or an Observational Study based on randomization and intervention.
List Advantages and Limitations:
    - Identify two advantages and two limitations of the chosen trial design, specific to the DiabeSafe study, using Lesson 7 content.
Write the Justification:
    - In 150-200 words, explain:
        - Why you classified the trial as RCT or Observational.
        - How the design aligns with the study’s goals (e.g., long-term safety).
        - Why this design is suitable, considering factors like ethics or budget.
    - Reference the scenario and lesson content in simple language.
Create the Deliverable:
    - Open OMEGA WORD.
    - Use this template for your submission:


Student Name: [Your Name]

1. Trial Design Classification:
[State whether the DiabeSafe study is an RCT or Observational Study]

2. Advantages:
- [Advantage 1]
- [Advantage 2]

3. Limitations:
- [Limitation 1]
- [Limitation 2]

4. Justification (150-200 words):
[Write your explanation here]


Submit the Deliverable.",10
course_3,ch_3_01,les_3_01_08,task_3_01_08_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,Basics of Trial Documentation.,Trial Documentation Organization and Timeline Sequencing,"You are a junior clinical research assistant at MediCore Labs, working on a clinical trial for DiabeSafe, a new drug for type 2 diabetes. Your team is setting up the electronic Trial Master File (eTMF) to store and organize essential trial documents. Your task is to categorize provided documents into the correct eTMF sections and reorder them based on their sequence in the trial timeline.

Deliverables

A Word document containing:
   Categorization of the five documents into their eTMF sections.
   Ordered list of the five documents based on the trial timeline.
   A 150-200-word explanation of the purpose of trial documentation and the compliance role of one document.

Estimated Time: 35-50 minutes",https://drive.google.com/file/d/1m_I_rqZTlidjRScINtuaVaV404Zl8MUC/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1hv0evcgi1kGS5icUm44ZwGyFZFJ3QAkl/view?usp=sharing,"Review the Reference Document:
    - Open the attached DiabeSafe eTMF Document List PDF.
    - Note the five documents listed and their descriptions.
Categorize the Documents:
    - Using Lesson 8 video content, match each document to one of the following eTMF sections: Protocol, Informed Consent Forms (ICFs), Investigator’s Brochure (IB), Case Report Forms (CRFs), or Regulatory Approvals.
    - List each document under its correct section.
Reorder the Documents by Trial Timeline:
    - Arrange the five documents in the order they would be prepared or used in the trial process (e.g., from obtaining approvals to collecting data).
    - Consider which documents are needed to start the trial (e.g., for regulatory approval or planning) versus those used later (e.g., for data collection).
Write the Explanation:
    - In 150-200 words, explain:
        - The overall purpose of trial documentation (e.g., compliance, transparency, audit readiness).
        - Why one specific document from the list is critical for compliance (e.g., how it ensures GCP standards or supports audits).
    - Use simple language and reference Lesson 8 content or the scenario.
Create the Deliverable:
    - Open OMEGA WORD.
    - Use this template for your submission:
            
        Student Name: [Your Name]
        
        1. Document Categorization:
        Protocol:
        - [Document Name]
        Informed Consent Forms (ICFs):
        - [Document Name]
        Investigator’s Brochure (IB):
        - [Document Name]
        Case Report Forms (CRFs):
        - [Document Name]
        Regulatory Approvals:
        - [Document Name]
        
        2. Timeline Sequence:
        1. [Document Name]
        2. [Document Name]
        3. [Document Name]
        4. [Document Name]
        5. [Document Name]
        
        3. Explanation (150-200 words):
        [Write your explanation here]
Submit the Deliverable.",10
course_3,ch_3_01,les_3_01_09,task_3_01_09_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,Introduction to AI in Clinical Research.,AI in Clinical Research Application,"You are a junior clinical research assistant at MediCore Labs, working on a clinical trial for DiabeSafe, a new drug for type 2 diabetes. Your team uses an AI tool to support trial operations, including analyzing data and ensuring Good Clinical Practice (GCP) compliance. You’ve been given a report from the AI tool summarizing its findings on the DiabeSafe trial, and your task is to analyze its role in maintaining compliance.

Deliverables

A Word document containing:
   A 150-200-word explanation of AI’s role in clinical research and how one use case ensures GCP compliance.
Submission method: OMEGA WORD.

Estimated Time: 30-45 minutes",https://drive.google.com/file/d/1bIlyGZpG_kow2aFAXrPapqpUAPht8YZI/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1Lm9C1MAXYQH8bh1OLUQ21U60OklDHK0V/view?usp=sharing,"Review the Reference Document:
    - Open the attached DiabeSafe AI Tool Report PDF.
    - Note the AI tool’s findings and applications described in the report.
Write the Explanation:
    - In 150-200 words, explain:
        - The overall role of AI in clinical research (e.g., automation, efficiency, compliance).
        - How one of the identified use cases from the report helps ensure GCP compliance (e.g., by flagging deviations or ensuring data integrity).
    - Use simple language and reference Lesson 9 content or the scenario.
Create the Deliverable:
    - Open OMEGA WORD.
    - Paste & submit the document.
Submit the Deliverable.",10
course_3,ch_3_01,les_3_01_10,task_3_01_10_1,Pro Training in Clinical Research,,Foundations of Clinical Research & GCP Basics,GCP Audit Trails Basics.,GCP Audit Trail Entry,"You are a junior clinical research assistant at MediCore Labs, working on a clinical trial for DiabeSafe, a new drug for type 2 diabetes. Your team uses an electronic Trial Master File (eTMF) with an AI-supported audit trail system to track all trial actions. You’ve been tasked with filling out an audit trail document after correcting a data entry error in a patient’s Case Report Form (CRF) for an incorrect blood sugar level and explaining the importance of audit trails.

Deliverables

A Word document containing:
   The completed audit trail entry with all key components (User ID, Action, Timestamp, Reason).
   A 150-200-word explanation of the purpose of audit trails and the compliance role of one component.

Estimated Time: 30-45 minutes",https://drive.google.com/file/d/1o-Ck29UgdR9wvrAdR6atk9I3_-5G20YG/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/12cUjbbE5CaHX_D22X4HKYn-c7aAnkBw7/view?usp=sharing,"Review the Reference Document:
    - Open the attached DiabeSafe Audit Trail Form PDF.
Write the Explanation:
    - In 150-200 words, explain:
        - The overall purpose of audit trails in clinical trials (e.g., transparency, compliance, fraud prevention).
        - Why one specific component of your audit trail entry (e.g., Reason, Timestamp) is critical for GCP compliance.
    - Use simple language and reference Lesson 10 content or the scenario.
Submit the Deliverable:
    - Paste the final draft in OMEGA WORD & submit.",
,,,,Pro Training in Clinical Research,,,,,,,,,,10
course_3,ch_3_02,les_3_02_01,task_3_02_01_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Protocol Structure Overview.,Protocol Summary Submission,"You are a junior clinical research assistant at VitaHealth Solutions, working on a clinical trial for CardioVita, a new drug to lower blood pressure in patients with hypertension. Your team is developing the trial protocol, the official blueprint for the study, and needs you to complete a protocol summary to outline key elements of the trial.

Deliverables

A completed Clinical Trial Protocol Summary Submission containing:
   Filled fields for Study Title, Phase, Objectives, Population and Criteria, Intervention/Methods, Endpoints.
   A 150-200-word explanation in the Full Protocol Summary section.
   A completed Self-Assessment Checklist confirming alignment with the scenario.
Submission method: Via the course platform or provided digital link.

Estimated Time: 30-45 minutes",https://drive.google.com/file/d/1HnMGJLii9QdMilPlLzklflpGpjpraZFY/view?usp=sharing,https://tally.so/r/mDlZkq | https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1gZQE_qjuenmTjHWlvidgHra5O2A-sOxt/view?usp=sharing,"Review the Reference Document:
    - Open the attached CardioVita Trial Details PDF.
    - Note the trial details for Study Title, Phase, Objectives, Population and Criteria, Intervention/Methods, and Endpoints.
Create the Protocol Summary:
    - Complete the following fields using the reference document:
        Study Title: The name of the CardioVita trial.
        Phase: Select the appropriate trial phase (Phase I, II, III, or IV).
        Objectives: State primary and secondary objectives (1-2 sentences each).
        Population and Criteria: Describe the participant eligibility criteria.
        Intervention/Methods: Detail the treatment and procedures.
        Endpoints: List primary and secondary endpoints.
        Full Protocol Summary: Write a 150-200-word explanation of the purpose of a clinical trial protocol and why one section (e.g., Objectives, Safety/Ethics) is critical for the CardioVita trial.
        Self-Assessment Checklist: Check all applicable boxes (Includes phase and objectives, Details population and criteria, Covers intervention and endpoints, Aligns with lesson scenario).
    - Ensure entries are accurate, concise, and aligned with Lesson 11 content.
Submit the Deliverable in OMEGA WORD.",10
course_3,ch_3_02,les_3_02_02,task_3_02_02_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Objectives & Endpoints.,Objectives and Endpoints Summary,"You are a junior clinical research assistant at NexaPharma, working on a clinical trial for PulseCalm, a new drug to manage hypertension. Your team is designing the trial protocol and needs you to define the trial’s objectives and endpoints, ensuring they meet the SMART criteria, and summarize them in a protocol submission form.

Deliverables

A completed Clinical Trial Protocol Summary Submission Form
",https://drive.google.com/file/d/1x1te-hEFihOFwsp9WC5RUykx91MmG9gZ/view?usp=sharing,https://tally.so/r/mDlZkq,https://drive.google.com/file/d/1SKwQBDTsZNFqa14v1vUYrdPcVeYH1kZ2/view?usp=sharing,"Review the Reference Document:
    - Open the attached PulseCalm Trial Details PDF.
    - Note the trial details for Study Title, Phase, Objectives, Population and Criteria, Intervention/Methods, and Endpoints.
Fill Out the Protocol Summary Form:
    - Access the digital Clinical Trial Protocol Summary Submission Form via the course platform or provided link.
    - Complete the following fields using the reference document:
        Study Title: The name of the PulseCalm trial.
        Phase: Select the appropriate trial phase (Phase I, II, III, or IV).
        Objectives: State primary and secondary objectives (1-2 sentences each), ensuring they meet SMART criteria.
        Population and Criteria: Describe the participant eligibility criteria.
        Intervention/Methods: Detail the treatment and procedures.
        Endpoints: List primary and secondary endpoints tied to the objectives.
        Full Protocol Summary: Write a 150-200-word explanation of the purpose of trial objectives and endpoints and why SMART criteria are critical for the PulseCalm trial.
        Self-Assessment Checklist: Check all applicable boxes (Includes phase and objectives, Details population and criteria, Covers intervention and endpoints, Aligns with lesson scenario).
    - Ensure entries are concise, measurable, and aligned with Lesson 12 content.
Submit the Deliverable:
    - Submit the completed digital form via the course platform or provided link (e.g., Google Forms, course portal).
    - Ensure the form is fully completed and submitted by the deadline.",10
course_3,ch_3_02,les_3_02_03,task_3_02_03_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Study Population & Inclusion/Exclusion.,Study Population Screening,"You are a junior clinical research assistant at BioSynth Labs, working on a clinical trial for NeuroRelief, a new drug to reduce migraine frequency in adults. Your team is defining the trial’s study population and needs you to apply inclusion and exclusion criteria to screen mock patient data and summarize the results in a protocol submission form.

Deliverables

A completed Clinical Trial Protocol Summary Submission Form.",https://drive.google.com/file/d/1Lb8Gd1atLTkCCbWL_XnYDuSpYNFSOVmz/view?usp=sharing,https://tally.so/r/mDlZkq,https://drive.google.com/file/d/1oFNywQYrwwABZnRHwwbTuzTSti-wRPBo/view?usp=sharing,"Review the Reference Document:
    - Open the attached NeuroRelief Patient Screening Data PDF.
    - Note the trial details (Study Title, Phase, Population and Criteria) and the mock patient profiles to screen.
Fill Out the Protocol Summary Form:
    - Access the digital Clinical Trial Protocol Summary Submission Form via the course platform or provided link.
    - Complete the following fields using the reference document:
        Study Title: The name of the NeuroRelief trial.
        Phase: Select the appropriate trial phase (Phase I, II, III, or IV).
        Objectives: State primary and secondary objectives (1-2 sentences each).
        Population and Criteria: Describe the inclusion and exclusion criteria, and summarize screening results (e.g., number of patients included/excluded).
        Intervention/Methods: Detail the treatment and procedures.
        Endpoints: List primary and secondary endpoints.
        Full Protocol Summary: Write a 150-200-word explanation of the purpose of inclusion and exclusion criteria and why they are critical for the NeuroRelief trial’s safety.
        Self-Assessment Checklist: Check all applicable boxes (Includes phase and objectives, Details population and criteria, Covers intervention and endpoints, Aligns with lesson scenario).
    - Ensure entries are concise, accurate, and aligned with Lesson 13 content.
Submit the Deliverable:
    - Submit the completed digital form via the course platform or provided link (e.g., Google Forms, course portal).
    - Ensure the form is fully completed and submitted by the deadline.",10
course_3,ch_3_02,les_3_02_04,task_3_02_04_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Interventions & Dosing.,Dosing Schedule Documentation,"You are a junior clinical research assistant at TruMed Innovations, working on a clinical trial for OsteoFlex, a new drug to improve joint mobility in patients with osteoarthritis. Your team is developing the trial protocol and needs you to document the intervention and dosing schedule using a provided form, based on trial details, to ensure safe and consistent administration.

Deliverables

A completed Dosing Schedule Form",https://drive.google.com/file/d/1E1pboPHPmgw0Cp4w4Yn-CI9laMAGTAuw/view?usp=sharing,https://tally.so/r/mZx1d0,https://drive.google.com/file/d/1Mb-ZRprJhSLsCT9lS2t4uz4HN_qctHJt/view?usp=sharing,"Review the Reference Document:
    - Open the attached OsteoFlex Trial Details PDF.
    - Note the trial details for the intervention, dosing schedule, and participant parameters.
Fill Out the Dosing Schedule Form:
    - Access the digital Dosing Schedule Form via the course platform or provided link.
    - Complete the following fields using the reference document:
        Study Title: The name of the OsteoFlex trial.
        Intervention Type: Specify the type of intervention (e.g., drug, device, behavioral).
        Intervention Details: Describe the intervention (e.g., drug name, form, dose).
        Dosing Schedule: Detail the dose, frequency, and duration.
        Participant Parameters: Note key participant characteristics affecting dosing (e.g., age, weight).
        Comments: Write a 150-200-word explanation of the purpose of dosing schedules and their importance for the OsteoFlex trial’s safety.
    - Ensure entries are concise, accurate, and aligned with Lesson 14 content.
Submit the Deliverable:
    - Submit the completed digital form via the course platform or provided link (e.g., Google Forms, course portal).
    - Ensure the form is fully completed and submitted by the deadline.",10
course_3,ch_3_02,les_3_02_05,task_3_02_05_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Schedule of Assessments.,Assessment Schedule Creation,"You are a junior clinical research assistant at BioSynth Labs, working on a clinical trial for NeuroRelief, a new drug to reduce migraine frequency in adults. Your team is defining the trial’s study population and needs you to apply inclusion and exclusion criteria to screen mock patient data and summarize the results in a protocol submission form.

Deliverables

A completed Clinical Trial Protocol Summary Submission Form.",https://drive.google.com/file/d/1gzToQAEjnV2jiWgqI2ecTDANs0PpzjNf/view?usp=sharing,https://tally.so/r/w7QaeR,https://drive.google.com/file/d/1rqwVRLaOYBbo_uvlMSknJ6xqKNZ2j99I/view?usp=sharing,"Review the Reference Document:
    - Open the attached LungEase Trial Details PDF.
    - Note the trial details for assessment types (Screening, Baseline, Follow-Up, Safety) and their timing.
Fill Out the Assessment Schedule Form:
    - Access the digital Assessment Schedule Form via the course platform or provided link.
    - Complete the following fields using the reference document:
        Study Title: The name of the LungEase trial.
        Assessment Type: Specify the type (e.g., Screening, Baseline, Follow-Up, Safety).
        Timing: Detail when each assessment occurs (e.g., Week 0, Weeks 2–12).
        Details: Describe what data is collected (e.g., lung function test, adverse events).
        Comments: Write a 150-200-word explanation of the purpose of a schedule of assessments and its importance for the LungEase trial’s data quality.
    - Ensure entries are concise, accurate, and aligned with Lesson 15 content.
Submit the Deliverable:
    - Submit the completed digital form via the course platform or provided link (e.g., Google Forms, course portal).
    - Ensure the form is fully completed and submitted by the deadline.",10
course_3,ch_3_02,les_3_02_06,task_3_02_06_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Risk Assessment in Protocols.,Risk Assessment Documentation.,"You are a junior clinical research assistant at NovaCure Therapeutics, working on a clinical trial for SleepWell, a new drug to improve breathing in patients with sleep apnea. Your team is developing the trial protocol and needs you to identify and categorize potential risks using a risk assessment form, based on provided trial data, to ensure participant safety and trial integrity.

Deliverables

A completed Risk Assessment Form.",https://drive.google.com/file/d/1T2ctdSuD8YUGJi8dAYrMlJWcdacz0lty/view?usp=sharing,https://tally.so/r/nPobye,https://drive.google.com/file/d/1ky8ki9x7t11vTWeTlnDyZMmgH3AUf1AX/view?usp=sharing,"Review the Reference Document:
    - Open the attached SleepWell Trial Risk Data PDF.
    - Note the trial details and identified risks, including their types (safety, data, protocol) and potential severity.
Fill Out the Risk Assessment Form:
    - Access the digital Risk Assessment Form via the course platform or provided link.
    - Complete the following fields using the reference document:
        Study Title: The name of the SleepWell trial.
        Risk Type: Specify the risk type (e.g., Participant Safety, Data, Protocol).
        Risk Description: Describe the specific risk (e.g., mild drowsiness).
        Risk Level: Categorize as Low, Moderate, or High.
        Mitigation Strategy: Propose a way to address the risk (e.g., monitor side effects).
        Comments: Write a 150-200-word explanation of the purpose of risk assessment and its importance for the SleepWell trial’s safety.
    - Ensure entries are concise, accurate, and aligned with Lesson 16 content.
Submit the Deliverable:
    - Submit the completed digital form via the course platform.",10
course_3,ch_3_02,les_3_02_07,task_3_02_07_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,AI-Assisted Protocol Writing.,AI-Assisted Protocol Drafting,"You are a junior clinical research assistant at VitaCore Biotech, working on a clinical trial for GlucoClear, a new drug to manage blood glucose levels in patients with type 2 diabetes. Your team is using an AI tool (e.g., ChatGPT, Grok) to draft and refine the Study Design section of the trial protocol. You'll use AI to create a draft, refine it for accuracy, specificity, and ethical compliance, and submit the final version.

Deliverables

OMEGA WORD doc In 100-150 words, explaining
   How AI helped make the study document proper (e.g., initial structure, refinements).
   Why ethical considerations are critical for the GlucoClear trial (e.g., preventing bias, ensuring compliance).
Use simple language and reference Lesson 17 content or the scenario.",https://drive.google.com/file/d/1u-34jvjcwyJtiCYr6M6QoRgPF3g_L_p2/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1k-zA9hwpy3zK4D4H4CfWGIMpqVtJcPVm/view?usp=sharing,"Review the Reference Document:
    - Open the attached GlucoClear Trial Basics PDF.
    - Note the trial details (phase, population, objectives, etc.) to use in your AI prompt.
Draft with AI:
    - Craft a prompt for an AI tool (e.g., ""Draft a Study Design section for a Phase II randomized controlled trial testing GlucoClear in 150 adults with type 2 diabetes over 12 weeks, including trial type, randomization, and blinding."").
    - Use the AI tool to generate the initial draft of the Study Design section.
Refine the Draft:
    - Use the AI tool again to refine the draft (e.g., prompt: ""Improve this Study Design draft for clarity, specificity, and ethical compliance: [paste draft]"").
    - Make further manual edits to ensure it is accurate, specific (e.g., detail randomization), and ethically sound (e.g., avoid bias in population description, align with GCP).
    - The final section should be concise, professional, and ready for a protocol.
Write the Reflection:
    - In 100-150 words, explain:
        - How AI helped make the study document proper (e.g., initial structure, refinements).
        - Why ethical considerations are critical for the GlucoClear trial (e.g., preventing bias, ensuring compliance).
    - Use simple language and reference Lesson 17 content or the scenario.
Create the Deliverable & submit in OMEGA WORD.",10
course_3,ch_3_02,les_3_02_08,task_3_02_08_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Protocol Amendments.,AI-Assisted Protocol Amendment Pitch,"You’re a junior clinical research assistant at ArtiCure Labs, working on a clinical trial for FlexiJoint, a new drug for arthritis pain relief. After noticing 25% of participants reporting nausea, your team proposes reducing the dose from 20 mg to 15 mg. You’re tasked with using an AI tool (e.g., ChatGPT, Grok, Claude) to draft a compelling protocol amendment pitch to the ethics board, convincing them of the change’s necessity, and refining it for clarity and compliance.

Deliverables

A single omega doc In 100-150 words, explain:
How AI helped craft a compelling pitch (e.g., structure, phrasing).
Why ethical considerations are critical for the FlexiJoint amendment (e.g., participant safety, regulatory trust).",https://drive.google.com/file/d/12z4RmMY6vxb1UkWe-hfIQzaOyXFTt0o5/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1PgWmG8maCuXVtoA6NeVJC7MnI-iO-QzK/view?usp=sharing,"Review the Reference Document:
    - Open the attached FlexiJoint Amendment Context PDF.
    - Note the trial details, dose change rationale, and ethical considerations for crafting the pitch.
Draft with AI:
    - Craft a prompt for an AI tool (e.g., “Draft a 200-300 word protocol amendment pitch to an ethics board for reducing the FlexiJoint dose from 20 mg to 15 mg due to nausea in 25% of participants, emphasizing safety and GCP compliance.”).
    - Use the AI tool to generate the initial pitch.
Refine the Pitch:
    - Use the AI tool again to improve the draft (e.g., prompt: “Refine this amendment pitch for clarity, persuasiveness, and GCP compliance: [paste draft]”).
    - Make manual edits to ensure:
        - Persuasiveness (e.g., strong safety rationale, clear justification).
        - Clarity (e.g., specific participant group, dose details).
        - Ethical/GCP compliance (e.g., mention IRB/FDA submission, updated consent forms).
    - Keep the final pitch concise (200-300 words) and professional, like a memo to an IRB.
Write the Reflection:
    - In 100-150 words, explain:
        - How AI helped craft a compelling pitch (e.g., structure, phrasing).
        - Why ethical considerations are critical for the FlexiJoint amendment (e.g., participant safety, regulatory trust).
    - Use simple language and reference Lesson 18 content or the scenario.
Create the Deliverable and submit in OMEGA WORD.",10
course_3,ch_3_02,les_3_02_09,task_3_02_09_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Statistical Considerations in Protocols.,AI-Assisted Statistical Report Creation,"You are a junior clinical research assistant at MediPulse Pharma, working on a clinical trial for CholestAway, a new drug to lower cholesterol in adults with hyperlipidemia. Your team needs a comprehensive statistical report for the trial protocol, including sample size estimation, statistical tests, analysis plans, and visuals like graphs and pie charts to illustrate key concepts. You’ll use an AI tool (e.g., Perplexity, ChatGPT, Grok) to research, calculate, and generate the report, refining it for accuracy and GCP compliance.

Deliverables
 File Name: Stat_Report_[YourName].pdf
 The PDF must include:
    1. Final Statistical Report (400–500 words)
         Sample size estimation
         Statistical tests and analysis plan
         Power analysis graph (power vs. sample size)
         Pie chart for participant demographics
         GCP compliance details (e.g., ITT approach, handling missing data)
   2.Reflection (100–150 words)
         Explanation of how AI was used for research, calculation, and refinement of the report",https://drive.google.com/file/d/1iXm8yaIwTo7785_gTKSk8HoPbi8VmQmw/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1vuebxKt4GD5y1mh2TNlqR78LajnY2fMx/view?usp=sharing,"Review the Reference Document:
    - Open the attached CholestAway Trial Basics PDF.
    - Note the trial details, statistical parameters, and suggested AI prompts for research and generation.
Research and Generate with AI:
    - Use Perplexity AI.
    - Craft a prompt for an AI tool (e.g., “Design a statistical report for a Phase III trial testing CholestAway to detect a 10% LDL reduction, including sample size calculation with 80% power, 5% significance, analysis plan, and generate a graph for power vs sample size and a pie chart for demographics.”).
    - Use the AI tool to generate the initial report, calculations, and visuals (e.g., request base64 encoded images or code to create graphs).
Refine the Report:
    - Use the AI tool again to improve the report (e.g., prompt: “Refine this statistical report for advanced details, accuracy, and GCP compliance, adding a power curve graph and demographics pie chart: [paste draft]”).
    - Make manual edits to ensure:
        - Advanced elements (e.g., power analysis graph, hypothesis testing specifics).
        - Accuracy (e.g., correct sample size, appropriate statistical test).
        - GCP compliance (e.g., intention-to-treat, handling missing data).
    - Include at least two visuals (e.g., graph for power vs sample size, pie chart for participant demographics).
    - Keep the final report organized (400-500 words) and professional.
Create the Deliverable:
    - In a text editor, compile:
        - The final refined statistical report (400-500 words, with embedded visuals).
        - Your reflection (100-150 words).
    - Export as a PDF named `Stat_Report_[YourName].pdf`.
Submit the Deliverable:
    - Upload the PDF in ΩMEGA WORD",10
course_3,ch_3_02,les_3_02_10,task_3_02_10_1,Pro Training in Clinical Research,,Clinical Trial Protocol Development,Protocol Review & Approval.,omegamentorship,,,,,,10
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_03,les_3_03_01,task_3_03_01_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Site Selection Criteria.,Site Selection Criteria Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are tasked with evaluating three shortlisted sites for a Phase III clinical trial of OncoVax, an immunotherapy for Stage II colorectal cancer. Dr. Emily Chen, your supervisor, requires a data-driven recommendation to select the most suitable site based on standardized criteria.

Deliverables

Scorecard: A Google Docs spreadsheet containing scores, weighted calculations, total scores, rankings, and justifications for each site.
Recommendation Report: A 250–300-word Google Docs document, professionally formatted and addressed to Dr. Chen.
OMEGA Submission: Links to the scorecard and report, plus a 50-word reflection, uploaded to OMEGA Word",https://drive.google.com/file/d/1y8PYXeRTp7SUesrklzmY365mcYJoPknq/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/16Er8OiQ_JYPyYvJ4gUj9lV6sRVbizEvs/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the OncoVax trial requirements, detailed site profiles, and scorecard template. Ensure you understand the trial’s specific needs before proceeding.
Evaluate Sites: For each site, assign a score (1–5, where 1 is poor and 5 is excellent) for each criterion (Patient Pool, Staff Expertise, Facilities & Infrastructure, Past Performance, Location & Accessibility) based on how well it meets the trial requirements. Provide a 1–2 sentence justification for each score, referencing specific data from the site profiles.
Complete Scorecard: Copy the scorecard template from the reference document into a Google Docs spreadsheet. For each criterion:
    - Enter the score (1–5).
    - Calculate the weighted score: Score × (Weight ÷ 100). For example, a Patient Pool score of 4 with a 30% weight yields 4 × 0.30 = 1.2.
    - Sum the weighted scores for a total (out of 5) per site.
    - Rank sites from highest to lowest total score.
Draft Recommendation Report: In a Google Docs document, write a 250–300-word report addressed to Dr. Chen. Include:
    - A summary of the trial’s key requirements.
    - A comparison of the sites based on scorecard results.
    - A recommended site with a clear, data-supported justification.
    - One strategy to mitigate any identified risks (e.g., addressing past compliance issues).
Write Reflection: In 50 words, describe how the weighted scorecard facilitated or challenged your decision-making process.
Submit via OMEGA: Upload links to your scorecard and report, along with the reflection, to the OMEGA Word Portal",
course_3,ch_3_03,les_3_03_02,task_3_03_02_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Feasibility Assessments.,Feasibility Assessments Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are evaluating a site for a Phase II oncology trial for LungVita, a novel therapy for non-small cell lung cancer (NSCLC). Dr. Sarah Patel, your supervisor, has provided data on one potential site and requests a feasibility assessment to determine its suitability. Your task is to assess the site’s readiness using standardized criteria and recommend whether it should proceed to site selection.

Deliverables

Feasibility Questionnaire: A Google Docs table with site responses, Pass/Fail evaluations, and justifications for each criterion.
Recommendation Report: A 200–250-word Google Docs document, professionally formatted and addressed to Dr. Patel.
Prophecy Submission: Links to the questionnaire and report, plus a 50-word reflection, uploaded to OMEGA.",https://drive.google.com/file/d/1hsTJaH3YgpKGlx2iMhahOImd6hWwQZnf/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1t9BFh5JpZ6UYKELl3HJ7GIdDKKzv5o4K/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the LungVita trial requirements, site profile, and feasibility questionnaire template. Familiarize yourself with the trial’s specific needs before proceeding.
Complete Feasibility Questionnaire: Using the site profile in the reference document, fill out the questionnaire in a Google Docs table. For each criterion (Recruitment Potential, Staff & Capacity, Facilities, Regulatory Compliance, Past Experience):
    - Record the site’s response based on the provided data.
    - Evaluate each criterion as Pass or Fail by comparing the response to the trial requirements.
    - Provide a 1–2 sentence justification for each Pass/Fail decision, referencing specific data.
Determine Site Feasibility: Based on the questionnaire, decide if the site is feasible (all criteria Pass) or not feasible (any criterion Fails). Justify your overall decision in 2–3 sentences, summarizing key strengths or deficiencies.
Draft Recommendation Report: In a Google Docs document, write a 200–250-word report addressed to Dr. Patel. Include:
    - A summary of the LungVita trial requirements.
    - Key findings from the feasibility questionnaire.
    - Your recommendation (feasible or not feasible) with data-supported justification.
    - One suggestion to address any identified risks or deficiencies (e.g., additional training for staff).
Write Reflection: In 50 words, describe how completing the questionnaire with clear criteria helped or challenged your assessment process.
Submit via Omega  portal: Upload links to your questionnaire table, recommendation report, and reflection to the omega word portal.",
course_3,ch_3_03,les_3_03_03,task_3_03_03_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Investigator Qualification.,Investigator Qualification Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are reviewing the CV of Dr. Maria Lopez for the role of Principal Investigator (PI) in a Phase II cardiovascular trial for CardioVita, a new therapy for hypertension. Dr. Sarah Patel, your supervisor, requires an assessment to confirm Dr. Lopez’s qualifications meet the trial’s needs.

Deliverables

Qualification Table: A Google Docs table with Pass/Fail evaluations and justifications for each criterion.
Recommendation Report: A 150–200-word Google Docs document, professionally formatted and addressed to Dr. Patel.
Prophecy Submission: Links to the qualification table and report, uploaded to OMEGA.",https://drive.google.com/file/d/1CXQBClnP02D_c9x6L9bfBjkjE69Hw6r2/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1siQ_YdFXdUZRdsiYrnPOhGGYqAEQZ6wt/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the CardioVita trial requirements, Dr. Lopez’s CV, and PI qualification criteria.
Evaluate CV: Compare Dr. Lopez’s CV to the trial’s PI qualification criteria (Education, Experience, Licensing & Certification, Availability, Regulatory & Compliance Knowledge). For each criterion:
    - Assign a Pass or Fail based on whether the CV meets the requirement.
    - Provide a 1–2 sentence justification, citing specific CV details.
Complete Qualification Table: In a Google Docs table, record the Pass/Fail evaluation and justification for each criterion. Use the template provided in the reference document.
Draft Recommendation Report: In a Google Docs document, write a 150–200-word report addressed to Dr. Patel. Include:
    - A summary of the CardioVita trial’s PI requirements.
    - Key findings from the CV evaluation.
    - A recommendation on whether Dr. Lopez is qualified as a PI or better suited as a Sub-Investigator, with justification.
    - One suggestion to address any identified gaps (e.g., training updates).
Submit via Prophecy: Upload links to the qualification table and recommendation report to the Prophecy platform.",
course_3,ch_3_03,les_3_03_04,task_3_03_04_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Site Contracts & Budgeting.,Site Contracts & Budgeting Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are preparing a site budget for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with completing a digital budget form for a site expected to enroll 100 patients. The budget will support contract negotiations with the sponsor, ensuring financial clarity and resource availability.

Deliverables

Budget Form: A completed digital form with estimated costs, justifications, student name, and auto-calculated total budget.",https://drive.google.com/file/d/1qjRW3-X0W3r3m8EkkkSj6NSYjPLMZsqJ/view?usp=sharing,https://tally.so/r/nGMOve,https://drive.google.com/file/d/1ZIdh5iFXrrv0DCS1ctuZNgjxE41RwS2x/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, site responsibilities, and instructions to access the digital budget form.
Complete Digital Budget Form: Access the digital budget form via the link in the reference document. For each budget category (Staff Salaries, Equipment & Supplies, Participant Costs, Institutional Overheads, Contingency):
    - Enter a realistic estimated cost in USD based on trial needs and site responsibilities.
    - Provide a 1–2 sentence justification for each cost, explaining its necessity for the trial.
    - Enter your name in the student information field.
    - The form will auto-calculate the total budget.
Submit via ZANE OMEGA: Save the digital form submission confirmation (link or screenshot) and upload it to the  OMEGA WORD ",
course_3,ch_3_03,les_3_03_05,task_3_03_05_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Regulatory Submissions for Sites.,Regulatory Submissions for Sites Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are preparing a mock Investigational New Drug (IND) submission package for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with using AI to generate summaries for the submission components for a site enrolling 100 patients.

Deliverables

Submission Form: A completed digital form with your name and four ChatGPT-generated summaries for the IND submission components.
",https://drive.google.com/file/d/1UllMZD81s3NbiWF1M9wLUjxTrueSVOo9/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/12sR5cisRU-yM2bFhPHNIL1VeFYsb6Q5u/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, IND submission components, and ChatGPT prompt guidelines.
Use ChatGPT: Access ChatGPT (chatgpt.com). For each IND submission component (Study Protocol, Investigator Qualifications, Preclinical/Clinical Safety Data, Ethics Approvals):
    - Use the provided prompts in the reference document to generate a concise summary (50–75 words each).
    - Copy each summary into the digital submission form (link in the reference document).
    - Ensure summaries align with trial requirements and are suitable for an IND submission.
Complete Digital Submission Form: Access the digital form via the link in the reference document. Enter:
    - Your name in the student information field.
    - The four ChatGPT-generated summaries for the IND components.
    - The form will auto-save your entries.
Submit via ZANE OMEGA: Save the digital form submission confirmation (link or screenshot) and upload it to the OMEGA WORD ",
course_3,ch_3_03,les_3_03_06,task_3_03_06_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Study Start-Up Meetings (SSUM).,Study Start-Up Meetings (SSUM) Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are preparing for a Study Start-Up Meeting (SSUM) for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with role-playing as the site coordinator in a virtual SSUM, using ChatGPT to respond to sponsor/CRO prompts and receive feedback for a site enrolling 100 patients.

Deliverables

Submission Form: A completed SSUM form.",https://drive.google.com/file/d/1Qgt1v4zioTR2XorAzTej2HXKoVhSMQeb/view?usp=sharing,https://tally.so/r/nGMOaZ,https://drive.google.com/file/d/1R3ZhOM14oJsgfzC-gOn4hH8TykfAZ5BL/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, SSUM agenda items, and ChatGPT prompt guidelines.
Use ChatGPT for SSUM Simulation: Access ChatGPT. Input the provided SSUM simulation prompts from the reference document to role-play as the site coordinator. For each prompt (covering Protocol Review, Recruitment Plans, Site Readiness, Safety & Reporting):
    - Provide a concise response (50–75 words each) addressing the prompt as if speaking to the sponsor/CRO.
    - Ask ChatGPT for feedback on your response’s clarity, completeness, and professionalism using the feedback prompt in the reference document.
    - Copy your response and ChatGPT’s feedback into the digital form (link in the reference document).
Complete Digital Submission Form: Access the digital form via the link in the reference document. Enter:
    - Your name in the student information field.
    - The four responses and corresponding ChatGPT feedback for the SSUM prompts.
    - The form will auto-save your entries.
Submit via ZANE OMEGA: Save the digital form submission confirmation (link or screenshot) and upload it to the ZANE OMEGA platform.",
course_3,ch_3_03,les_3_03_07,task_3_03_07_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,AI in Site Feasibility.,AI in Site Feasibility Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are evaluating three sites for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with using the free version of ChatGPT to simulate an AI-driven feasibility assessment, ranking the sites based on provided datasets and recommending the top two for selection.

Deliverables

Submission Form: A completed OMEGA WORD DOC with your name, feasibility scores, rationales for each site, and a recommendation for the top two sites.",https://drive.google.com/file/d/1nD6F02HIanhDjpOQv_Du1qsS-Z7vsxJH/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1AFOdhSIe6_T8PLMsKEpRGnvQx3nDdY9f/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, site datasets, and ChatGPT prompt guidelines.
Use ChatGPT for Feasibility Simulation: Access ChatGPT. For each site (Site A, Site B, Site C):
    - Input the provided prompt with the site’s dataset (from the reference document) to generate a feasibility score (0–100) and a brief rationale (50–75 words).
    - Rank the sites from highest to lowest score.
    - Copy & paste the scores, rationales, and your top two site recommendations into OMEGA WORD and submit.",
course_3,ch_3_03,les_3_03_08,task_3_03_08_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Training Site Staff.,Training Site Staff Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are preparing a staff training log for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with using the free version of ChatGPT to create a training log for a site enrolling 100 patients, including AI-generated quiz questions to assess staff competency.

Deliverables

Submission Form: A completed digital input in OMEGA WORD with your name and four training log entries, each including staff details, a ChatGPT-generated quiz question, and result.",https://drive.google.com/file/d/1GVdRqFG3kVn39rtPGG_Jo9sW3BMeUF0I/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1R5E9AdYHLQT0WUFWVEtrbJcF7125mtDR/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, training module details, and ChatGPT prompt guidelines.
Use ChatGPT for Training Log: Access the free version of ChatGPT (chatgpt.com). For each training module (Protocol Training, GCP Training, Data Collection, Safety Reporting):
    - Use the provided prompts in the reference document to generate one multiple-choice quiz question (with four answer options and the correct answer) to assess staff competency.
    - Create a training log entry for a sample staff member, including their name, role, module completion date, and quiz result (e.g., Pass: 100%).
    - Copy the log entries (staff details and quiz questions) into the digital form (link in the reference document).
Complete & submit in OMEGA WORD.",
course_3,ch_3_03,les_3_03_09,task_3_03_09_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Site Activation Checklists.,Site Activation Checklists Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are validating a site activation checklist for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with using the free version of ChatGPT to review a mock checklist for a site enrolling 100 patients, identifying any gaps and confirming readiness.

Deliverables

A completed word doc in OMEGA WORD with your name, validation status for each checklist item, rationales for Incomplete items, and overall site readiness status.",https://drive.google.com/file/d/1Ogg4ms7SdSSZDvk-K3J3h9Pg36lCV8pw/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1IMbA9cKumghhvD-XmN-ZzlYfB8UMY2L2/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, mock checklist, and ChatGPT prompt guidelines.
Use ChatGPT for Checklist Validation: Access ChatGPT. Input the provided prompt with the mock checklist data from the reference document to:
    - Validate each checklist item (Regulatory Approvals, Contracts, Staff Training, Facilities & Equipment, Protocol Ready, Essential Documents, System Access) as Complete or Incomplete.
    - Generate a brief rationale (50–75 words) for any Incomplete items, explaining the gap.
    - Confirm overall site readiness (Ready or Not Ready).
    - Copy the validation results, rationales, and readiness status into the digital form (link in the reference document).
Submit in OMEGA WORD ",
course_3,ch_3_03,les_3_03_10,task_3_03_10_1,Pro Training in Clinical Research,,Site Selection & Study Start-Up,Common Start-Up Pitfalls.,Common Start-Up Pitfalls Task,"As a Clinical Research Coordinator at Zenith Clinical Solutions, you are troubleshooting a delayed site for a Phase II diabetes trial, DiabetaCare, testing a new oral medication. Dr. Sarah Patel, your supervisor, has tasked you with using a free web-based AI text generator to diagnose start-up pitfalls for a site enrolling 100 patients and propose solutions to ensure readiness.

Deliverables

A completed DOC with your name, up to three start-up pitfalls with AI-generated solutions, and a one-sentence prevention recommendation.",https://drive.google.com/file/d/1087DJIY1svLM0YfOLfVhlaJBUOUjhKRI/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/13AuG8rrnUjae2bfcaQDq7iQPYJi-pJDC/view?usp=sharing,"Review Reference Document: Consult the attached PDF for the DiabetaCare trial requirements, mock delayed site scenario, and AI text generator prompt guidelines.
Use AI Text Generator for Diagnosis: Access a free web-based AI text generator (e.g., via a search for ""free AI text generator""). Input the provided prompt with the mock delayed site scenario from the reference document to:
    - Identify up to three start-up pitfalls (e.g., regulatory delays, incomplete training).
    - Generate a brief solution (50–75 words each) for each pitfall, explaining how to address it.
    - Paste the pitfalls and solutions into OMEGA WORD.
 Submit in OMEGA WORD ",
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_04,les_3_04_01,task_3_04_01_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Recruitment Strategies Overview.,Designing a Recruitment Strategy for a Phase II Oncology Trial,"You are the clinical trial coordinator for a Phase II clinical trial evaluating a new immunotherapy drug for patients with non-small cell lung cancer (NSCLC) in the United States. The trial requires 150 participants aged 18–75 with stage III or IV NSCLC who have not responded to first-line chemotherapy. The trial is conducted across five sites in urban and suburban areas. Recruitment has been slow, with only 30 participants enrolled after three months, against a target completion within six months. The sponsor has allocated a modest budget for recruitment activities, and you must ensure compliance with FDA regulations and ethical guidelines.

Deliverables

A recruitment strategy plan (1–2 pages) that includes:
   Target population definition.
   Proposed recruitment channels (traditional and modern).
   Budget allocation considerations.
   Ethical and regulatory considerations.
A sample recruitment advertisement (e.g., flyer, social media post, or radio script) tailored to the target population.
A brief monitoring plan to track recruitment progress and adapt strategies if needed.",https://drive.google.com/file/d/1D1B6XksBJO4IcfBvca6SU4oODGKLumg0/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1peVhrc_NI0dK-RbTL9iIuluMEbLSvsKX/view?usp=sharing,"Review Trial Protocol: Analyze the inclusion/exclusion criteria (age 18–75, stage III/IV NSCLC, failed first-line chemotherapy) and sample size (150 participants) to understand recruitment needs.
Define Target Population: Specify demographics (age, disease stage, geographic location) and patient characteristics (e.g., health literacy, access to care).
Select Recruitment Channels:
    - Choose at least two traditional strategies (e.g., physician referrals, community outreach).
    - Choose at least two modern strategies (e.g., social media ads, clinical trial registries).
    - Justify selections based on the target population and budget constraints.
Address Ethical/Regulatory Requirements:
    - Ensure recruitment materials align with FDA and IRB guidelines (e.g., no coercive language, clear risk/benefit disclosure).
    - Incorporate privacy protections (e.g., HIPAA compliance).
    - Promote diversity and equity in recruitment.
Develop Recruitment Advertisement:
    - Create a concise, IRB-compliant advertisement for one chosen channel (e.g., a Facebook post or clinic flyer).
    - Include trial purpose, eligibility criteria, benefits/risks, and contact information.
Design Monitoring Plan:
    - Define metrics (e.g., enrollment rate, source of participants).
    - Outline a process for reviewing progress (e.g., weekly reports) and adjusting strategies if targets are not met.
Compile Deliverables:
    - Write the recruitment strategy plan (1–2 pages, structured with headings).
    - Attach the sample advertisement.
    - Include the monitoring plan as a subsection or table.",
course_3,ch_3_04,les_3_04_02,task_3_04_02_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Patient Eligibility Screening.,Assessing Patient Eligibility for a Phase III Hypertension Trial,"You are a clinical research coordinator at a trial site conducting a Phase III clinical trial evaluating a new antihypertensive drug for patients with uncontrolled hypertension. The trial requires 200 participants aged 30–70 years with a confirmed diagnosis of hypertension (blood pressure ≥140/90 mmHg). The trial is conducted across three urban sites in the United States, with a screening period of four weeks. Your role is to assess three potential participants’ medical records to determine their eligibility based on the trial’s inclusion and exclusion criteria, create an eligibility checklist, and verify which patients qualify for the trial while ensuring compliance with FDA regulations.

Deliverables

An eligibility checklist template designed for the trial, listing all inclusion and exclusion criteria.
Completed eligibility checklists for three hypothetical participants, indicating whether each is eligible or ineligible based on their medical records.
A brief narrative (200–300 words) explaining the screening process, ethical considerations, and documentation requirements applied in assessing the three participants.
4. Submit in OMEGA WORD.
",https://drive.google.com/file/d/1gltwp1_M6mX2PRSwHnD8xptPi5k65wHD/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1qrqxc7zdPbMHuCoXl3tN9WmeTS638w9Z/view?usp=sharing,"Review Trial Protocol: Examine the inclusion and exclusion criteria provided in the reference document to understand eligibility requirements.
Create Eligibility Checklist Template:
    - Design a checklist with sections for inclusion and exclusion criteria based on the trial protocol.
    - Include fields for participant ID, checkboxes for each criterion, final eligibility decision, and comments.
Analyze Participant Data: Use the provided hypothetical participant data (Reference 1) to assess eligibility for each of the three participants against the checklist.
Complete Eligibility Checklists:
- For each participant, fill out the checklist, marking whether they meet each inclusion and exclusion criterion.
- Indicate the final eligibility decision (eligible or ineligible) with a brief justification in the comments section.
Write Narrative:
- Describe the screening process applied to the three participants (e.g., informed consent, medical history review, tests).
- Address ethical considerations (e.g., informed consent timing, data confidentiality).
- Explain documentation requirements (e.g., source documents, audit readiness).
- Ensure the narrative is concise, professional, and aligned with regulatory standards.
Compile Deliverables: 
- Paste everything into OMEGA WORD.
- Submit the eligibility checklist template.
- Include completed checklists for all three participants.
- Attach the narrative as a separate section.",
course_3,ch_3_04,les_3_04_03,task_3_04_03_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Informed Consent Process.,Reviewing an Informed Consent Form for a Phase II Diabetes Trial,"You are a clinical research coordinator at a trial site conducting a Phase II clinical trial evaluating a new oral medication for type 2 diabetes. The trial requires 100 participants aged 18–65 years with uncontrolled diabetes (HbA1c ≥7%). As part of the trial setup, you are tasked with reviewing a draft informed consent form (ICF) to ensure it meets regulatory requirements before submission to the Institutional Review Board (IRB).

Deliverables

A list of missing or incomplete elements in the provided draft ICF, based on ICH-GCP requirements.
A brief explanation (100–150 words) of why the identified elements are critical for ethical and regulatory compliance.
PASTE ON OMEGA WORD.",https://drive.google.com/file/d/1gA-S1p-kYwH5hkQ6teKt2Qa0sDJCAJrD/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1_cNhNQCi6hX99rA-Du6AraFmnL5hn1rj/view?usp=sharing,"Review ICH-GCP Requirements: Refer to the reference document summarizing ICH-GCP guidelines for essential ICF elements.
Analyze Draft ICF: Examine the provided draft ICF (Reference 1) and compare it against the ICH-GCP requirements.
Identify Missing/Incomplete Elements:
    - List any essential elements (e.g., study purpose, risks, participant rights) that are absent or inadequately addressed in the draft ICF.
    - Note specific issues (e.g., vague language, missing contact information).
Write Explanation:
    - Explain why the identified missing or incomplete elements are critical for ethical and regulatory compliance.
    - Keep the explanation concise, professional, and focused on participant protection and trial integrity.
Compile Deliverables:
    - Submit the list of missing/incomplete elements.
    - Include the brief explanation as a separate section.",
course_3,ch_3_04,les_3_04_04,task_3_04_04_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Diversity & Inclusion in Recruitment.,Enhancing Diversity in Recruitment for a Phase III Asthma Trial,"You are a clinical research coordinator for a Phase III clinical trial evaluating a new inhaler for adults with moderate-to-severe asthma. The trial aims to enroll 150 participants aged 18–70 years across three urban and two rural sites in the United States. The sponsor has noted that previous asthma trials underrepresented ethnic minorities and rural populations, impacting the generalizability of results. Your task is to review the trial’s recruitment plan to identify barriers to diverse recruitment and propose strategies to improve inclusion.

Deliverables

A list of two barriers to recruiting ethnic minorities and rural populations for the trial.
A brief proposal (100–150 words) recommending two specific strategies to address the identified barriers, ensuring inclusivity and regulatory compliance.",https://drive.google.com/file/d/1bKeYsT9gQHij6hg7WDrWz2qRKDxM6Mrh/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1M4JiwsQOAHffUJuvewmmKLuM-lM4FuFh/view?usp=sharing,"Review Trial Context: Examine the trial details and recruitment challenges outlined in the reference document.
Identify Barriers:
    - List two specific barriers to recruiting ethnic minorities and rural populations, based on the reference document’s information.
    - Ensure barriers are realistic and relevant to the trial scenario.
Propose Strategies:
    - Recommend two specific, practical strategies to overcome the identified barriers.
    - Ensure strategies align with regulatory expectations (e.g., FDA Diversity Action Plan) and promote inclusivity.
Write Proposal:
    - Explain how each strategy addresses a barrier and supports diverse recruitment.
    - Keep the proposal concise, professional, and focused on participant access and equity.
Compile Deliverables:
    - Submit the list of two barriers.
    - Include the brief proposal as a separate section.
    - Paste them all inside OMEGA WORD.",
course_3,ch_3_04,les_3_04_05,task_3_04_05_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Retention Techniques.,Improving Participant Retention in a Phase III Cardiovascular Trial,"You are a clinical research coordinator for a Phase III clinical trial evaluating a new cholesterol-lowering drug for adults with high cardiovascular risk. The trial requires 200 participants aged 40–75 years to attend monthly clinic visits for 12 months across three urban sites in the United States. After three months, the trial team notices a 15% dropout rate, primarily due to participants citing long travel times to clinic visits as a barrier. Your task is to identify this retention challenge and propose a practical solution to improve participant retention.

Deliverables

A brief identification of the retention challenge based on the trial scenario.
A short proposal (100–150 words) recommending one specific retention strategy to address the challenge, ensuring ethical and regulatory compliance.
Submit in OMEGA WORD.",https://drive.google.com/file/d/1ila8UblpHI7n496t7uzcIHoue1hoOw45/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1DcWtHa01zki-VyEIAovndcw6N4Oyno-S/view?usp=sharing,"Review Trial Context: Examine the trial details and retention challenge outlined in the reference document.
Identify Retention Challenge:
    - Clearly state the primary reason for participant dropouts (e.g., long travel times to clinic visits).
    - Ensure the challenge is specific and relevant to the trial scenario.
Propose Retention Strategy:
    - Recommend one practical, patient-centered strategy to address the identified challenge.
    - Ensure the strategy aligns with ethical and regulatory principles (e.g., IRB approval, non-coercive).
Write Proposal:
    - Explain how the strategy addresses the retention challenge and supports participant engagement.
    - Keep the proposal concise, professional, and focused on participant retention and trial integrity.
Compile Deliverables:
    - Submit the identified retention challenge.
    - Include the brief proposal as a separate section.",
course_3,ch_3_04,les_3_04_06,task_3_04_06_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,AI-Powered Patient Matching.,Simulating AI-Powered Patient Matching for a Phase II Oncology Trial,"You are a clinical research coordinator at a trial site in Ireland conducting a Phase II clinical trial evaluating a new targeted therapy for patients with metastatic breast cancer. The trial requires 80 participants aged 18–70 years with HER2-positive breast cancer who have progressed after first-line treatment. Using an AI-powered patient matching tool, you need to review a set of de-identified patient records from electronic health records (EHRs) at Irish hospitals to identify potential matches for the trial.

Deliverables

A list of eligible patients from the provided records, based on the trial criteria.
A brief explanation (100–150 words) of how AI improves the matching process in this scenario, including ethical considerations.
Submit in OMEGA WORD.",https://drive.google.com/file/d/105wil-XnHSessRqc9ycxqowK7Aq80DNG/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1c9hdy-ln4cyHOS6cgQwyXx7qjhlu0I8-/view?usp=sharing,"Review Trial Criteria: Examine the inclusion and exclusion criteria provided in the reference document.
Analyze Patient Data: Use the hypothetical patient data (Reference 1) to compare each patient's profile against the trial criteria, simulating the AI matching workflow (input criteria, data mining, NLP processing, matching algorithm).
Identify Matches:
    - List the patient IDs that match the criteria (eligible) and briefly note why others do not.
Write Explanation:
    - Describe how AI enhances efficiency, accuracy, and diversity in matching.
    - Address ethical considerations (e.g., data privacy, bias risks).
    - Keep the explanation concise, professional, and aligned with regulatory standards.
Compile Deliverables:
    - Submit the list of eligible patients.
    - Include the brief explanation as a separate section.
    - All into OMEGA WORD.",
course_3,ch_3_04,les_3_04_07,task_3_04_07_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Consent Documentation.,Reviewing Consent Documentation for a Phase III Diabetes Trial,"You are a clinical research coordinator at a trial site in the United Kingdom conducting a Phase III clinical trial evaluating a new insulin therapy for patients with type 1 diabetes. The trial requires 120 participants aged 18–65 years. As part of an internal audit preparation, you are tasked with reviewing a sample informed consent form (ICF) and associated documentation to ensure compliance with regulatory standards and best practices.

Deliverables

A list of errors or deficiencies in the provided consent documentation sample.
A brief explanation (100–150 words) of why correcting these issues is critical for regulatory and ethical compliance.
Submit in OMEGA WORD.",https://drive.google.com/file/d/1tk6cyTC0JcfnD_bZSGtrQMpHc3OpMVfz/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1tmFLISi5nYe9Fp5HbtSAX_jwKEzpQ8Mu/view?usp=sharing,"Review Regulatory Requirements: Examine the reference document outlining ICH-GCP, EU Clinical Trial Regulation, and best practices for consent documentation.
Analyze Consent Documentation: Review the sample ICF and associated records (Reference 1) to identify any errors or deficiencies (e.g., missing signatures, incomplete dates).
List Errors/Deficiencies:
    - Identify specific issues in the documentation, referencing the regulatory standards and best practices.
    - Ensure the list is clear and relevant to the trial context.
Write Explanation:
    - Explain why the identified issues could compromise ethical or regulatory compliance.
    - Keep the explanation concise, professional, and focused on participant protection and trial integrity.
Compile Deliverables:
    - Submit the list of errors or deficiencies.
    - Include the brief explanation as a separate section.",
course_3,ch_3_04,les_3_04_08,task_3_04_08_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Handling Recruitment Challenges.,Addressing Recruitment Challenges for a Phase II Alzheimer’s Trial,"You are a clinical research coordinator at a trial site in India conducting a Phase II clinical trial evaluating a new drug for early-stage Alzheimer’s disease. The trial aims to enroll 100 participants aged 50–75 years with mild cognitive impairment across three sites in Mumbai, Delhi, and Bangalore. After two months, only 20 participants have been enrolled due to low awareness of clinical trials among potential participants and their families. Your task is to identify this recruitment challenge and propose a practical solution to improve enrollment.

Deliverables

A brief identification of the recruitment challenge based on the trial scenario.
A short proposal (100–150 words) recommending one specific strategy to address the challenge, ensuring ethical and regulatory compliance. Submit in OMEGA WORD.",https://drive.google.com/file/d/1coTg89CypGLvB-j3p2lTScLpd6KjMgoW/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1WYtXTMfpSjquO1u40tbOTxWiwGQTWP-6/view?usp=sharing,"Review Trial Context: Examine the trial details and recruitment challenge outlined in the reference document.
Identify Recruitment Challenge:
    - Clearly state the primary reason for low enrollment (e.g., low awareness of clinical trials).
    - Ensure the challenge is specific and relevant to the trial scenario in India.
Propose Strategy:
    - Recommend one practical, culturally appropriate strategy to address the identified challenge.
    - Ensure the strategy aligns with ethical and regulatory principles (e.g., DCGI requirements, non-coercive).
Write Proposal:
    - Explain how the strategy addresses the recruitment challenge and supports enrollment.
    - Keep the proposal concise, professional, and focused on participant engagement and trial success.
Compile Deliverables:
    - Submit the identified recruitment challenge.
    - Include the brief proposal as a separate section.",
course_3,ch_3_04,les_3_04_09,task_3_04_09_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Metrics & Reporting Recruitment.,Analyzing Recruitment Metrics for a Phase III Cardiovascular Trial,"You are a clinical research coordinator at a trial site in Ireland conducting a Phase III clinical trial evaluating a new anticoagulant drug for patients with atrial fibrillation. The trial aims to enroll 150 participants aged 40–80 years across four sites in Dublin, Cork, Galway, and Limerick. After three months, recruitment is lagging, and you need to review the recruitment metrics to identify a specific issue and propose a solution to improve performance.

Deliverables

A brief identification of one recruitment metric issue based on the trial’s recruitment data.
A short proposal (100–150 words) recommending one specific strategy to address the identified issue, ensuring alignment with regulatory and ethical standards.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/13PhzpwN0sDGC8rvpLNWAZvvmN4a6xfxw/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1JW-EqfTpz5q8Jc-fWJBoejaKSOuIbXBv/view?usp=sharing,"Review Trial Data: Examine the recruitment metrics and trial details provided in the reference document.
Identify Recruitment Metric Issue:
    - Select one specific issue from the metrics (e.g., high screen failure rate, low enrollment rate).
    - Ensure the issue is clear, relevant, and supported by the data provided.
Propose Strategy:
    - Recommend one practical, evidence-based strategy to address the identified metric issue.
    - Ensure the strategy complies with ethical and regulatory requirements (e.g., ICH-GCP, EU Clinical Trial Regulation).
Write Proposal:
    - Explain how the strategy addresses the metric issue and improves recruitment.
    - Keep the proposal concise, professional, and focused on trial progress.
Compile Deliverables:
    - Submit the identified recruitment metric issue.
    - Include the brief proposal as a separate section.",
course_3,ch_3_04,les_3_04_10,task_3_04_10_1,Pro Training in Clinical Research,,Patient Recruitment & Informed Consent,Ethical AI in Recruitment.,Auditing Ethical AI Recruitment for a Phase II Parkinson’s Trial,"You are a clinical research coordinator at a trial site in London, UK, managed by Parexel International, a leading contract research organization (CRO) with offices in Uxbridge, London. The Phase II clinical trial evaluates a new neuroprotective drug for early-stage Parkinson’s disease, aiming to enroll 90 participants aged 40–70 years across three sites: London (King’s College Hospital), Manchester (Salford Royal Hospital), and Birmingham (Queen Elizabeth Hospital). An AI-powered recruitment tool, NeuroMatch AI, is being used to screen electronic health records (EHRs) for eligible patients. Your task is to audit the tool’s deployment plan to identify one ethical risk and propose a specific improvement to ensure ethical compliance.

Deliverables

Identification of one ethical risk in the AI recruitment tool’s deployment based on the provided plan.
A short proposal (100–150 words) recommending one specific improvement to mitigate the identified risk, ensuring alignment with ethical and regulatory standards.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1Gly7pr1XrDHMx7MvRBY1XA7MVyUl9u6k/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1LKoIDZNY5hMTt0OjVkpJSFuEVWGUbtMk/view?usp=sharing,"Review Deployment Plan: Examine the AI recruitment tool’s deployment details and ethical considerations outlined in the reference document.
Identify Ethical Risk:
    - Select one specific ethical risk (e.g., bias, transparency) relevant to the trial context and ethical AI principles.
Propose Improvement:
    - Recommend one practical, targeted improvement to address the identified risk.
    - Ensure compliance with regulatory guidelines (e.g., EMA, GDPR, MHRA) and ethical principles like fairness and transparency.
Write Proposal:
    - Explain how the improvement mitigates the risk and supports ethical recruitment.
    - Keep the proposal concise, professional, and focused on participant trust and trial integrity.
Compile Deliverables:
    - Submit the identified ethical risk.
    - Include the brief proposal as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_05,les_3_05_01,task_3_05_01_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),CRF Design Principles.,Reviewing CRF Design for a Phase III Hypertension Trial,"You are a clinical research coordinator at a trial site in Dublin, Ireland, managed by ICOM Clinical Solutions, a contract research organization with offices in Sandyford, Dublin. The Phase III clinical trial evaluates a new antihypertensive drug for patients with uncontrolled hypertension, aiming to enroll 120 participants aged 30–70 years across three sites: Dublin (St. James’s Hospital), Cork (Cork University Hospital), and Galway (University Hospital Galway). As part of CRF development, you are tasked with reviewing a draft electronic Case Report Form (eCRF) to identify one design flaw and propose a correction to ensure data accuracy and compliance.

Deliverables

Identification of one design flaw in the draft eCRF based on the provided sample.
A short proposal (100–150 words) recommending one specific correction to address the flaw, ensuring alignment with CRF design principles and regulatory standards.",https://drive.google.com/file/d/1JWWGFtcZZ3wk9fWWpWSERgkyhoPD1kvd/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1-hZR-A890jOkQWaoutWGvE4KeEXLN72N/view?usp=sharing,"Review CRF Sample: Examine the draft eCRF details and design principles outlined in the reference document.
Identify Design Flaw:
    - Select one specific flaw (e.g., unclear field, missing edit check) that impacts data accuracy or usability.
    - Ensure the flaw is relevant to the trial context and CRF design principles.
Propose Correction:
    - Recommend one practical correction to improve the eCRF’s clarity, consistency, or compliance.
    - Ensure alignment with ICH-GCP, 21 CFR Part 11, and CDISC/CDASH standards.
Write Proposal:
    - Explain how the correction addresses the flaw and supports data integrity.
    - Keep the proposal concise, professional, and focused on trial data quality.
Compile Deliverables:
    - Submit the identified design flaw.
    - Include the brief proposal as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_02,task_3_05_02_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),"Data Collection Methods (EDC, Paper).",Selecting Data Collection Method for a Phase II Diabetes Trial,"You are a clinical research coordinator at a trial site in Mumbai, India, managed by Apex Clinical Research Pvt. Ltd., a contract research organization with offices in Bandra, Mumbai. The Phase II clinical trial evaluates a new oral antidiabetic drug for patients with type 2 diabetes, aiming to enroll 80 participants aged 18–65 years across two sites: Mumbai (Jaslok Hospital) and Pune (Ruby Hall Clinic). You are tasked with recommending whether to use a paper-based Case Report Form (CRF) or an Electronic Data Capture (EDC) system for data collection, considering the trial’s needs and site capabilities.

Deliverables

A recommendation of one data collection method (paper CRF or EDC) for the trial.
A short justification (100–150 words) explaining why the chosen method is suitable, addressing trial requirements and regulatory compliance.",https://drive.google.com/file/d/1vToes-OTT88nwSy2x8uLq0Sc4NS0oGrh/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1X7Ddkw7xVLo-AUG6QMY-mYIL5_wR6pjH/view?usp=sharing,"Review Trial Context: Examine the trial details, site capabilities, and regulatory requirements outlined in the reference document.
Select Data Collection Method:
    - Choose either paper CRF or EDC based on the trial’s scope, site infrastructure, and data needs.
    - Ensure the choice is practical and relevant to the trial context in India.
Write Justification:
    - Explain why the selected method is appropriate, considering factors like cost, site capabilities, data accuracy, and regulatory compliance (e.g., ICH-GCP, CDSCO).
    - Keep the justification concise, professional, and focused on trial efficiency and data quality.
Compile Deliverables:
    - The recommended data collection method.
    - Include the brief justification as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_03,task_3_05_03_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),Source Data Verification (SDV).,Performing Source Data Verification for a Phase III Oncology Trial,"You are a clinical research associate (CRA) at a trial site in London, UK, managed by Precision Clinical Research Ltd., a contract research organization with offices in Bloomsbury, London. The Phase III clinical trial evaluates a new chemotherapy drug for patients with metastatic colorectal cancer, aiming to enroll 150 participants aged 18–75 years at King’s College Hospital, London. During a monitoring visit, you are tasked with performing Source Data Verification (SDV) by comparing a sample Electronic Data Capture (EDC) entry with source documents to identify one discrepancy and propose a resolution.

Deliverables

Identification of one discrepancy between the EDC entry and source documents based on the provided sample.
A short proposal (100–150 words) recommending one specific resolution to address the discrepancy, ensuring alignment with SDV best practices and regulatory standards.",https://drive.google.com/file/d/1o2W90I5oWgKbCaxB8k4N7XyxFH5Ai7mp/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1SENrzlsHlprCW6xAt-xHqXOWOs_UFBdL/view?usp=sharing,"Review Sample Data: Examine the EDC entry and source document details provided in the reference document.
Identify Discrepancy:
    - Select one specific discrepancy between the EDC entry and source documents (e.g., mismatched data, missing entry).
    - Ensure the discrepancy is relevant to the trial context and SDV principles.
Propose Resolution:
    - Recommend one practical resolution to correct the discrepancy, such as issuing a query or updating the EDC.
    - Ensure compliance with ICH-GCP, 21 CFR Part 11, and EU Clinical Trial Regulation standards.
Write Proposal:
    - Explain how the resolution addresses the discrepancy and ensures data integrity.
    - Keep the proposal concise, professional, and focused on trial data quality.
Compile Deliverables:
    - Include the brief proposal as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_04,task_3_05_04_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),Query Management.,Drafting a Query for a Phase III Asthma Trial,"You are a clinical research associate (CRA) at a trial site in Manchester, UK, managed by Novellum Clinical Research Ltd., a contract research organization with offices in Didsbury, Manchester. The Phase III clinical trial evaluates a new inhaled corticosteroid for patients with moderate-to-severe asthma, aiming to enroll 100 participants aged 18–65 years at Salford Royal Hospital, Manchester. During a data review, you identify a discrepancy in an Electronic Data Capture (EDC) entry compared to source documents. Your task is to draft a query to resolve this discrepancy and ensure data accuracy.

Deliverables

A draft query addressing one specific discrepancy identified in the EDC entry.
A short explanation (100–150 words) justifying the query’s clarity and urgency, ensuring alignment with query management best practices and regulatory standards.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1KXCotZG3bEGBVye3C0p4B59JRoJRj4un/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1Bd7-Gm4k_vgWYS5aq7VQ86ni0xmN5WIy/view?usp=sharing,"Review Data Discrepancy: Examine the EDC entry and source document details provided in the reference document to identify the discrepancy.
Draft Query:
    - Write a concise, clear query addressing the specific discrepancy, directed to the site coordinator.
    - Include the patient ID, visit details, and a precise question to resolve the issue.
Write Explanation:
    - Justify why the query is clear, precise, and urgent (if applicable), referencing best practices.
    - Ensure compliance with ICH-GCP, 21 CFR Part 11, and EU Clinical Trial Regulation standards.
    - Keep the explanation professional, concise, and focused on data quality.
Compile Deliverables:
    - Make the draft query.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_05,task_3_05_05_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),Data Cleaning Basics.,Cleaning a Dataset for a Phase II Rheumatoid Arthritis Trial,"You are a clinical data manager at a trial site in Birmingham, UK, managed by VitaCore Clinical Research Ltd., a contract research organization with offices in Edgbaston, Birmingham. The Phase II clinical trial evaluates a new biologic drug for rheumatoid arthritis, aiming to enroll 60 participants aged 18–70 years at Queen Elizabeth Hospital, Birmingham. During a data cleaning review, you are tasked with examining a sample Electronic Data Capture (EDC) dataset, identifying one error, and correcting it to ensure data accuracy.

Deliverables

A corrected dataset entry for one identified error in the provided EDC sample.
A short justification (100–150 words) explaining the error, the correction, and its importance for data quality and regulatory compliance.",https://drive.google.com/file/d/10h9lRirMZ1mLfQ6h_jR5I0r1Qs3vV_d9/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1-9BnP850KWF8_gofGjEZZGqfBEHubEsk/view?usp=sharing,"Review Dataset: Examine the EDC dataset and source document details in the reference document to identify one error.
Correct Error:
    - Specify the erroneous data point and provide the corrected value in a table format.
    - Ensure the correction aligns with source data and trial requirements.
Write Justification:
    - Explain the identified error, how the correction was determined, and why it’s critical for data quality.
    - Ensure compliance with ICH-GCP, 21 CFR Part 11, and EU Clinical Trial Regulation standards.
    - Keep the justification concise, professional, and focused on data integrity.
Compile Deliverables:
    - Make the corrected dataset entry as a table.
    - Include the brief justification as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_06,task_3_05_06_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),AI in CRF Automation.,Evaluating AI-Generated CRF for a Phase II Oncology Trial,"You are a clinical data manager at a trial site in Dublin, Ireland, managed by Synergex Clinical Research Ltd., a contract research organization with offices in Ballsbridge, Dublin. The Phase II clinical trial evaluates a new targeted therapy for non-small cell lung cancer (NSCLC), aiming to enroll 80 participants aged 18–70 years at St. Vincent’s University Hospital, Dublin. An AI tool, CRFGenix, is used to auto-generate the trial’s electronic Case Report Form (eCRF) from the protocol. Your task is to review the AI-generated eCRF output, identify one limitation, and propose an enhancement to improve its functionality.

Deliverables

Identification of one limitation in the AI-generated eCRF output based on the provided sample.
A short proposal (100–150 words) recommending one specific enhancement to address the limitation, ensuring alignment with AI-CRF automation principles and regulatory standards.",https://drive.google.com/file/d/10NjijtVPO66V0FCceA6nMYuF7-S2ZbOu/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1Zngb9_B2IhKkqaIvkmbfFa_rXNsk--FX/view?usp=sharing,"Review AI-Generated eCRF: Examine the eCRF output and trial details in the reference document to identify one limitation.
Identify Limitation:
    - Select one specific limitation (e.g., missing field, unclear instruction) that impacts functionality or compliance.
    - Ensure the limitation is relevant to the trial context and AI-CRF principles.
Propose Enhancement:
    - Recommend one practical enhancement to improve the eCRF’s usability, accuracy, or compliance.
    - Ensure alignment with ICH-GCP, 21 CFR Part 11, and EU Clinical Trial Regulation standards.
Write Proposal:
    - Explain how the enhancement addresses the limitation and supports trial data quality.
    - Keep the proposal concise, professional, and focused on AI-driven efficiency.
Compile Deliverables:
    - Make the identified limitation.
    - Include the brief proposal as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_07,task_3_05_07_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),Handling Missing Data.,Handling Missing Data for a Phase III Heart Failure Trial,"You are a clinical data manager at a trial site in Galway, Ireland, managed by Galvita Clinical Research Ltd., a contract research organization with offices in Salthill, Galway. The Phase III clinical trial evaluates a new heart failure drug, aiming to enroll 100 participants aged 40–80 years at University Hospital Galway. During a data review, you identify missing data in a sample Electronic Data Capture (EDC) dataset. Your task is to select an appropriate statistical method to address one instance of missing data and justify its suitability.

Deliverables

A table specifying one missing data point in the dataset and the selected statistical method to address it, including a brief rationale.
A short justification (100–150 words) explaining why the chosen method is appropriate for the missing data type and aligns with regulatory standards.",https://drive.google.com/file/d/1QdvU84o-fZ4a21ylqTXGcgAXpxqtlt76/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1cRm3i_Zo9kegaDDWRtU5g2ABUMiGGT9w/view?usp=sharing,"Review Dataset: Examine the EDC dataset and source details in the reference document to identify one missing data point and its context.
Select Statistical Method:
    - Choose one statistical method (e.g., multiple imputation, LOCF) to address the missing data point.
    - Provide a brief rationale for the choice in a table, considering the type of missing data (MCAR, MAR, MNAR).
Write Justification:
    - Explain why the method suits the missing data type and trial context, ensuring compliance with ICH-GCP, EU Clinical Trial Regulation, and regulatory expectations.
    - Keep the justification concise, professional, and focused on data integrity.
Compile Deliverables:
    - Make the table with the missing data point, method, and rationale.
    - Include the brief justification as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_08,task_3_05_08_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),Data Security & Confidentiality.,Assessing Data Security for a Phase III Cardiovascular Trial,"You are a clinical data manager at a trial site in Galway, Ireland, managed by SecuraVita Clinical Research Ltd., a contract research organization with offices in Newcastle, Galway. The Phase III clinical trial evaluates a new anticoagulant drug for patients with atrial fibrillation, aiming to enroll 120 participants aged 40–80 years at University Hospital Galway. During a compliance review, you are tasked with evaluating the trial’s data security protocol to identify one vulnerability and propose a safeguard to ensure data confidentiality and integrity.

Deliverables

A risk assessment table identifying one data security vulnerability in the trial’s protocol and a proposed safeguard.
A short justification (100–150 words) explaining why the vulnerability poses a risk and how the safeguard ensures compliance with regulatory standards.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1NopzutmGjqwT6mgmd4lKgi0w2kZKAR9U/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1vdHir0hQhH-u_qxHdV203CAIzaNnfCQi/view?usp=sharing,"Review Security Protocol: Examine the data security protocol and trial details in the reference document to identify one vulnerability.
Document Vulnerability and Safeguard:
    - Create a table specifying the vulnerability and a proposed safeguard to mitigate it.
    - Ensure the safeguard is practical and aligns with best practices for data security.
Write Justification:
    - Explain the risk posed by the vulnerability and how the safeguard addresses it, referencing ICH-GCP, GDPR, and EU Clinical Trial Regulation standards.
    - Keep the justification concise, professional, and focused on data protection.
Compile Deliverables:
    - Include the brief justification as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_09,task_3_05_09_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),CRF Amendments & Versions.,Documenting a CRF Amendment for a Phase II Asthma Trial,"You are a clinical data manager at a trial site in Belfast, UK, managed by Novex Clinical Research Ltd., a contract research organization with offices in Lisburn Road, Belfast. The Phase II clinical trial evaluates a new bronchodilator for patients with moderate asthma, aiming to enroll 70 participants aged 18–65 years at Royal Victoria Hospital, Belfast. Following a protocol amendment, the CRF requires an update to include a new field. Your task is to document this change in a CRF Amendment Log entry.

Deliverables

A CRF Amendment Log entry documenting the CRF change, including version details and rationale, in a table format.
A short explanation (100–150 words) justifying the log entry’s clarity and its role in ensuring compliance with version control practices.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1xluuvxRK4kbTgL0ryJpidr0SIH_rveae/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1zZI7bljV8Wq3jmDFT8_Ws8bmVdwwJNQ4/view?usp=sharing,"Review Amendment Details: Examine the CRF amendment details and trial context in the reference document.
Document CRF Amendment Log Entry:
    - Create a table entry specifying the CRF version, change description, date, approver, and rationale.
    - Ensure the entry is concise, clear, and aligned with version control standards.
Write Explanation:
    - Justify the log entry’s clarity and its importance for traceability and regulatory compliance (e.g., ICH-GCP, EU Clinical Trial Regulation).
    - Keep the explanation professional, concise, and focused on version control.
Compile Deliverables:
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_05,les_3_05_10,task_3_05_10_1,Pro Training in Clinical Research,,Data Collection & Case Report Forms (CRFs),Intro to EDC Systems.,Creating an EDC User Access Plan for a Phase II Asthma Trial,"You are a clinical data manager at a trial site in Limerick, Ireland, managed by Limerix Clinical Research Ltd., a contract research organization with offices in Castletroy, Limerick. The Phase II clinical trial evaluates a new inhaled corticosteroid for moderate asthma, aiming to enroll 50 participants aged 18–65 years at University Hospital Limerick. As part of the EDC system setup, you are tasked with creating a user access plan to assign roles and permissions for the trial team, ensuring secure and compliant data entry.

Deliverables

An EDC user access plan table specifying roles, permissions, and team members for the trial.
A short explanation (100–150 words) describing how the access plan ensures secure data management and regulatory compliance.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/11MyLIiFUlxjZLYd4gywUl7tPNEoEexSQ/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1F9GwlynAfbLuWS-FNcs5YY8vYwAMvHUd/view?usp=sharing,"Review Trial Context: Examine the trial details and EDC requirements in the reference document to understand the team structure and data needs.
Create User Access Plan:
    - Design a table listing three team member roles (e.g., investigator, CRA, data manager), their permissions (e.g., data entry, query resolution), and assigned personnel.
    - Ensure permissions align with trial roles and security needs.
Write Explanation:
    - Explain how the access plan ensures secure data management and complies with ICH-GCP, 21 CFR Part 11, and EU Clinical Trial Regulation standards.
    - Keep the explanation concise, professional, and focused on data security.
Compile Deliverables:
    - Make the EDC user access plan table.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_06,les_3_06_01,task_3_06_01_1,Pro Training in Clinical Research,,Monitoring & Site Management,Monitoring Plan Development.,Creating a Monitoring Visit Schedule for a Phase III Diabetes Trial,"You are a clinical research associate (CRA) at a trial site in Dublin, Ireland, managed by Dublinary Clinical Research Ltd., a contract research organization with offices in Temple Bar, Dublin. The Phase III clinical trial evaluates a new insulin therapy for patients with type 1 diabetes, aiming to enroll 100 participants aged 18–65 years at St. James’s Hospital, Dublin. Your task is to create a monitoring visit schedule for the site, specifying the timing and type of visits to ensure data quality and participant safety.

Deliverables

A monitoring visit schedule table for St. James’s Hospital, listing the type, timing, and purpose of three monitoring visits.
A short explanation (100–150 words) justifying how the schedule supports trial oversight and regulatory compliance.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1HnR09TKkcXaI_XBvH4MfgNgHVv03Ymy5/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/19usIkLvmHj9rWm0WebDvtcj_Acf9HxmC/view?usp=sharing,"Review Trial Context: Examine the trial details and monitoring requirements in the reference document to understand the site’s needs.
Create Monitoring Visit Schedule:
    - Design a table listing three monitoring visits (e.g., initiation, routine, close-out), including visit type, timing (e.g., specific weeks or milestones), and purpose.
    - Ensure the schedule aligns with trial needs and risk-based monitoring principles.
Write Explanation:
    - Justify how the schedule ensures effective oversight, data quality, and compliance with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation concise, professional, and focused on trial monitoring goals.
Compile Deliverables:
    - Make the monitoring visit schedule table.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_02,task_3_06_02_1,Pro Training in Clinical Research,,Monitoring & Site Management,On-Site vs. Remote Monitoring.,Allocating Monitoring Activities for a Phase III Oncology Trial,"You are a clinical research associate (CRA) at a trial site in Manchester, UK, managed by Mancura Clinical Research Ltd., a contract research organization with offices in Chorlton, Manchester. The Phase III clinical trial evaluates a new immunotherapy drug for metastatic melanoma, aiming to enroll 120 participants aged 18–75 years at Salford Royal Hospital, Manchester. Given the trial’s high-risk safety profile due to potential immune-related adverse events (irAEs), you are tasked with recommending how to allocate on-site and remote monitoring activities to ensure effective oversight.

Deliverables

A one-sentence recommendation for allocating on-site and remote monitoring activities for the trial, based on its safety profile.
A short explanation (100–150 words) justifying how the allocation balances safety oversight with efficiency and complies with regulatory standards.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1qlsMC6rmMqiAt1FAA9_-MguEoYnoA1pB/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1WRG4FJjbQtpxGAixXg-ZCsoPHfEQxcet/view?usp=sharing,"Review Trial Context: Examine the trial details and monitoring needs in the reference document, focusing on the high-risk safety profile.
Draft Recommendation:
    - Write a single sentence recommending how to allocate on-site and remote monitoring activities, prioritizing safety oversight.
    - Ensure the recommendation is specific and aligned with risk-based monitoring principles.
Write Explanation:
    - Justify how the allocation addresses safety concerns, ensures data quality, and complies with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation concise, professional, and focused on trial monitoring goals.
Compile Deliverables:
    - Make the one-sentence recommendation.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_03,task_3_06_03_1,Pro Training in Clinical Research,,Monitoring & Site Management,Site Visits & Inspections.,Preparing a Routine Monitoring Visit Checklist for a Phase III Oncology Trial,"You are a clinical research associate (CRA) at a trial site in Limerick, Ireland, managed by Limerix Clinical Solutions Ltd., a contract research organization with offices in Raheen, Limerick. The Phase III clinical trial evaluates a new chemotherapy drug for patients with advanced breast cancer, aiming to enroll 100 participants aged 18–75 years at University Hospital Limerick. Your task is to prepare a checklist for a routine monitoring visit to ensure compliance and data quality.

Deliverables

A routine monitoring visit checklist table listing three key activities to be performed at the site, including their purpose.
A short explanation (100–150 words) justifying how the checklist supports effective monitoring and regulatory compliance.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/12l6flpl-BrtofGALWY8ydcwAkCqK8lMT/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1iGGnwtj6Gzx7NsTpCYDOJovHX0C6Njbh/view?usp=sharing,"Review Trial Context: Examine the trial details and monitoring requirements in the reference document to understand the site’s needs.
Create Checklist:
    - Design a table listing three key routine monitoring visit activities (e.g., SDV, consent review) and their purpose.
    - Ensure activities align with trial needs and focus on critical data/processes.
Write Explanation:
    - Justify how the checklist ensures effective oversight, data quality, and compliance with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation concise, professional, and focused on monitoring goals.
Compile Deliverables:
    - Make the routine monitoring visit checklist table.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_04,task_3_06_04_1,Pro Training in Clinical Research,,Monitoring & Site Management,Deviation & Non-Compliance Management.,Completing a Deviation Report Form for a Phase III Cardiovascular Trial,"You are a clinical research coordinator at a trial site in Belfast, UK, managed by Belfex Clinical Research Ltd., a contract research organization with offices in Malone, Belfast. The Phase III clinical trial evaluates a new anticoagulant drug for patients with atrial fibrillation, aiming to enroll 120 participants aged 40–80 years at Royal Victoria Hospital, Belfast. During a routine review on 19 September 2025, you identify a protocol deviation. Your task is to complete a Deviation Report Form to document the deviation and propose corrective and preventive actions (CAPA).

Deliverables

A completed Deviation Report Form table documenting the deviation, including impact level, actions, and responsible persons.
A short explanation (100–150 words) justifying the form’s completeness and its role in ensuring regulatory compliance.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1PWop1PveI-q6DnyMUD_uAOQ8rzoYwrhu/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1Qq4GmXyOcn8P3VKLwy0t4EP-IePB-KH_/view?usp=sharing,"Review Deviation Scenario: Examine the deviation details and trial context in the reference document.
Complete Deviation Report Form:
    - Fill out a condensed version of the form, including date, name/role, incident description, impact level, immediate action, root cause, CAPA details (corrective and preventive), responsible persons, follow-up dates, and closure status.
    - Ensure entries are clear, concise, and aligned with deviation management principles.
Write Explanation:
    - Justify the form’s completeness and its role in ensuring traceability and compliance with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation professional, concise, and focused on deviation management.
Compile Deliverables:
    - Make the Deviation Report Form.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_05,task_3_06_05_1,Pro Training in Clinical Research,,Monitoring & Site Management,Investigator Oversight.,Creating an Investigator Oversight Checklist for a Phase III Diabetes Trial,"You are a clinical research associate (CRA) at a trial site in Edinburgh, UK, managed by EdinVita Clinical Research Ltd., a contract research organization with offices in Leith, Edinburgh. The Phase III clinical trial evaluates a new insulin therapy for patients with type 2 diabetes, aiming to enroll 100 participants aged 18–65 years at Western General Hospital, Edinburgh. Your task is to create a checklist for the Principal Investigator (PI) to ensure effective oversight of the informed consent process, a critical responsibility area.

Deliverables

An investigator oversight checklist table listing three key tasks for the PI to oversee the informed consent process, including their purpose.
A short explanation (100–150 words) justifying how the checklist supports effective oversight and regulatory compliance.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1PxTQMOcvRJyfUHYC0rnUzfowogftmw-F/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1fgZ-q1_wsTAG5bXadPh1d9BFkjyjvblX/view?usp=sharing,"Review Trial Context: Examine the trial details and oversight requirements in the reference document, focusing on the informed consent process.
Create Oversight Checklist:
    - Design a table listing three key tasks for the PI to oversee the informed consent process, including the purpose of each task.
    - Ensure tasks are specific, practical, and aligned with PI responsibilities.
Write Explanation:
    - Justify how the checklist ensures robust oversight, participant safety, and compliance with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation concise, professional, and focused on investigator oversight.
Compile Deliverables:
    - Make the investigator oversight checklist table.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_06,task_3_06_06_1,Pro Training in Clinical Research,,Monitoring & Site Management,AI-Driven Monitoring Alerts.,Prioritizing an AI-Driven Monitoring Alert for a Phase III Oncology Trial,"You are a clinical research associate (CRA) at a trial site in Dublin, Ireland, managed by DubliCore Clinical Research Ltd., a contract research organization with offices in Temple Bar, Dublin. The Phase III clinical trial evaluates a new immunotherapy drug for metastatic colorectal cancer, aiming to enroll 100 participants aged 18–75 years at St. Vincent’s University Hospital, Dublin. The trial uses an AI-driven monitoring system that generates alerts for potential issues. Your task is to review a set of alerts and prioritize one for immediate action, justifying its urgency.

Deliverables

A prioritized alert statement identifying one AI-driven monitoring alert from the provided scenarios and a one-sentence rationale for its priority.
A short explanation (100–150 words) justifying why the selected alert is the most urgent and how addressing it ensures trial compliance and participant safety.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1M1W-uNIM8TyOk3I2cwINdhHnwVx4RncP/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1vyAIUavNd341RHPtzy3k2BLuYxiyJP53/view?usp=sharing,"Review Alert Scenarios: Examine the AI-driven alert scenarios and trial context in the reference document.
Prioritize Alert:
    - Select one alert from the provided scenarios and state it with a one-sentence rationale for why it is the most urgent.
    - Ensure the choice reflects the alert’s impact on safety, data integrity, or compliance.
Write Explanation:
- Justify the alert’s urgency and how addressing it supports trial oversight, referencing ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
- Keep the explanation concise, professional, and focused on trial monitoring goals.
Compile Deliverables:
- Make the prioritized alert statement with its rationale.
- Include the brief explanation as a separate section.
- Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_07,task_3_06_07_1,Pro Training in Clinical Research,,Monitoring & Site Management,Central vs. Local Monitoring.,Recommending Central and Local Monitoring Activities for a Phase III Oncology Trial,"You are a clinical research associate (CRA) at a trial site in Glasgow, UK, managed by GlasVita Clinical Research Ltd., a contract research organization with offices in Kelvinbridge, Glasgow. The Phase III clinical trial evaluates a new targeted therapy for metastatic lung cancer, aiming to enroll 150 participants aged 18–75 years at Glasgow Royal Infirmary. Given the trial’s high-risk safety profile due to potential severe adverse events (SAEs), you are tasked with recommending one central monitoring activity and one local monitoring activity to ensure effective oversight.

Deliverables

A monitoring recommendation table specifying one central monitoring activity and one local monitoring activity, each with a brief rationale.
A short explanation (100–150 words) justifying how the recommended activities balance safety oversight and efficiency while ensuring regulatory compliance.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1pl5ttpmhKnRZiRwBYk3aUBz3eEoUlNty/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1Z4pv67Hoc_YtvNSmMzsWuRzsOsi4NjKn/view?usp=sharing,"Review Trial Context: Examine the trial details and monitoring needs in the reference document, focusing on the high-risk safety profile.
Recommend Monitoring Activities:
    - Create a table recommending one central monitoring activity and one local monitoring activity, each with a one-sentence rationale.
    - Ensure activities address the trial’s safety concerns and align with risk-based monitoring principles.
Write Explanation:
    - Justify how the activities ensure effective oversight, participant safety, and compliance with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation concise, professional, and focused on monitoring goals.
Compile Deliverables:
    - Make the monitoring recommendation table.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_08,task_3_06_08_1,Pro Training in Clinical Research,,Monitoring & Site Management,Escalation Procedures.,Drafting an Escalation Notification for a Phase III Cardiovascular Trial,"You are a clinical research associate (CRA) at a trial site in Belfast, UK, managed by BelfiCore Clinical Research Ltd., a contract research organization with offices in Ormeau Road, Belfast. The Phase III clinical trial evaluates a new anticoagulant drug for patients with atrial fibrillation, aiming to enroll 120 participants aged 40–80 years at Royal Victoria Hospital, Belfast. During a routine monitoring visit on 19 September 2025, you identify a critical issue requiring escalation. Your task is to draft a one-sentence escalation notification and specify the escalation level to ensure timely resolution.

Deliverables

An escalation notification statement (one sentence) identifying the issue and specifying the escalation level (Site, Sponsor/CRO, Oversight Committees, Regulatory Authorities).
A short explanation (100–150 words) justifying the notification’s clarity and urgency, and how it aligns with regulatory requirements.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1YfFpapvoyyuZgGtRMerIDsWToq2_sq4x/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1WX39mByOhZd2aoWxb5CLUa4ZzerYVRuS/view?usp=sharing,"Review Issue Scenario: Examine the issue details and trial context in the reference document to understand the escalation need.
Draft Notification:
    - Write a one-sentence notification clearly describing the issue and specifying the escalation level.
    - Ensure the notification is concise and aligned with escalation procedures.
Write Explanation:
    - Justify the notification’s clarity, urgency, and chosen escalation level, referencing ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation professional, concise, and focused on escalation goals.
Compile Deliverables:
    - Make the escalation notification statement with the escalation level.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_09,task_3_06_09_1,Pro Training in Clinical Research,,Monitoring & Site Management,Monitoring Reports.,Drafting a Monitoring Visit Report Summary for a Phase III Cardiovascular Trial,"You are a clinical research associate (CRA) at a trial site in Galway, Ireland, managed by GalviCore Clinical Research Ltd., a contract research organization with offices in Salthill, Galway. The Phase III clinical trial evaluates a new anticoagulant drug for patients with atrial fibrillation, aiming to enroll 120 participants aged 40–80 years at University Hospital Galway. Following a routine monitoring visit on 19 September 2025, you are tasked with drafting a summary section for the Monitoring Visit Report (MVR) to document key findings and actions.

Deliverables

A one-paragraph MVR summary (3–5 sentences) outlining the key findings and actions from the routine monitoring visit.
A short explanation (100–150 words) justifying the summary’s clarity and its role in ensuring regulatory compliance and trial oversight.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/1jLqCA7-D4UbTKJTB29nSgWSrkgNl-zxR/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1aHxtwv9JsEGwpXgsx-SJTOtOVe7UFdlx/view?usp=sharing,"Review Visit Details: Examine the monitoring visit findings and trial context in the reference document.
Draft MVR Summary:
    - Write a concise paragraph (3–5 sentences) summarizing the key findings (e.g., deviations, consent issues) and actions taken or required.
    - Ensure the summary is clear, factual, and aligned with MVR components.
Write Explanation:
    - Justify the summary’s clarity and its role in documenting oversight, referencing ICH-GCP, EU Clinical Trial Regulation, and MHRA standards.
    - Keep the explanation professional, concise, and focused on monitoring report objectives.
Compile Deliverables:
    - Make the MVR summary paragraph.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
course_3,ch_3_06,les_3_06_10,task_3_06_10_1,Pro Training in Clinical Research,,Monitoring & Site Management,Close-Out Monitoring.,Resolving a Close-Out Complication in a Phase II Asthma Trial,"You are the Principal Investigator (PI) at a trial site in Dublin, Ireland, managed by DubliVita Clinical Research Ltd., a contract research organization with offices in Sandyford, Dublin. The Phase II clinical trial evaluating a new inhaled corticosteroid for moderate asthma concluded enrollment on 15 September 2025, with 60 participants at St. James’s Hospital, Dublin. During the close-out monitoring visit on 19 September 2025, the CRA identified a complication: a critical query on Patient ID IRE-001's Week 12 FEV1 data is unresolved due to a lost source document (spirometry report), and the site must resolve it before database lock on 30 September 2025 to avoid trial delays. As PI, you must simulate an email to the CRA and sponsor outlining your resolution plan, prioritizing actions to ensure compliance and closure.

Deliverables

A simulated email response (3–5 sentences) to the CRA and sponsor, detailing your prioritized resolution plan for the complication.
A short explanation (100–150 words) justifying the plan’s creativity in addressing the issue while ensuring regulatory compliance and trial closure.
Submit in OMEGA WORD or upload a pdf into OMEGA.",https://drive.google.com/file/d/10xtCEvSyAi9tn0zFWNiPqsHayIzbpoEc/view?usp=sharing,https://tally.so/r/wgyY8d,https://drive.google.com/file/d/1fZ4jo2RkBVlBnQFyLvCxVGzesvEQA7fF/view?usp=sharing,"Review Complication Details: Examine the close-out complication and trial context in the reference document.
Draft Simulated Email:
    - Write a concise email (3–5 sentences) as the PI, addressing the CRA and sponsor, outlining a prioritized resolution plan (e.g., reconstruct data, verify alternatives, document actions).
    - Make the plan creative, using available resources to resolve the lost document issue.
Write Explanation:
    - Justify the plan’s creativity, feasibility, and alignment with ICH-GCP, EU Clinical Trial Regulation, and MHRA standards for close-out.
    - Keep the explanation professional, concise, and focused on effective resolution.
Compile Deliverables:
    - Make the appropriate email response.
    - Include the brief explanation as a separate section.
    - Submit in OMEGA WORD or upload a pdf into OMEGA.",
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_07,les_3_07_01,task_3_07_01_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,AE Definitions & Classification.,,,,,,,
course_3,ch_3_07,les_3_07_02,task_3_07_02_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,SAE Reporting Timelines.,,,,,,,
course_3,ch_3_07,les_3_07_03,task_3_07_03_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,Causality Assessment.,,,,,,,
course_3,ch_3_07,les_3_07_04,task_3_07_04_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,Pharmacovigilance Basics.,,,,,,,
course_3,ch_3_07,les_3_07_05,task_3_07_05_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,MedDRA Coding.,,,,,,,
course_3,ch_3_07,les_3_07_06,task_3_07_06_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,AI in AE Detection.,,,,,,,
course_3,ch_3_07,les_3_07_07,task_3_07_07_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,Safety Narratives.,,,,,,,
course_3,ch_3_07,les_3_07_08,task_3_07_08_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,DSMB & Safety Committees.,,,,,,,
course_3,ch_3_07,les_3_07_09,task_3_07_09_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,Post-Marketing Surveillance.,,,,,,,
course_3,ch_3_07,les_3_07_10,task_3_07_10_1,Pro Training in Clinical Research,,Adverse Events (AE) & Safety Reporting,AE Reconciliation.,,,,,,,
,,,,,,,,,,,,,,
course_3,ch_3_08,les_3_08_01,task_3_08_01_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,Global Regulatory Frameworks.,,,,,,,
course_3,ch_3_08,les_3_08_02,task_3_08_02_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,FDA/EMA Submission Processes.,,,,,,,
course_3,ch_3_08,les_3_08_03,task_3_08_03_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,GCP Inspections & Audits.,,,,,,,
course_3,ch_3_08,les_3_08_04,task_3_08_04_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,CAPA (Corrective & Preventive Actions).,,,,,,,
course_3,ch_3_08,les_3_08_05,task_3_08_05_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,Document Control in Compliance.,,,,,,,
course_3,ch_3_08,les_3_08_06,task_3_08_06_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,AI for Compliance Monitoring.,,,,,,,
course_3,ch_3_08,les_3_08_07,task_3_08_07_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,International Trials & Harmonization.,,,,,,,
course_3,ch_3_08,les_3_08_08,task_3_08_08_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,Ethics Committee/IRB Interactions.,,,,,,,
course_3,ch_3_08,les_3_08_09,task_3_08_09_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,Audit Trail Management.,,,,,,,
course_3,ch_3_08,les_3_08_10,task_3_08_10_1,Pro Training in Clinical Research,,Regulatory Compliance & Audits,Post-Audit Reporting.,,,,,,,
,,,,,,,,,,,,,,
course_3,ch_3_09,les_3_09_01,task_3_09_01_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Basic Statistical Concepts.,,,,,,,
course_3,ch_3_09,les_3_09_02,task_3_09_02_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Hypothesis Testing.,,,,,,,
course_3,ch_3_09,les_3_09_03,task_3_09_03_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Sample Size & Power Calculations.,,,,,,,
course_3,ch_3_09,les_3_09_04,task_3_09_04_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Survival Analysis Basics.,,,,,,,
course_3,ch_3_09,les_3_09_05,task_3_09_05_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Interim Analyses.,,,,,,,
course_3,ch_3_09,les_3_09_06,task_3_09_06_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,AI in Statistical Analysis,,,,,,,
course_3,ch_3_09,les_3_09_07,task_3_09_07_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Data Visualization for Trials.,,,,,,,
course_3,ch_3_09,les_3_09_08,task_3_09_08_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Handling Biases in Data.,,,,,,,
course_3,ch_3_09,les_3_09_09,task_3_09_09_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Statistical Software Overview.,,,,,,,
course_3,ch_3_09,les_3_09_10,task_3_09_10_1,Pro Training in Clinical Research,,Biostatistics & Data Analysis in Trials,Interpreting SAS Outputs.,,,,,,,
,,,,,,,,,,,,,,
course_3,ch_3_10,les_3_10_01,task_3_10_01_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,AI for Protocol Optimization.,,,,,,,
course_3,ch_3_10,les_3_10_02,task_3_10_02_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,Predictive Analytics for Enrollment.,,,,,,,
course_3,ch_3_10,les_3_10_03,task_3_10_03_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,NLP for Unstructured Data.,,,,,,,
course_3,ch_3_10,les_3_10_04,task_3_10_04_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,Machine Learning in Patient Stratification.,,,,,,,
course_3,ch_3_10,les_3_10_05,task_3_10_05_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,AI-Driven Risk-Based Monitoring.,,,,,,,
course_3,ch_3_10,les_3_10_06,task_3_10_06_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,Blockchain & AI for Data Integrity.,,,,,,,
course_3,ch_3_10,les_3_10_07,task_3_10_07_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,AI Ethics & Bias in Trials.,,,,,,,
course_3,ch_3_10,les_3_10_08,task_3_10_08_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,Real-World Evidence (RWE) with AI.,,,,,,,
course_3,ch_3_10,les_3_10_09,task_3_10_09_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,"Future AI Trends (e.g., Digital Twins).",,,,,,,
course_3,ch_3_10,les_3_10_10,task_3_10_10_1,Pro Training in Clinical Research,,Advanced AI Applications in Clinical Trials,Integrating AI with CTMS/eTMF.,,,,,,,
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_11,les_3_11_01,task_3_11_01_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",eTMF Fundamentals.,,,,,,,
course_3,ch_3_11,les_3_11_02,task_3_11_02_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",CTMS Overview & Modules.,,,,,,,
course_3,ch_3_11,les_3_11_03,task_3_11_03_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",Workflow Automation in Systems.,,,,,,,
course_3,ch_3_11,les_3_11_04,task_3_11_04_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",Integration of EDC with CTMS.,,,,,,,
course_3,ch_3_11,les_3_11_05,task_3_11_05_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",Vendor Management in Systems.,,,,,,,
course_3,ch_3_11,les_3_11_06,task_3_11_06_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",AI Plugins for eTMF/CTMS.,,,,,,,
course_3,ch_3_11,les_3_11_07,task_3_11_07_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",Scalability for Multi-Site Trials.,,,,,,,
course_3,ch_3_11,les_3_11_08,task_3_11_08_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",System Validation & 21 CFR Part 11.,,,,,,,
course_3,ch_3_11,les_3_11_09,task_3_11_09_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",Reporting & Analytics in CTMS.,,,,,,,
course_3,ch_3_11,les_3_11_10,task_3_11_10_1,Pro Training in Clinical Research,,"eTMF, CTMS & Trial Management Systems",Troubleshooting System Issues.,,,,,,,
,,,,Pro Training in Clinical Research,,,,,,,,,,
course_3,ch_3_12,les_3_12_01,task_3_12_01_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",End-to-End Trial Review.,,,,,,,
course_3,ch_3_12,les_3_12_02,task_3_12_02_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",Advanced Simulation Strategies.,,,,,,,
course_3,ch_3_12,les_3_12_03,task_3_12_03_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",Portfolio Building with AI.,,,,,,,
course_3,ch_3_12,les_3_12_04,task_3_12_04_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",Interview Prep for CRC Roles.,,,,,,,
course_3,ch_3_12,les_3_12_05,task_3_12_05_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",Networking in Clinical Research.,,,,,,,
course_3,ch_3_12,les_3_12_06,task_3_12_06_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",,,,,,,,
course_3,ch_3_12,les_3_12_07,task_3_12_07_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",,,,,,,,
course_3,ch_3_12,les_3_12_08,task_3_12_08_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",,,,,,,,
course_3,ch_3_12,les_3_12_09,task_3_12_09_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",,,,,,,,
course_3,ch_3_12,les_3_12_10,task_3_12_10_1,Pro Training in Clinical Research,,"Capstone Integration, Career Prep & Battle Readiness",,,,,,,,
,,,,,,,,,,,,,,
course_4,ch_4_01,les_4_01_01,task_4_01_01_1,Pro Training in Regulatory Affairs,Navigate complex regulatory landscapes to achieve approvals and maintain compliance efficiently.,,,,,,,,,
course_4,ch_4_01,les_4_01_02,task_4_01_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_03,task_4_01_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_04,task_4_01_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_05,task_4_01_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_06,task_4_01_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_07,task_4_01_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_08,task_4_01_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_01,les_4_01_09,task_4_01_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_01,task_4_02_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_02,task_4_02_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_03,task_4_02_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_04,task_4_02_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_05,task_4_02_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_06,task_4_02_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_07,task_4_02_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_08,task_4_02_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_09,task_4_02_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_02,les_4_02_10,task_4_02_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_01,task_4_03_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_02,task_4_03_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_03,task_4_03_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_04,task_4_03_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_05,task_4_03_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_06,task_4_03_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_07,task_4_03_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_08,task_4_03_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_09,task_4_03_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_03,les_4_03_10,task_4_03_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_01,task_4_04_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_02,task_4_04_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_03,task_4_04_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_04,task_4_04_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_05,task_4_04_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_06,task_4_04_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_07,task_4_04_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_08,task_4_04_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_09,task_4_04_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_04,les_4_04_10,task_4_04_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_01,task_4_05_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_02,task_4_05_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_03,task_4_05_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_04,task_4_05_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_05,task_4_05_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_06,task_4_05_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_07,task_4_05_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_08,task_4_05_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_09,task_4_05_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_05,les_4_05_10,task_4_05_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_01,task_4_06_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_02,task_4_06_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_03,task_4_06_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_04,task_4_06_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_05,task_4_06_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_06,task_4_06_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_07,task_4_06_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_08,task_4_06_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_09,task_4_06_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_06,les_4_06_10,task_4_06_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_01,task_4_07_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_02,task_4_07_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_03,task_4_07_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_04,task_4_07_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_05,task_4_07_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_06,task_4_07_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_07,task_4_07_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_08,task_4_07_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_09,task_4_07_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_07,les_4_07_10,task_4_07_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_01,task_4_08_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_02,task_4_08_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_03,task_4_08_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_04,task_4_08_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_05,task_4_08_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_06,task_4_08_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_07,task_4_08_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_08,task_4_08_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_09,task_4_08_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_08,les_4_08_10,task_4_08_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_01,task_4_09_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_02,task_4_09_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_03,task_4_09_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_04,task_4_09_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_05,task_4_09_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_06,task_4_09_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_07,task_4_09_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_08,task_4_09_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_09,task_4_09_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_09,les_4_09_10,task_4_09_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_01,task_4_10_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_02,task_4_10_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_03,task_4_10_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_04,task_4_10_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_05,task_4_10_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_06,task_4_10_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_07,task_4_10_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_08,task_4_10_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_09,task_4_10_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_10,les_4_10_10,task_4_10_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_01,task_4_11_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_02,task_4_11_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_03,task_4_11_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_04,task_4_11_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_05,task_4_11_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_06,task_4_11_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_07,task_4_11_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_08,task_4_11_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_09,task_4_11_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_11,les_4_11_10,task_4_11_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_01,task_4_12_01_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_02,task_4_12_02_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_03,task_4_12_03_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_04,task_4_12_04_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_05,task_4_12_05_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_06,task_4_12_06_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_07,task_4_12_07_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_08,task_4_12_08_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_09,task_4_12_09_1,Pro Training in Regulatory Affairs,,,,,,,,,,
course_4,ch_4_12,les_4_12_10,task_4_12_10_1,Pro Training in Regulatory Affairs,,,,,,,,,,
,,,,,,,,,,,,,,
course_5,ch_5_01,les_5_01_01,task_5_01_01_1,Pro Training in Medical Affairs,Bridge clinical evidence and strategy to support medical decision-making and stakeholder engagement.,,,,,,,,,
course_5,ch_5_01,les_5_01_02,task_5_01_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_03,task_5_01_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_04,task_5_01_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_05,task_5_01_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_06,task_5_01_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_07,task_5_01_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_08,task_5_01_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_01,les_5_01_09,task_5_01_09_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_01,task_5_02_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_02,task_5_02_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_03,task_5_02_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_04,task_5_02_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_05,task_5_02_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_06,task_5_02_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_07,task_5_02_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_08,task_5_02_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_09,task_5_02_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_02,les_5_02_10,task_5_02_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,,,,,,,,,,,
course_5,ch_5_03,les_5_03_01,task_5_03_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_02,task_5_03_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_03,task_5_03_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_04,task_5_03_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_05,task_5_03_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_06,task_5_03_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_07,task_5_03_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_08,task_5_03_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_09,task_5_03_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_03,les_5_03_10,task_5_03_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,,,,,,,,,,,
course_5,ch_5_04,les_5_04_01,task_5_04_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_02,task_5_04_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_03,task_5_04_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_04,task_5_04_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_05,task_5_04_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_06,task_5_04_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_07,task_5_04_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_08,task_5_04_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_09,task_5_04_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_04,les_5_04_10,task_5_04_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,,,,,,,,,,,
course_5,ch_5_05,les_5_05_01,task_5_05_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_02,task_5_05_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_03,task_5_05_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_04,task_5_05_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_05,task_5_05_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_06,task_5_05_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_07,task_5_05_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_08,task_5_05_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_09,task_5_05_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_05,les_5_05_10,task_5_05_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,,,,,,,,,,,
course_5,ch_5_06,les_5_06_01,task_5_06_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_02,task_5_06_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_03,task_5_06_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_04,task_5_06_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_05,task_5_06_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_06,task_5_06_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_07,task_5_06_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_08,task_5_06_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_09,task_5_06_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_06,les_5_06_10,task_5_06_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_01,task_5_07_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_02,task_5_07_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_03,task_5_07_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_04,task_5_07_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_05,task_5_07_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_06,task_5_07_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_07,task_5_07_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_08,task_5_07_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_09,task_5_07_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_07,les_5_07_10,task_5_07_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_01,task_5_08_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_02,task_5_08_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_03,task_5_08_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_04,task_5_08_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_05,task_5_08_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_06,task_5_08_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_07,task_5_08_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_08,task_5_08_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_09,task_5_08_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_08,les_5_08_10,task_5_08_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_01,task_5_09_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_02,task_5_09_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_03,task_5_09_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_04,task_5_09_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_05,task_5_09_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_06,task_5_09_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_07,task_5_09_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_08,task_5_09_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_09,task_5_09_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_09,les_5_09_10,task_5_09_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_01,task_5_10_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_02,task_5_10_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_03,task_5_10_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_04,task_5_10_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_05,task_5_10_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_06,task_5_10_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_07,task_5_10_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_08,task_5_10_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_09,task_5_10_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_10,les_5_10_10,task_5_10_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_01,task_5_11_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_02,task_5_11_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_03,task_5_11_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_04,task_5_11_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_05,task_5_11_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_06,task_5_11_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_07,task_5_11_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_08,task_5_11_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_09,task_5_11_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_11,les_5_11_10,task_5_11_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_01,task_5_12_01_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_02,task_5_12_02_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_03,task_5_12_03_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_04,task_5_12_04_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_05,task_5_12_05_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_06,task_5_12_06_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_07,task_5_12_07_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_08,task_5_12_08_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_09,task_5_12_09_1,Pro Training in Medical Affairs,,,,,,,,,,
course_5,ch_5_12,les_5_12_10,task_5_12_10_1,Pro Training in Medical Affairs,,,,,,,,,,
,,,,,,,,,,,,,,
course_6,ch_6_01,les_6_01_01,task_6_01_01_1,Pro Training in Clinical Data Management,"Organize, validate, and analyze clinical trial data to enable accurate and reliable study outcomes.",,,,,,,,,
course_6,ch_6_01,les_6_01_02,task_6_01_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_03,task_6_01_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_04,task_6_01_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_05,task_6_01_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_06,task_6_01_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_07,task_6_01_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_08,task_6_01_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_01,les_6_01_09,task_6_01_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_01,task_6_02_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_02,task_6_02_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_03,task_6_02_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_04,task_6_02_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_05,task_6_02_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_06,task_6_02_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_07,task_6_02_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_08,task_6_02_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_09,task_6_02_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_02,les_6_02_10,task_6_02_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_01,task_6_03_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_02,task_6_03_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_03,task_6_03_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_04,task_6_03_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_05,task_6_03_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_06,task_6_03_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_07,task_6_03_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_08,task_6_03_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_09,task_6_03_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_03,les_6_03_10,task_6_03_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_01,task_6_04_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_02,task_6_04_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_03,task_6_04_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_04,task_6_04_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_05,task_6_04_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_06,task_6_04_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_07,task_6_04_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_08,task_6_04_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_09,task_6_04_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_04,les_6_04_10,task_6_04_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_01,task_6_05_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_02,task_6_05_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_03,task_6_05_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_04,task_6_05_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_05,task_6_05_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_06,task_6_05_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_07,task_6_05_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_08,task_6_05_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_09,task_6_05_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_05,les_6_05_10,task_6_05_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_01,task_6_06_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_02,task_6_06_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_03,task_6_06_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_04,task_6_06_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_05,task_6_06_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_06,task_6_06_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_07,task_6_06_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_08,task_6_06_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_09,task_6_06_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_06,les_6_06_10,task_6_06_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_01,task_6_07_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_02,task_6_07_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_03,task_6_07_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_04,task_6_07_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_05,task_6_07_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_06,task_6_07_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_07,task_6_07_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_08,task_6_07_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_09,task_6_07_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_07,les_6_07_10,task_6_07_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_01,task_6_08_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_02,task_6_08_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_03,task_6_08_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_04,task_6_08_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_05,task_6_08_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_06,task_6_08_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_07,task_6_08_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_08,task_6_08_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_09,task_6_08_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_08,les_6_08_10,task_6_08_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_01,task_6_09_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_02,task_6_09_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_03,task_6_09_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_04,task_6_09_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_05,task_6_09_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_06,task_6_09_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_07,task_6_09_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_08,task_6_09_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_09,task_6_09_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_09,les_6_09_10,task_6_09_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_01,task_6_10_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_02,task_6_10_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_03,task_6_10_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_04,task_6_10_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_05,task_6_10_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_06,task_6_10_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_07,task_6_10_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_08,task_6_10_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_09,task_6_10_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_10,les_6_10_10,task_6_10_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_01,task_6_11_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_02,task_6_11_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_03,task_6_11_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_04,task_6_11_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_05,task_6_11_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_06,task_6_11_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_07,task_6_11_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_08,task_6_11_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_09,task_6_11_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_11,les_6_11_10,task_6_11_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
,,,,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_01,task_6_12_01_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_02,task_6_12_02_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_03,task_6_12_03_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_04,task_6_12_04_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_05,task_6_12_05_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_06,task_6_12_06_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_07,task_6_12_07_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_08,task_6_12_08_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_09,task_6_12_09_1,Pro Training in Clinical Data Management,,,,,,,,,,
course_6,ch_6_12,les_6_12_10,task_6_12_10_1,Pro Training in Clinical Data Management,,,,,,,,,,
